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8  |  CHAPTER 1
Benzodiazepines (BZDs) are a class of psychotropic drugs with anxiolytic, 
muscle-relaxant and hypnotic properties.1 In clinical practice, they are 
mainly used to manage the symptoms of anxiety and insomnia.1 BZDs 
are the most prescribed psychotropic drugs worldwide and although 
it has regularly been stated that prescription rates have declined 
during the past 15 years,2 statistics reveal that the prevalence of BZD 
use has actually remained quite stable.3 There is a broad evidence-
based knowledge foundation for the effects of short-term use of BZDs, 
but studies in long-term users are less common. Instead, oftentimes, 
clinicians’ observations seem to form the basis of ideas on long-term BZD 
use and related prescribing decisions. However, as many BZD users are 
long-term users, prescribing decisions for these patients should be based 
on clinical research conducted in representative samples. An obvious 
reason for the lack of randomized clinical long-term trials in chronic BZD 
users is not only of pragmatic but also of ethical nature. It is not justified 
to administer BZDs for more than a few weeks, due to the high risk of side 
effects and dependence development. Up to now, prospective research is 
lacking for a number of the possible determinants and consequences of 
long-term BZD use. Therefore, the thesis on hand aims to investigate 
the determinants and consequences of long-term BZD use in subjects at 
different stages of psychopathology and healthy controls. 
This introduction consists of four parts: In part A, an overview 
of the indications, prevalence and subjects at risk of BZD use will be 
provided. The possible influence of the prescribers on BZD use will also be 
discussed. In part B, the working mechanism of BZDs and physiological 
consequences of long-term BZD use will be described. In part C, the 
cognitive side effects of the BZDs and especially their effects on reaction 
time (RT) will be addressed with a special focus on chronic use. Finally, 
in part D, the studied sample, the structure as well as the aims of this 
thesis will be outlined.
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PArt A) BZD Use, iNAPProPriAte Use, AND tHe 
iNFLUeNce oF BZD PrescriBers 
indications of BZD Use
In the Netherlands, BZDs are registered for the short-term treatment of 
insomnia and anxiety disorders.1,4 Besides, BZDs are used as preoperative 
drugs and for emergency sedation as well as to treat epilepsy, alcohol 
withdrawal symptoms, febrile seizures, and acute insults. The British 
National Formulary divides BZDs into anxiolytics, used for the reduction 
of anxiety symptoms (ATC-code N05BA) and hypnotics (ATC codes N05CD 
for BZDs and N05CF for BZD related compounds) used for the short-
term treatment of insomnia. This categorization is commonly used, but 
arbitrary, as both types of BZDs have similar actions. Anxiolytics will 
induce sleep when administered at night and hypnotics will have anxiolytic 
effects when used during the day at the respective dosages.5 Differences 
between anxiolytics and hypnotics are related to their duration of action, 
which depends on the metabolic half-life and the presence of active 
metabolites. Nevertheless, also long-acting BZDs such as nitrazepam 
and flurazepam are considered as hypnotics, although they were proven 
to have residual effects the next day.6 The most common BZDs in the 
Netherlands are summarized in table 1.1,6,7 
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table 1: Common BZD Agonists
Drug










Alprazolam Xanax 1mg Anxiolytic
Bromazepam Lexotanil 10mg Anxiolytic
Brotizolam Lendormin 0,25mg Anxiolytic
Chlordiazepoxide Chlordiazepoxide 20mg Anxiolytic
Clobazam Frisium, Urbadan 20mg Anxiolytic
Clorazepate Clorazepaat, Tanxene 13,3mg Anxiolytic
Diazepam Diazepam, Stesolid, Valium 10mg Anxiolytic
Flunitrazepam Flunitrazepam, Rohypnol 1mg Hypnotic
Flurazepam Dalmadorm, Flurazepam 30mg Hypnotic
Loprazolam Dormonoct 1mg Hypnotix




Midazolam Dormicum 7,5mg Hypnotic
Nitrazepam Mogadon, Nitrazepam 10mg Hypnotic
Oxazepam Oxazepam, Seresta 33,3mg Anxiolytic
Prazepam Reapam 20mg Anxiolytic
Temazepam Normison, Temazepam 20mg Hypnotic
Zolpidem Stilnoct 20mg Hypnotic
Zopiclone Zimovane 13mg Hypnotic
BZDs are registered8 and proven effective for the short-term symptomatic 
relief of insomnia as they accelerate sleep onset, reduce nocturnal 
awakenings, and increase total sleep time.1,9,10 This has been proven 
in several randomized controlled trials.11-13 However, BZDs also reduce 
the duration of slow wave sleep and rapid eye movement sleep.1,14 For 
these reasons in addition to BZDs’ risk of side effects, tolerance, and 
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dependence development, prescription guidelines recommend to limit 
BZD prescriptions to the short-term treatment of severe insomnia, which 
is considered to be disabling or extremely distressing1 and could not 
be relieved by sleep hygiene and information about the normal sleep 
cycle.8 Guidelines recommend treating transient insomnia caused by a 
disruption of the circadian rhythm such as in overnight travel or shift 
work with an occasional BZD.1 Short term insomnia due to temporary 
environmental stress may be treated by BZDs for a maximum of two 
weeks.1 Chronic insomnia is usually secondary to other conditions, thus 
it is more effective to treat the cause of insomnia than the insomnia 
itself.1 Further, BZDs do not seem to maintain effectiveness in longer-
term treatment of sleep problems1,15,16 and chronic use was found to be 
associated with complex changes of sleep architecture leading to poor 
quality of sleep.6 Therefore, long-term BZD use is not recommendable.
Regarding anxiety, a large number of randomized controlled trials 
have proven the effectiveness of BZDs in the short-term, symptomatic 
treatment of social phobia,17,18 general anxiety disorder,19 panic 
disorder,20,21,22 and acute states of anxiety. The United Kingdom Committee 
on Safety of Medicines advised to limit BZD prescriptions to two to four 
weeks for anxiety that is severe, disabling or causing unacceptable 
distress.1 Single doses of BZDs may be used to prevent predictable, 
acute stress reactions such as air travel or dental appointments in 
phobic patients. Yet, psychological therapies are preferable in the long-
run.1 Very short-term treatment of one to seven days may be indicated 
for stress reactions after catastrophic events such as natural disasters 
and accidents, as spontaneous resolution is common.1 BZDs are not 
recommended after the death of a loved person as they may inhibit the 
grieving process, but a few days of use may be justified.1 Intermittent 
treatment of two to four weeks can be of value in episodic anxiety often 
observed in chronic generalized anxiety disorder, but the longer the 
duration of treatment the less the benefit.1 The anxiolytic effects of BZDs 
may be more resistant to tolerance than the sedative, anticonvulsant or 
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muscle-relaxant effects and enduring anxiolytic effectiveness for two to 
six months was proven by several clinical trials.23-25 In contrast, other 
studies did not detect differences between BZDs and placebo in long-term 
use,26 indicating that the anxiolytic effect is not maintained. Furthermore, 
long-term BZD users were regularly found to suffer from severe anxiety 
and insomnia although these are the symptoms that BZDs are supposed 
to reduce. This suggests that BZDs do not sufficiently reduce insomnia 
and anxiety symptoms (anymore) in long-term users. However, as results 
are inconsistent, it is unclear when tolerance to BZDs anxiolytic effects 
develops and if BZDs are effective in the reduction of stress and anxiety 
symptoms when used chronically.
the Prevalence of BZD Use 
The prevalence of BZD use in the Netherlands has been quite stable over 
the past 15 years. In 1996, 1.3 million individuals used BZDs with the 
ATC codes N05BA, 0.8 million used BZDs with the ATC code N05CD, and 
0.1 million used BZDs with the ATC code N05CF.3 These numbers cannot 
be added as many BZD users concomitantly use different types of BZDs. 
Interestingly, the number of BZD users had hardly changed 12 years later 
when 1.2 million (ATC code N05BA), 0.7 million (ATC code N05CD) and 
0.2 million (ATC code N05CF) subjects used the different groups of BZDs.3 
In 2010 – only two years later – these numbers differed dramatically: 
Only 0.3 million (ATC code N05BA), 0.1 million (N05CD), and 0.4 million 
(N05CF) subjects used BZDs.3 This decrease of the “official” BZD use was 
due to a Dutch governmental measure in January 2009 that aimed to 
reduce unnecessary and inappropriate BZD use and its accompanying 
costs.27,28 Since then, BZDs are only compensated by Dutch health 
care insurance if patients must use BZDs due to lacking alternatives 
(epilepsy, treatment resistant anxiety, psychiatric comorbidity, palliative 
sedation).27,28 Yet, the Dutch foundation of pharmaceutical core numbers 
stated that the much lower prevalence numbers did not represent the 
true user numbers. Instead, the majority of users had not discontinued 
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their BZD use but paid for the drugs themselves.3 Accordingly, the actual 
number of BZD users in the Netherlands was estimated at 1.5 million,29 
which corresponds to a prevalence rate of 9.0% (for the total Dutch 
population of 16,6 million people) and indicates that BZD use has not 
decreased much in the past 20 years.30 The BZD use in the Netherlands 
seems to be comparable to the use in other countries. Lader et al. reviewed 
papers of different countries and reported that the prevalence rates of 
BZD use range between 2.2% and 17.6%.6
the initiation of BZD Use
As the indications for BZD use are restricted, even in a population of 
subjects who mainly suffer from depression and/or anxiety, it is interesting 
to identify the determinants of BZD use. It will provide clinicians with a 
clearer picture of actual BZD use and how far that behaviour diverges 
from the treatment guidelines. Longitudinal research on new-onset BZD 
use is scarce and the identified predictors differ between studies. In these 
studies, the initiation of BZD use was found to be predicted by female 
gender,31 older age,31 divorce,31 psychopathology,32 insomnia,33 alcohol 
abuse,32 antidepressant use,32 smoking,33 poor physical health,33 and 
joint pain.33 These studies were restricted to very specific samples such 
as retired workers31 and elderly subjects.32 Additionally, the associations 
of changes in psychopathology over time and life events with BZD use 
have not been studied in longitudinal research, although they may very 
well precede transitions in BZD use. In order to identify the independent 
determinants of the initiation of BZD use, we included the previously 
identified determinants of BZD use plus a number of new determinants 
into a multivariate model. We were also interested if the predictors of BZD 
use in a sample mainly consisting of anxious and depressed subjects 
would be similar to those identified in the previous samples (which were 
constituted by very specific groups of subjects such as elderly persons or 
retired workers). 
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chronic BZD Use
The persisting high prevalence of (chronic) BZD use despite the limited 
indications makes it interesting to determine its correlates. Cross-sectional 
studies identified several sociodemographic (sex,34 age,34 education,34 
unemployment35), psychological (psychopathology,35 antidepressant 
use,35 neuroticism36), and physical (chronic illnesses,36 pain,37 GP visits38) 
correlates of BZD use. However, these studies differed in the correlates 
they included so that findings were not always comparable. Further, 
they did not always conduct a multivariate analysis34,38 so that the 
independent correlates of BZD use could not be identified. Therefore, 
a study which includes all important previously identified correlates of 
BZD use in one multivariate model is needed, in order to identify the 
independent correlates of BZD use. However, cross-sectional research 
provides no information of the order in which the investigated variables 
occur, so that it is unclear if an identified correlate actually is a risk 
factor or otherwise related to BZD use. Longitudinal studies are superior 
as they permit to identify the risk factors that precede chronic BZD use. 
Previous longitudinal research identified a number of sociodemographic 
(gender,39 age,33,40,41 being divorced,39), health related (psychopathology,42 
insomnia,39,42 poor physical health,39,43 number of GP contacts,39 pain,33 
chronic diseases,44 antidepressant use32) and BZD use related (dosage,43 
duration,43 half-life,41 past use, 40,42,44,45 daily use,40 hypnotic use43) 
predictors of continued BZD use. 
However, again, findings were inconsistent between studies, 
possibly due to the investigation of different and small sets of determinants 
per study, distinct definitions of the outcome variable (such as three 
months43 /six months33/ three years39 of BZD use, psychotropic use46) as 
well as different measurement methods of BZD use (pharmacy records,33 
observing medication containers,39 self-report46). Further, studies 
focused on different study samples (such as elderly subjects33,39,46 or BZD 
users only43) which may also have differentially influenced the results. 
Changes of psychopathology and life events have not been investigated 
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yet as possible determinants, although they might precede transitions 
in BZD use. Therefore, to identify the risk factors of transitions in BZD 
use, prospective research is needed, which includes the most important 
predictors identified in previous research, plus those that have not been 
considered previously, and investigates them in a multivariate model. 
inappropriate BZD Use
BZDs are relatively safe when an overdose is taken, and symptoms 
of severe poisoning are rare in young, healthy adults.47 However, 
hypotension and coma have been reported in elderly subjects and 
children48,49 and seniors were repeatedly found to experience cognitive 
impairments, psychomotor slowing, and reduced functional autonomy 
subsequent to BZD use.50 Further, higher doses of BZDs were found to 
cause respiratory depression and may therefore be dangerous to patients 
with severe chronic obstructive pulmonary disease.51 Younger adults 
may also experience complications when a BZD overdose is combined 
with alcohol, opiates, and tricyclic antidepressants. BZD use was also 
found to strongly increase suicidal and non-suicidal deaths in patients 
suffering from schizophrenia.52 Long-term use was associated with the 
development of dependence as well as lasting memory impairments. 
To prevent these unwanted effects, international prescription 
guidelines recommend cautious prescription of BZDs with dosages 
lower or equal to the defined daily dosage (as developed by the World 
Health Organization) for a maximum duration of two weeks for insomnia 
and two months for anxiety.4,8 Still, BZD users and prescribers do not 
always adhere to these guidelines and chronic BZD use is a common 
phenomenon. In 2009, the average BZD user in the Netherlands received 
175 daily dosages, equalling approximately six months of average BZD 
use.3 Research has also shown that many BZD users receive prescriptions 
for more than one type of BZD, although they all have comparable effects 
(in different potencies).53 Using several BZDs concomitantly for different 
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indications (e.g. anxiety, sleep and muscle spasms) can easily and 
unnecessarily lead to dose escalation. 
The identification of subjects at risk of inappropriate BZD 
use would allow medical doctors to make more balanced prescribing 
decisions. Up to now, only the correlates of long-term use were studied. 
In these studies, sex,54,55 age,54,55 education,56 psychological33,57 and 
physical health,33,57 antidepressant use,57 daily BZD use,40 and use of 
higher potency BZDs41 were identified as important correlates of long-
term BZD use. Research on the correlates of inappropriate use as a 
whole (including dosage and concomitant use of >1 type of BZD) does not 
exist yet, although these guideline deviations regularly occur. Therefore, 
research on the correlates of inappropriate BZD use is needed. 
BZD Dependence 
When BZDs were originally introduced in clinical practice, they were 
thought to be free of addictive properties. However, since the early 
1970s it is apparent that BZDs can produce physiological dependence 
and withdrawal symptoms. According to the Diagnostic and Statistical 
Manual of Mental Disorder Fourth Edition - Text Revision (DSM-IV-
TR) substance dependence (including BZD dependence) is defined as 
a maladaptive pattern of substance use leading to clinically significant 
impairment or distress, as manifested by three (or more) of the following, 
occurring any time in the same 12-month period (Table 2). 
Research suggests that a substantial proportion of users will 
develop BZD dependence, also at low doses.58,59 With 9.5% - 40.0% of 
outpatient BZD users developing dependence, the prevalence is high.6,58-61 
Nevertheless, clinicians often seem to overlook BZD dependence,62 
downplay its importance63 or fail to discuss it with their patients.63 
According to the CASA National Survey of Primary Care Physicians 
and Patients on Substance Abuse, less than one third of primary care 
physicians screen for substance abuse.64 The generation of a risk profile 
of subjects vulnerable of BZD dependence may help the treating GPs to 
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prevent BZD dependence in certain subjects or at least to identify the 
problem at an early stage and discuss it with the patient. 
In previous research, BZD dependence was found to be associated 
with sociodemographic factors (female gender,65 lower age,66 non-Dutch 
cultural origin,66 and retirement66), psychological and physical health 
factors (negative mood,67 depression,66,68 anxiety,65,66,68 antidepressant 
use,69 hostility,66 a lower quality of life,68 and somatization67), addiction 
related factors (treatment for dependence66), and BZD use related factors 
(a high daily dosage66,69 and long-term BZD use66,69). However, findings 
differed between studies, amongst others due to differing samples65,66,68,69 
and definitions of BZD dependence.65-70 Most importantly, the majority of 
the studies applied dichotomous (yes/no) definitions of dependence,65,68 
while the clinical expression of BZD dependence is better modeled 
using several subscales70 and severity dimensions such as in the BZD 
Dependence Self-Report Questionnaire (Bendep-SRQ).71
Only one previous study has investigated the correlates of these 
three subscales of the Bendep-SRQ.66 Higher age, depressive disorder, 
duration and dosage of BZD use were associated with higher scores 
on problematic use.66 Anxiety disorder and a longer duration of BZD 
use were associated with more preoccupation.66 Lower age, retirement, 
duration of BZD use and a higher dosage were associated with more 
table 2: DSM-IV-TR Criteria of Substance Dependence
Tolerance (marked increase in amount; marked decrease in effect)
Characteristic withdrawal symptoms; substance taken to relieve withdrawal
Substance taken in larger amount and for longer period than intended
Persistent desire or repeated unsuccessful attempt to quit
Much time/activity to obtain, use, recover
Important social, occupational, or recreational activities given up or reduced
Use continues despite knowledge of adverse consequences (e.g., failure to fulfill 
role obligation, use when physically hazardous)
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lack of compliance.66 Being an outpatient in a substance addiction center 
was associated with higher scores on all three subscales.66 However, 
this study did not examine the impact of several potential physical and 
addiction-related correlates such as chronic illnesses, pain, and alcohol 
dependence. For this reason, a study determining the independent 
sociodemographic, psychological, physical, addiction-related, and BZD 
use-related correlates of the BZD dependence severity dimensions is 
needed.
GP characteristics, Patient characteristics, and BZD Use 
GPs may contribute to the inappropriate BZD use of their patients. 
However, in the previous investigations of risk factors of patient BZD use, 
the focus was mainly on patient characteristics while GP characteristics 
received less attention. Existing research on the physician correlates of 
patient BZD use was mainly of qualitative nature.63,72-78 These studies 
reported that the majority of physicians were aware of and supported the 
treatment guidelines. 73,75,77 Yet, BZDs were frequently and inappropriately 
prescribed due to a lack of time,72,74,79-81 alternatives,77,79,80,82 and 
skills,74,79-81 the idea that BZDs are the appropriate treatment for 
vulnerable patients,73,79,82 and the wish to maintain a good-doctor patient 
relationship.74,75,80,81
Quantitative studies on the physician characteristics associated 
with patient BZD use were scarce. Physician correlates of BZD use were 
male gender,83,84 personal usage of BZDs,85 being a general practitioner 
(as opposed to a psychiatrist),83,85 allowing patients to influence 
prescription decisions,84 prolongation of prescriptions without direct 
doctor-patient contact,84 and multiple drug prescribing.86 Several studies 
did not identify any significant physician factors of BZD use87,88 or found 
inconsistent results.83-86,89 Quantitative studies on physician correlates 
of inappropriate BZD use have not been conducted yet. However, one 
study investigated the correlates of long-term BZD use and found that 
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practice and patient characteristics were more important predictors than 
physician characteristics.90 
Most of the above mentioned studies did not correct for patient 
characteristics83-85 so it is unclear if the differences found were due to 
variation between physicians or due to differences between the treated 
patients. The attitudes of physicians towards depression and anxiety, 
guideline implementation, and collaboration with health care specialists 
have also received little attention,83,87,89,90 although these attitudes may 
influence the patients’ BZD use. Therefore, a study which investigates the 
general practitioner (GP) correlates of patient BZD use and inappropriate 
BZD use and corrects for important patient correlates of BZD use is 
needed in order to tell whether GP characteristics affect patient BZD use 
or if it is rather due to certain characteristics of the treated patients that 
GPs prescribe BZDs (inappropriately). 
PArt B) tHe BioLoGicAL coNseQUeNces oF BZD 
Use 
the Working Mechanism of BZDs
BZDs exert their action by binding to the receptor for gamma-aminobutric 
acid (GABA) and potentiating the effect of the inhibitory neurotransmitter 
GABA. There are three types of GABA-receptors: A, B, and C. The BZDs 
bind to GABAA, while baclofen (Lioresal) binds to GABAB.91 GABA is 
the most abundant inhibitory neurotransmitter in the human central 
nervous system.92 Depending on the brain region 20-50% of all neurons 
use GABA as neurotransmitter.91,93 GABAA receptors are ion channels 
through which chloride anions pass when GABA binds to the GABAA 
receptor.91 This leads to a hyperpolarization of the postsynaptic neuron, 
and renders it less sensitive to excitatory neurotransmitters so that 
neuronal activity is inhibited. BZDs enhance the inhibitory effect of 
GABA as they increase the frequency of GABA induced chloride channel 
openings.91 This reduces the turnover of several neurotransmitters 
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involved in emotional expression such as norepinephrine and serotonin 
and has a calming effect on many functions of the brain.94 The main sites 
of action of the BZDs are in the spinal cord, where BZDs mediate muscle 
relaxation, the brain stem and the cerebellum, where they cause ataxia, 
and the limbic and cortical areas, where they are involved in emotional 
experience and behaviour.6 
The GABAA receptor consists of five subunits and was found to 
be assembled from a family of at least 15 subunits (α1-6, ß1-3, γ1-3, θ, 
and p1-2) into different receptor complexes in rats.95 The most common 
receptors consist of two alphas, two betas and one gamma (α2ß2γ).96 
GABAA receptors that are made of different subunit combinations differ 
in properties, distributions in the brain and clinical effects. The α1 
subunit is the most abundant in most areas of the adult brain.97 Yet, 
in the hypothalamus and the hippocampus, α2 is the most dominant 
subunit,97,98 while in the deep cortical layers α3 is the major subunit.98 
Hence, different BZDs can have different affinities for different GABAA 
receptor subunit combinations, the activation of which may result in 
different pharmacological actions.99 BZDs bind at the interface of the α 
(α1, α2, α3, or α5) and the γ subunit of the GABAA receptor. 
Studies in knock-out mice investigated the effect of BZDs on 
certain GABAA receptor subtypes. These studies found that agonists for 
α1 were associated with hypnotic, amnesic, anticonvulsive and addictive 
effects,96 agonists for α2 mediated anxiolytic and myorelaxant effects,96 
agonists for α3 subunits were associated with anxiolytic and analgesic 
effects,96 and inverse agonists for α5 improved learning and memory. 
Possible (Long-term) effects on the Hypothalamic-Pituitary-Adrenal 
(HPA) axis
The hypothalamic - pituitary - adrenal (HPA) axis is a complex set of 
direct influences and feedback interactions among the hypothalamus, 
the pituitary gland, and the adrenal glands. It controls reactions to stress 
and regulates many body processes, including digestion, the immune 
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system, mood and emotions, sexuality, energy storage and expenditure. 
It plays a central role in the body’s neuroendocrine reaction to stress.100 
As BZDs bind to GABAA receptors, which are densely located in the 
paraventricular nucleus (PVN) of the hypothalamus,97,98 they may directly 
affect the HPA axis. Especially the α2 subunit of the GABAA receptor, 
which has been associated with the anxiolytic effects of BZDs, has been 
found to be abundant in the hypothalamus.97 Possibly, BZDs inhibit 
the production of the corticotrophin-releasing-hormone (CRH) via their 
action on the GABAA receptor in the PVN of the hypothalamus, leading to 
less secretion of the adrenocorticotropic hormone (ACTH) in the pituitary 
gland, and to less production of cortisol in the adrenal cortices. This 
effect on the HPA axis may underlie BZDs’ anxiolytic and stress reducing 
action.
A number of studies investigated the acute effects of BZDs on the 
HPA axis and mostly reported decreased cortisol levels after administration 
of BZDs.101-105 This suggests that BZDs acutely suppress the HPA axis. 
These suppressed cortisol levels were found to increase again 30 minutes 
to 2,5 hours later, indicating that this effect is transient.106,107 
Whether BZDs acute cortisol suppressant effect is maintained in 
long-term use, received less attention in the past. There was only one 
small cross-sectional study which reported similar cortisol levels in long-
term BZD users (> 3 months) and non-users.108 This implies that BZDs 
do not maintain their full cortisol-suppressing effects during longer 
term use. In contrast, an additional dosage of BZDs (on top of the BZD 
dosage that chronic users took on a daily basis) still affected the HPA axis 
in chronic users. Additional research is needed in order to investigate 
whether tolerance to BZDs effects on the HPA axis develops in chronic 
BZD use.
Possible (Long-term) effects on the Autonomic Nervous system
The autonomic nervous system (ANS) consists of the sympathetic 
nervous system (SNS), which stimulates “rest-and-digest” activities, 
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and the parasympathetic nervous system (PNS), which mobilizes the 
fight-or-flight response. In research, PNS activity is often measured 
through respiratory sinus arrhythmia (RSA) which is an index of heart 
rate variability (HRV).109 SNS activity can be measured through the pre-
ejection period (PEP) which is a widely used, valid index of sympathetic 
effects on cardiac contractility.110,111 Heart rate (HR) reflects the control of 
PNS and SNS on the heart.109,111
Based on animal research, BZDs were suggested to suppress 
(stress-induced) sympathetic activation by enhancing the sympatho-
inhibitory effects of GABA on presympathetic neurons in the PVN of 
the hypothalamus.112,113 Alternatively, BZDs have been hypothesized 
to enhance direct GABAergic inhibition of cardiac vagal neurons and 
GABAergic inhibition in the nucleus tractus solitarii and thereby decrease 
HRV.114 However, BZDs may also affect the ANS via GABA in other 
brain structures (such as nucleus ambiguous,115 caudal ventrolateral 
medulla,115 rostral ventrolateral medulla,115 medullary raphe nuclei116), 
as GABA is localized in many discrete autonomic centers of the brain. 
The above mentioned hypotheses have been investigated in short-
term intervention studies with humans with the following results. In 
line with the hypothesis that BZDs suppress SNS activity, BZDs were 
found to suppress stress-induced increases of sympathetic activity.117-119 
In contrast, in other research studies BZDs heightened sympathetic 
outflow,114 did not have any effects on the SNS120 or increased HR.114,121-125 
During rest, BZDs were either reported to decrease sympathetic tone126-128 
or not to have any effect at all.120,124,129,130 Corresponding to the hypothesis 
that BZDs have vagolytic effects, BZDs were commonly found to attenuate 
HRV114,121,122,124,125,131,132 and to increase HR.114,121-125 Only two studies 
reported elevated HRV128,133 and HR120 after BZD administration.
Opposite to intervention studies, observational research on the 
effects of BZDs on the ANS is less common. BZDs’ effects on the SNS 
activity have not been investigated yet. Regarding PNS activity, cross-
sectional research of our own group did not find significant differences 
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in HRV and HR between BZD users and non-users.109 The discrepancy of 
this finding with previous research may be due to the joint investigation 
of different types of BZDs with possibly opposing effects,128 which may 
have covered BZDs’ effects on the ANS in long-term users. Alternatively, 
only frequent BZD use or high BZD dosages may lead to alterations of 
ANS activity. Finally, long-term users may develop tolerance to the effects 
of BZDs on the ANS so that they no longer differ from non-users. 
As BZDs effects on the SNS as well as the potential effects of 
type of BZD, dosage, duration and frequency of BZD use on the ANS 
have not been studied previously, additional research is needed. Further, 
longitudinal research on BZDs effects on the ANS is eligible in order to 
validate cross-sectional results. 
PArt c) seDAtiVe AND AtteNtioN iMPAiriNG 
eFFects oF BZDs 
cognitive effects of BZDs in short-term and long-term Use
BZD use interferes with multiple cognitive functions. The most common 
problems of short-term BZD use are unintended subjective sedation134 
(e.g., sleepiness and mental slowness), objective sedation135 (e.g., 
cognitive processing speed and psychomotor slowing), inattention,136 and 
anterograde impairments of memory.136,137 Increased sedation and altered 
psychomotor skills impair everyday tasks such as driving or operating 
machinery.138 Therefore, BZD use increases the risk of (traffic) accidents, 
(workplace) injuries and falls with possibly resulting hip fractures.139 This 
risk rises at higher age and increased doses and when BZD are used 
concomitantly with alcohol.140,141
While the side effects of BZD use in short-term users are firmly 
established,136 research in chronic users is less frequent. The existent 
research revealed that tolerance to BZDs side effects seems to develop 
(differentially) over time.142 Memory deficits were found to persist in long-
term use on most memory tasks,142-144 indicating that tolerance to these 
24  |  CHAPTER 1
effects never fully develops. Tolerance to the subjective and objective 
sedative effects of BZDs was detected in long-term users142,144 and 
experimental research reported that tolerance began to develop already 
after two weeks of use. Other research studies found sustained attention 
impairments in chronic BZD users,145 but no impairments of simple 
reaction time.145
BZDs effects on objective sedation and attention impairments are 
often measured by ‘reaction time’ (RT),146,147 which is defined as the time 
interval between a sensory stimulus and response.148,149 Prolonged RTs 
in BZD users would indicate sedation or inattention or both.150 Only a 
few studies investigated the effects of long term use on RT and reported 
inconsistent results. One cross-sectional, observational study did not 
detect longer RTs in chronic BZD users as compared to healthy controls.151 
In contrast, another study found longer RTs in chronic BZD users with 
anxiety than in healthy non-users,150 but did not investigate whether the 
increased RTs were due to psychopathology or the use of BZDs.150 As 
psychopathology was found to increase RT in previous research, this may 
be the reason for the increased RT detected in this study. Consistently, 
a different study found longer RTs in depressed subjects (half of whom 
used BZDs) as compared to healthy volunteers.152 When analyses were 
repeated in the depressed group only, RTs did not differ between BZD-
users and non-users.152 This suggests that the increased RTs were due to 
psychopathology rather than BZD use. 
This longitudinal research has several limitations. Most studies 
investigated a small number142 of healthy volunteers153 for a duration 
shorter than three months153, although the majority of BZD users suffers 
from psychopathology and administers BZDs for a much longer duration 
of use. Further, these studies did not correct for established confounders 
of BZD use and RT (level of education, psychopathology,150,154 physical 
health150,152 and antidepressant use150). Therefore, observational research 
that investigates a large sample representative of the average BZD user 
(i.e. long duration of use, comorbid psychopathology) and corrects for 
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important confounders is needed in order to determine whether in long-
term BZD use the effects of BZD on RT remain or tolerance develops. 
PArt D) stUDieD sAMPLe AND oUtLiNe oF tHe 
tHesis 
the Netherlands study of Depression and Anxiety
The present thesis is based on a large depression and anxiety cohort: 
The Netherlands Study of Depression and Anxiety (NESDA). NESDA is 
an ongoing, multicenter, longitudinal, observational cohort study of 2981 
adults aged 18-65 years. The major aims of the NESDA study were: 1) 
describing the long-term prognosis of depression and anxiety disorders, 
2) examining the determinants and consequences of depression and 
anxiety disorders, and 3) evaluating patients’ expectations, evaluations 
and provision of mental health care and their association with the 
long-term course and consequences of these disorders.155 NESDA was 
designed to be representative of individuals with depressive and anxiety 
disorders in different health care settings and different developmental 
stages of illness.155 Therefore, subjects with no symptoms (‘controls’), 
those with earlier episodes or at risk, and those with current depression 
and/or anxiety disorders were recruited from two population studies 
(the ‘Adolescents at Risk of Anxiety and Depression’ study, n=261 and 
the ‘Netherlands Mental Health Survey and Incidence Study’ n=303), 
65 general practices (n=1610), and specialized mental health care 
institutions (n=807) throughout the Netherlands.155 The mean age of the 
study sample was 41.9 years at baseline (standard deviation [SD] = 13.0) 
and 66.4% was female.
The NESDA interviews were performed by trained interviewers and 
recorded on tape in order to secure quality of data. The baseline interview 
took place between 2004 and 2007, had a duration of 3 – 4 hours, and 
consisted of a blood draw, autonomic nervous system measurements, 
saliva sampling, a medical exam, an in-person interview, computer tasks, 
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and self-report questionnaires. The study protocol was approved by the 
ethical review board of each participating centre and all subjects signed 
an informed consent at the baseline assessment. A detailed description of 
the NESDA rationals, methods, and measures can be found elsewhere.155 
After two and four years, a face-to-face follow-up was conducted with 
a response of 87.1%.156 During this second measurement most of the 
baseline assessments were repeated.157
Benzodiazepine Use in NesDA
BZD use at baseline and follow-up (including z-drugs; anatomical 
therapeutic codes [ATC codes] N05BA, N05CD, N03AE01, and N05CF) 
was defined as having used BZDs (daily or less often) in the month prior to 
the baseline and follow-up interview respectively. BZD use was recorded 
by investigation of drug containers or self-report (if drug containers had 
been forgotten). Besides BZD use in general, five indicators of BZD use 
were investigated: type of BZD, frequency of BZD use, daily BZD dosage, 
duration of BZD use, and BZD dependence severity. 
Aim
The main questions of this thesis are:
1)  What are the correlates of BZD use in general, inappropriate use 
and dependence and what physician characteristics are associated 
with patient BZD use?
2)  Is long-term BZD use associated with alterations of the HPA axis 
or the ANS? 
3)  Is BZD use associated with prolonged RTs in chronic users?
outline of the thesis
The main objective of this thesis is to describe the epidemiology of long term 
BZD use as well as its long term consequences. This thesis is structured into 
three sections: In section one, the correlates of BZD use, new use, chronic 
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use, inappropriate use, and BZD dependence severity are investigated. The 
possible influence of the prescribing physicians on patient BZD use is also 
considered. In section two, the focus is on the physiological consequences 
of long-term BZDs use on the HPA axis and the ANS. In section three, 
cognitive effects of BZDs in long-term users are addressed.
Section 1
Chapter 2 describes the cross-sectional sociodemographic, psychological 
and physical correlates of BZD use and inappropriate BZD use.
Chapter 3 addresses the most important risk factors of initiated and 
continued BZD use during a two-year follow-up period.
Chapter 4 investigates the cross-sectional correlates of BZD dependence 
severity as measured with the Bendep-SRQ.58
Chapter 5 presents the general practitioner correlates of patient BZD use 
and inappropriate use. 
Section 2
Chapter 6 covers the cross-sectional association between chronic BZD 
use and various salivary cortisol measures. The question is 
whether tolerance to the cortisol suppressant effects of BZDs 
arises in long-term BZD use.
Chapter 7 explores the relationship between transitions in BZD use and 
changes on various autonomic nervous system measures during 
a two-year follow-up.
Section 3
Chapter 8 examines the association between long-term BZD use and 
reaction time as measured by the implicit association task (IAT)158 
during a two-year follow-up. We aimed to elucidate whether BZDs 
sedative and attention impairing effects remain or tolerance 
develops in long-term use. 
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ABstrAct
Aim: Results on correlates of benzodiazepine (BZD) use in general and 
inappropriate use were inconsistent and mostly univariate. The relative 
importance of sociodemographic, psychological and physical correlates 
has never been investigated in a comprehensive, multivariate model.
Methods: We included 429 BZD users and 2423 non-users from the 
Netherlands Study of Depression and Anxiety (NESDA) in order to 
investigate sociodemographic, psychological and physical correlates of 
BZD use and inappropriate use by logistic and linear regression analyses.
results: BZDs were used by a considerable proportion of the 
2852 NESDA participants (15.0%). BZD use was independently 
associated with older age, singleness, unemployment, treatment in 
secondary care, higher medical consumption, (more severe) anxiety, 
depression (OR[95%CI]=1.95[1.29,2.93]), comorbidity, insomnia, SSRI 
(OR[95%CI]=2.05[1.55,2.70]), TCA, and other antidepressant (OR[95% 
CI]=2.44[1.64,3.62]) use. Overall, BZD use was rarely in accordance 
with all guidelines, mainly because most users (82.5%) exceeded the 
recommended duration of safe use. Inappropriate use was independently 
associated with older age (β = 0.130) and chronic illnesses (β = 0.120). 
Higher scores on agreeableness were associated with less inappropriate 
use.
conclusions: Mentally or physically vulnerable subjects were most 
likely to use BZDs. The most vulnerable (i.e. old and physically ill) BZD 
users were at highest risk of inappropriate BZD use. Without further 
evidence of BZDs effectiveness in long-term use, caution in initiating BZD 
prescriptions is recommended, particularly when patients are chronically 
ill and old, as those are most likely to display inappropriate use. 
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iNtroDUctioN
Benzodiazepines (BZDs) are commonly prescribed as a treatment of anxiety 
and insomnia.2-5 Remarkably, BZDs are also inappropriately used for pain,6 
somatic illnesses,1 and less specific stress responses.7,8 Although there is 
still controversy about the potential for abuse, dependence, withdrawal 
symptoms, and side effect, prevalence rates of BZD use are high and 
vary between 7.5% and 21.3% across countries.9-12 Due to these high 
prevalence rates, it is informative to obtain a profile of the average BZD user. 
Specific subject characteristics such as sociodemographic factors (female 
sex,5,12-15 older age,3,5,12-16 lower education,14 and unemployment12,13,15), 
psychological characteristics (worse mental health,3,13,15-17 antidepressant 
use,13,18 and elevated neuroticism14,15,17) and physical health factors 
(chronic illnesses or other physical health problems,1,13-18 higher medical 
consumption,18 and pain complaints6) were found to be associated with 
BZD use in previous studies. A number of these variables,5,12,13 but not 
all,14,15,17 were identified as important correlates of BZD use in the majority 
of studies. Several studies did not look at the determinants independently 
by using a multivariate analysis3,5,14,17,18 and no joint investigation of all 
determinants has been conducted yet.
When BZDs are used as indicated, i.e. at standard therapeutic 
doses, during a short time period, and only one type of BZD at a time, 
treatment is usually without strong side effects.19 Inappropriate BZD 
use is accompanied by adverse health consequences including cognitive 
impairment, risk of falling, traffic accidents, and dependence.6,20-23 
Further, there is little evidence for the effectiveness of BZDs during 
chronic use.24 Therefore, several national and international guidelines 
were formed that – although showing some differences– all recommended 
a conservative practice of prescription, including short-term use.25-27 
However, more than 20 years after the notion that long-term BZD use 
should be discouraged, still more than 50% of current BZD users are 
chronic users (i.e., using BZDs for more than 3 months).12,28,29 To prevent 
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inappropriate use, it is important to determine which users become 
inappropriate users. To date, the determinants of inappropriate use 
have not been investigated. Only the determinants of long-term use have 
been studied, yet with inconsistent results and without considering the 
other aspects of inappropriate use (i.e., dosage and number of BZD types 
used). In those studies, sex,29-31 age,28-33 education,32 psychopathology,32-34 
physical health,30,33,34 pain complaints,34 daily BZD use,28 use of higher 
potency BZDs,31 and antidepressants33 were identified as correlates of 
long-term BZD use. 
To the best of our knowledge, we are the first study to investigate 
the relative importance of a comprehensive set of potential correlates 
of BZD use and inappropriate use in a study among 2852 subjects 
at various stages of psychopathology participating in the Netherlands 
Study of Depression and Anxiety (NESDA). We first explored the 
sociodemographic, psychological and physical correlates of BZD use. 




Subjects participated in the baseline assessment of the Netherlands 
Study of Depression and Anxiety (NESDA), an 8-year longitudinal cohort 
study of 2981 respondents aged 18 to 65 years.35 NESDA was designed to 
be representative of individuals with depressive and/or anxiety disorders 
in different health care settings and developmental stages of illness.35 
Psychiatric status did not seem to be predictive of the initial (non)-
response in the NESDA study. (Non)-response was driven by age and sex, 
i.e. older women more often participated in the NESDA study and young 
men less often.35 Subjects were recruited from the community, general 
practice and specialized mental health care institutions throughout the 
Netherlands. They completed a medical exam, an in-person interview, 
CORRELATES OF (INAPPROPRIATE) BENZODIAZEPINE USE: THE 
NETHERLANDS STUDY OF DEPRESSION AND ANXIETY (NESDA)  |  47
and several self-report questionnaires. The study protocol was approved 
by the Ethical Review Board of each participating centre and all subjects 
signed an informed consent at the baseline assessment. 
We excluded subjects with one or more missing values on BZD 
use, inappropriate use, sociodemographic, psychological or physical 
characteristics (n=94). An exception was made for missing values on the 
Insomnia Rating Scale (IRS) where mean imputation was used due to 
the high number of missings (n=300). We also excluded subjects with 
epilepsy (n=29), as epilepsy is an indication that justifies prolonged BZD 
use.36
To obtain an indication of the main correlates of BZD use (aim 
[1]), two groups were defined: subjects who reported BZD use in the 
month prior to the baseline interview (‘BZD users’, n=429) and those 
reporting no use of BZDs in the last month (‘non-users’, n=2423). For 
the investigation of appropriateness of BZD use (aim [2]) only BZD users 
were considered and further categorized according to appropriateness of 
BZD use.
Benzodiazepine Use
Two indicators of BZD use were investigated: BZD use and appropriateness 
of BZD use. 
BZD use during the month prior to baseline interview was 
registered by observation of drug containers brought to the interview 
(in 73.4% of cases) or self-report (in 26.6% of cases). Information was 
collected about name, dose, number of tablets, and duration of BZD use. 
Medication was coded according to the Anatomical Therapeutic Code/
Defined Daily Dose (ATC/DDD) system developed by the World Health 
Organization (WHO) collaborating Centre for Drug Statistics Methodology. 
BZDs were classified as ATC-coded groups N05BA, N05CD, N05CG, 
and N03AE01. The so called “Z-drugs”, of which in the Netherlands 
only zopiclone and zolpidem (ATC code N05CF) are available, were 
also included in our analyses, as studies on long-term adverse effects, 
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withdrawal and tolerance development for these drugs are still lacking. 
The daily BZD dose was computed according to the coding system of the 
ATC and DDD system.37 The Mean Daily Dose was calculated by dividing 
individual daily doses (in mg) of BZDs by the DDD for the particular 
BZD.38 For patients using BZDs other than diazepam, an equivalent 
daily dose was calculated with the conversion tables commonly used 
by general practitioners’ (GPs)39 and 10 mg of diazepam were regarded 
equivalent to 1 mg alprazolam, 10 mg bromazepam, 0.25 mg brotizolam, 
20mg clobazam, 20 mg chlordiazepoxide, 13.3 mg clorazepate, 8 mg 
clonazepam, 30 mg flurazepam, 1 mg loprazolam, 2 mg lorazepam, 1 mg 
lormetazepam, 7.5 mg midazolam, 10 mg nitrazepam, 33 mg oxazepam, 
20 mg prazepam, 20 mg temazepam, 20 mg zolpidem and 13 mg zopiclone. 
Dosages were summed when more than one BZD was used. Types of 
BZDs were subdivided into short acting (t1/2 < 24h) and long acting (t1/2 
≥ 24h) BZDs. Duration of use was categorized as short-term (≤ 3 months) 
or long-term (> 3 months). The number of different types of BZDs used 
was categorized into 1, 2, or 3. BZDs were further divided into anxiolytics 
(ATC code N05BA, n=263) and hypnotics (ATC codes N05CD and N05CF, 
n=147). 
Appropriateness of use was based on the Dutch practice guidelines 
for anxiety and insomnia26,27 and the British National Institute of Health 
and Clinical Excellence treatment guidelines for general practitioners.25 
The following criteria for appropriate use were derived: 
1. mean daily dosage ≤ DDD as defined by the WHO
2. duration of benzodiazepine use ≤ 3 months in case of no 
concomitant antidepressant (AD) use and ≤ 2 months in case of 
concomitant AD use
3. only one type of BZDs is used at a time 
Based on the number of appropriateness criteria not met by a subject, an 
inappropriateness score (range 0 – 3) was calculated. An inappropriateness 
score of 0 indicated that a subject met all three appropriateness criteria 
(i.e. appropriate use) whereas an inappropriateness score of 3 indicated 
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that none of the appropriateness criteria was met (i.e. highly inappropriate 
use).
Demographic, Psychological and Physical characteristics 
Based on previous studies, various potential correlates of BZD use 
and appropriateness of BZD use were included and grouped into: 
sociodemographic characteristics (age, gender, education, marital status, 
and work status), psychological characteristics (current psychopathology, 
health care setting, severity of anxiety or depression symptoms, insomnia, 
antidepressant use, and personality traits) and physical characteristics 
(number of chronic diseases, medical consumption; pain complaints, and 
smoking).5,12-15,29,32-34,40
Sociodemographic characteristics- Gender, age, education level (in 
years), work status (employed vs. unemployed), and partner status (living 
with partner vs. single) were reported in the baseline interview.
Psychological characteristics- In NESDA, depressive (dysthymia 
or Major Depressive Disorder, MDD) and anxiety (panic disorder with 
or without agoraphobia, generalized anxiety disorder or social phobia) 
diagnoses were measured by the Composite International Diagnostic 
Interview (CIDI, life time version 2.1), which classifies diagnoses according 
to the DSM-IV criteria. Current diagnoses were defined as those in 
the last year. The severity of generalized anxiety and panic symptoms 
were assessed with the Beck Anxiety Inventory (BAI).41 The presence of 
insomnia was determined using the Insomnia Rating Scale (IRS).42 The 
severity of depressive symptoms was measured by the cognitive/mood 
scale of the Inventory of Depressive Symptomatology Self Report (IDS-
SR).43 In order to avoid overlap with the BAI and IRS, we did not include 
the anxiety/arousal and sleep scales of the IDS-SR. So as to make the 
score of BAI, IDS-SR and IRS comparable, z-scores were calculated and z 
transformed values were used for regression analyses. Personality traits 
were assessed with the Neuroticism Extraversion Openness-Five Factor 
Inventory (NEO-FFI), a 60-item questionnaire measuring five personality 
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domains: neuroticism, extraversion, agreeableness, conscientiousness, 
and openness to experience.44 Antidepressant use was reported during 
the interview. The ATC-coded groups N06AA, N06AB, N06AF, N06AX and 
N06AG were classified as antidepressants. 
Physical characteristics - An inventory of somatic diseases was 
made by detailed questions of the presence of the following chronic 
illnesses: chronic lung disease, heart condition, diabetes mellitus, stroke, 
arthritis, rheumatism, cancer, hypertension, ulcer, intestinal problems, 
liver disease, chronic fatigue syndrome, allergy, thyroid gland, head injury 
or other injuries. Based on the number of chronic diseases a subject 
suffered from, a score ranging from 0 to 17 was calculated. Medical 
consumption was defined as the number of GP consultations in the six 
months prior to the interview, as assessed with the Perceived Need for 
Care Questionnaire (PNCQ).45 Pain complaints were measured with the 
Chronic Graded Pain Scale and pain severity (consisting of pain intensity 
and disability) was summarized by the Chronic Pain Grade according to 
Korff et al., which is a score ranging from 0 to 4.46 Smoking was reported 
during the interview. 
statistical Analyses
Sample characteristics and characteristics of BZD use were expressed 
by frequencies, means or medians, and compared using c2 statistics 
(for categorical variables), analysis of variance (ANOVA, for normally 
distributed, continuous variables), and Mann-Whitney U-test (for non-
normally distributed, continuous variables). Non-normally distributed 
values were naturally log transformed for regression analyses. 
Univariate logistic and linear regression analyses were carried out 
to identify correlates of BZD use (vs. non-use as the reference category) 
and inappropriate use (inappropriateness score ranging from 0-3). Odds 
ratios with 95% confidence intervals (OR [95 % CI]) and standardized betas 
(β) were provided as outcome measures. All independent variables with P 
< 0.10 in univariate analyses were entered in the multivariate regression 
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models. The P value was set at P < 0.10 (instead of P < 0.05) in order 
to avoid missing important determinants of BZD use that do not reach 
significance in univariate analysis at P < 0.05 but will when correcting 
for possible confounders in multivariate analyses. The following variables 
were considered: [1] demographic variables: gender, age, education 
level, work status, and partner status, [2] psychological characteristics: 
current psychopathology, health care setting, severity of anxiety and 
depression symptoms, insomnia, antidepressant use, and personality 
traits, [3] physical characteristics: number of chronic diseases, medical 
consumption, pain complaints and smoking. The analysis was adjusted 
for sex and age. Significance in the multivariate model was inferred at P 
<0.05.
Finally, we compared anxiolytic and hypnotic users on possible 
characteristics of BZD use using c2 statistics (for categorical variables), 
ANOVA (for normally distributed, continuous variables), and Mann-
Whitney U-test (for non-normally distributed, continuous variables) to 
find out whether there would be group differences. Significance was 
inferred at P < 0.05. All analyses were conducted with SPSS 16.0 for 
Windows.
resULts
characteristics of BZD Use
Of the 2852 subjects, 429 (15.0%) had used a BZD in the past month. 
Table 1 shows the sociodemographic, psychological, and physical 
characteristics of BZD users as compared to non-users. 
BZD users were older (mean 46.3 vs. 41.2 years, P<0.001), 
more likely to be single (36.4% versus 29.6%, P=0.005), and more likely 
to be unemployed (51.7% vs. 28.4%, P<0.001). Further, BZD users 
displayed worse physical (3.0 vs. 2.0 medical consumption, P<0.001) 
and psychological health (BAI score of mean 20.0 vs. 8.0 respectively, 
P<0.001). 
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Sex (% female) 66.1 68.1 0.43
Age (years) 41.2 (40.7 – 41.7) 46.3 (45.0 – 47.5) <0.001
Partner status (% single) 29.6 36.4 0.005
Employment status (% not working) 28.4 51.7 <0.001
Education level (years) 12.0 (10.0 – 15.0) 11.0 (9.0 – 15.0) <0.001
Treatment in secondary care (%) 24.2 49.0 <0.001
Physical health
Medical consumption 2.0 (1.0 – 3.0) 3.0 (2.0 – 5.0) <0.001
Chronic illnesses 1.8 (1.8 – 1.9) 2.5 (2.3 – 2.6) <0.001
Pain 1.5 (1.5 – 1.6) 2.1 (2.0 – 2.2) <0.001
Smoking (%) 28.9 24.2 0.05
Psychological characteristics 
Current Diagnosis (%) <0.001
MDD Only 15.1 17.5
Anxiety Only 14.6 18.2
Comorbid disorder 23.1 49.0
IRS 8.0 (4.0 – 10.0) 10.0 (8.0 – 15.0) <0.001
BAI 8.0 (3.0 – 16.0) 20.0 (10.0 – 28.0) <0.001
IDS-SR Mood/Cognition Scale 5.0 (2.0 – 11.0) 12.0 (6.0 – 16.5) <0.001





Neuroticism 23.5 (23.1 – 23.8) 28.7 (27.9 – 29.6) <0.001
Extraversion 25.4 (25.1 – 25.7) 21.8 (21.1 – 22.4) <0.001
Openness 26.4 (26.2 – 26.7) 25.3 (24.7 – 25.9) <0.001
Agreeableness 31.9 (31.7 – 32.1) 31.2 (30.7 – 31.7) 0.02
Conscientiousness 30.5 (30.2 – 30.7) 28.8 (28.2 – 29.3) <0.001
BAI indicates Beck’s anxiety index; IDS-SR indicates Inventory of Depressive Symptomatology; 
IRS indicates Insomnia Rating Scale: MDD indicates Major Depressive Disorder; SSRI indicates 
Selective Serotonin Reuptake Inhibitor; TCA indicates Tricyclic Antidepressant. Means (95% 
confidence intervals) are given for age, chronic illnesses, pain, and personality traits. Medians 
(interquartile range) are given for education level, medical consumption IRS, BAI, and IDS as 
these values are not normally distributed. Percentages are given for categorical variables. P is 
derived by analysis of variance (ANOVA) for quantitative, normally distributed variables, Mann 
Whitney U-test for continuous, non-normally distributed variables, or χ² statistics for categorical 
variables. Significance is inferred at P<0.10.
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Table 2 shows the effect of putative correlates of BZD use as opposed to 
non-use among all subjects. Univariate P values of these analyses are 
shown in Table 1 which comprises group comparisons conducted with 
ANOVAs. An ANOVA results in exactly the same P value as a regression 
analysis. 
In multivariate analyses, the following variables were significant 
correlates of BZD use: older age (OR=1.48), singleness (OR=1.34), 
unemployment (OR=1.56), treatment in secondary care (OR=1.55), higher 
medical consumption (OR=1.41), a diagnosis of depression (OR=1.56), 
anxiety (OR=1.95) and comorbidity (OR=1.78), higher scores on the IRS 
(OR=1.35) and BAI (OR=1.65) questionnaires, use of SSRIs (OR=2.05), 
TCAs (OR=1.84), and other antidepressants (OR=2.44).
In the comparison between anxiolytic and hypnotic users, groups 
were similar on most variables, except of the following: Anxiolytic users 
were younger (45.3 vs. 47.8, P=0.04), had more often a diagnosis of 
anxiety (25.2 vs. 14.9%, P=0.02), less often a diagnosis of depression 
(15.9 vs. 28.9%, P=0.009), had lower scores on insomnia (9.0 vs. 13.0, 
P≤0.001), and higher scores on agreeableness (31.8 vs. 30.5, P=0.02, 
data not shown). 
Appropriateness of BZD Use
In Table 3, we present the characteristics of BZD use among the 429 BZD 
users. The median daily dosage used was 2.5 mg of diazepam equivalents 
(interquartile range [IQR]: 0.7 – 6.0) and the median duration of BZD 
use was 24 months (IQR: 5.0 – 84.0). The most frequently used BZD was 
oxazepam (44.3%), followed by temazepam (14.9%), diazepam (14.7%) 
and alprazolam (6.1%). 
Only 17.5% of all BZD users took BZDs for the appropriate 
duration of three months whereas 82.5% of users took BZDs for a much 
longer period. The remaining appropriateness criteria were met more 
frequently. The majority of the BZD users (86.0%) did not exceed the 
recommended DDD as defined by the WHO and 84.4% of users had only 
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Sex (female) 1.09 (0.88 – 1.36) 0.43 1.09 (0.84 – 1.42) 0.53
Age (per 10 years) 1.34 (1.22 – 1.48) <0.001 1.48 (1.34 – 1.63) <0.001
Partner status (single) 1.36 (1.10 – 1.69) 0.005 1.34 (1.05 – 1.71) 0.02
Employment status (not working) 2.71 (2.20 – 3.33) <0.001 1.56 (1.22 – 1.99) <0.001
Education level (years) 0.30 (0.20 – 0.43) <0.001 0.89 (0.56 – 1.43) 0.64
Health care setting (secondary 
care)
3.00 (2.43 – 3.71) <0.001 1.55 (1.16 – 2.07) 0.003
Physical health
Medical consumption 2.39 (2.04 – 2.79) <0.001 1.41 (1.17 – 1.69) <0.001
Chronic illnesses 1.28 (1.20 – 1.35) <0.001 1.02 (0.95 – 1.11) 0.54
Pain 1.63 (1.49 – 1.79) <0.001 1.09 (0.97 – 1.23) 0.13
Smoking 0.79 (0.62 – 1.00) 0.05 0.96 (0.73 – 1.26) 0.77
Psychological characteristics 
Current Diagnosis 
MDD Only 1.19 (0.91 – 1.56) 0.21 1.56 (1.02 – 2.40) 0.04
Anxiety Only 1.30 (1.00 – 1.71) 0.06 1.95 (1.29 – 2.93) 0.001
Comorbid disorder 3.20 (2.59 – 3.95) <0.001 1.78 (1.17 – 2.70) 0.008
IRS 2.13 (1.85 – 2.45) <0.001 1.35 (1.16 – 1.56) 0.001
BAI 2.72 (2.37 – 3.13) <0.001 1.65 (1.34 – 2.03) <0.001
IDS-SR Mood/Cognition Scale 2.29 (2.00 – 2.62) <0.001 0.90 (0.72 – 1.13) 0.36
Antidepressant use (past month)
SSRI 3.27 (2.60 – 4.12) <0.001 2.05 (1.55 – 2.70) <0.001
TCA 3.06 (1.88 – 4.98) <0.001 1.84 (1.07– 3.16) 0.03
Others 3.74 (2.67 – 5.24) <0.001 2.44 (1.64 – 3.62) <0.001
Personality Characteristics
Neuroticism 1.07 (1.06 – 1.08) <0.001 0.99 (0.97 – 1.02) 0.61
Extraversion 0.93 (0.92 – 0.95) <0.001 1.00 (0.98 – 1.02) 0.78
Openness 0.97 (0.95 – 0.99) <0.001 0.99 (0.97 – 1.01) 0.29
Agreeableness 0.98 (0.96 – 1.00) 0.02 1.01 (0.99 – 1.04) 0.26
Conscientiousness 0.96 (0.94 – 0.97) <0.001 1.00 (0.98 – 1.02) 0.92
BAI indicates Beck’s anxiety index; IDS indicates Inventory of Depressive Symptomatology; IRS 
indicates Insomnis Rating Scale; MDD indicates Major Depressive Disorder; SSRI indicates 
Selective Serotonin Reuptake Inhibitor; TCA indicates Tricyclic Antidepressant. All variables with 
P<0.10 in univariate analyses are entered in the multivariate model. Significance is inferred at P 
< 0.05 in the multivariate model.*: The P values are optained by univariate analyses. ** : The P 
values are obtained by multivariate analyses. 
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Short acting (%, t1/2 < 24h)  81.1
Long acting (%, t1/2  ≥ 24h) 18.9
Mean daily dose (mg / day)1 2.5 (0.7 – 6.0)
Duration of use (months) 24.0 (5.0 – 84.0) 
Daily BZD use (%) 38.5
Number of different types of BZDs used concomitantly (%)
1            84.4
2 14.0
3 1.6








Mean Daily Dose/ DDD2 ≤ 1(%) 86.0
Duration of use ≤ 3 months (%) 17.5






1Expressed as diazepam equivalents, 2 DDD indicates defined daily dose (DDD for diazepam: 
10 mg / day), 3 an appropriateness score of 0 indicates that all appropriateness criteria are 
met (appropriate use), an appropriateness score of 3 indicates that none of the criteria is met 
(inappropriate use)
Median (interquartile range) is given for mean daily dose and duration of use. Percentages are 
given for categorical variables.
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Sex (female) -0.003 0.96 0.018 0.72
Age (years) 0.153 0.001 0.130 0.008
Partner status (single) 0.065 0.18
Employment status (not working) 0.114 0.02 0.073 0.14
Education level (years) -0.078 0.11




Medical consumption -0.043 0.37





MDD Only -0.067 0.16
Anxiety Only -0.028 0.56
Comorbid disorder 0.060 0.21
IRS  0.013 0.79
BAI 0.075 0.12
IDS-SR Mood/Cognition Scale 0.076 0.12
Personality Characteristics
Neuroticism 0.008 0.87
Extraversion -0.113 0.02 -0.043 0.40
Openness -0.098 0.04 -0.065 0.18
Agreeableness -0.126 0.009 -0.111 0.03
Conscientiousness -0.017 0.73
BAI indicates Beck’s anxiety index; IDS-SR indicates Inventory of Depressive Symptomatology 
Self Report; IRS indicates Insomnia Rating Scale; MDD indicates Major Depressive 
Disorder; SSRI indicates Selective Serotonin Reuptake Inhibitor; TCA indicates Tricyclic 
Antidepressant.1 Inappropriate BZD use is calculated with an inappropriateness score. 
An inappropriateness score of 0 indicates that all appropriateness criteria are met, an 
inappropriateness score of 3 indicates that none of the criteria is met. All variables with 
P < 0.10 are entered in the multivariate model. Significance in the multivariate analysis is 
inferred at P < 0.05.
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a prescription for one type of BZD at a time. However, mainly due to 
the high duration of BZD use of most users, only 15.2% of BZD users 
met all three appropriateness criteria, whereas 64.3% met two criteria, 
13.8% met one and 6.8% of users did not meet any criterion (highly 
inappropriate use). 
Table 4 shows the effect of potential correlates of inappropriate 
BZD use among all BZD users. Age (β = 0.130) and chronic illnesses (β = 
0.120) were significantly associated with higher inappropriate BZD use. 
Higher scores on agreeableness were associated with lower inappropriate 
use (β = -0.111).
DiscUssioN
BZDs were used by a considerable proportion of the 2852 NESDA 
participants (15.0%). BZD use was independently associated with older 
age, singleness, unemployment, treatment in secondary care, high 
medical consumption, (more severe) anxiety, depression, comorbidity, 
(more severe) insomnia, and antidepressant use. Inappropriate BZD use 
was independently associated with older age and chronic illnesses. High 
scores on agreeableness were associated with less inappropriate use. 
Overall, BZD use was rarely in accordance with all guidelines, mainly 
because most users (82.5%) exceeded the recommended maximum 
duration for safe use. 
Although the uncritical enthusiasm about BZD use is over since 
many decades,30,47,48 BZDs are still not only used for the treatment of 
severe insomnia and anxiety (other than epilepsy), but also to alleviate 
stress caused by adverse life circumstances such as unemployment49 
as well as pain6 and other somatic complaints.1 Largely corresponding 
to earlier findings, our results show that mainly the physically 
and mentally more vulnerable, e.g., the old,5,13,29 unemployed,12,13,15 
psychologically,3,13,15-17,32-34 and physically14,18,34 ill subjects are using BZDs 
and use these BZDs inappropriately. There seems to be a tendency from 
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relatively invulnerable subjects being non-users, mildly vulnerable being 
users and highly vulnerable being inappropriate users. Consistently, 
vulnerable subjects reported lower perceived support50,51,52 as well as 
more maladaptive coping strategies18,32,50-53 and were found to display 
more emotional arousal when facing stressful events as compared to less 
vulnerable subjects.49 They might substitute those deficits by BZDs49,52 
and be more likely to ask their medical doctors (MDs) for tranquillizers 
to alleviate their distress. MDs themselves might also be more likely 
to prescribe BZDs to vulnerable subjects as compared with all other 
problems those people have due to unemployment, chronic illnesses 
and psychopathology, BZD use seems to be the least concerning issue. 
A number of qualitative research studies investigated the prescription 
habits of MDs and found that the majority of questioned MDs were aware 
of the guidelines54,55 and supported conservative prescription practice of 
BZDs.54 A reported reason for prescribing nonetheless was feeling poorly 
equipped to solve the emotional problems of their troubled patients,56 
but wanting to alleviate their distress55 and maintain a good doctor- 
patient relationship.54,55 If MDs received more (psychological) education 
on how to communicate their reasons for declining prescriptions to the 
patients, they might prescribe less and initiate BZD discontinuation more 
often.54,56,57 
As could be expected, anxiolytic BZDs were more often used 
in cases of anxiety disorders, and hypnotic BZDs more often in cases 
of insomnia. However, it also seems that the drugs are insufficient to 
provide therapeutic relief as otherwise lower anxiety and insomnia scores 
were to be expected in the respective groups. Group differences on age 
and agreeableness were unexpected and difficult to explain.
In general, the high percentage of inappropriate users in NESDA is 
disconcerting. The majority (84.8%) of users did not use BZDs according 
to international guidelines,25-27 mainly due to exceeding the maximum 
duration of recommended use. This is striking considering that for 
more than 20 years BZDs have been known to cause side effects and 
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dependence and evidence for the drug’s effectiveness in long-term use 
is controversial.7,8 In addition, several NESDA subjects surpassed the 
recommended daily dosage (14.0%) and used more than one type of BZD 
concomitantly (15.6%). Dosage escalation is generally unsafe, as side 
effects become more pronounced and can have adverse consequences 
ranging from low performance at work to falls and traffic accidents.6,20-22 
BZDs should be reserved for the severely anxious who have tried AD 
medication with no effect and have BZDs as last treatment option. 
However, BZD prescriptions cannot be discontinued without providing 
patients with alternative coping strategies. Training should be conducted 
to strengthen BZD users’ coping skills,11,58 self-efficacy and positive 
outcome expectations11 and to lessen their disengagement beliefs11 as such 
efforts may increase the chance of successful BZD discontinuation.11,58 In 
spite of all objections and in view of the restricted financial resources in 
the health sector, it is clear that prescribing BZDs takes less time than 
providing psychological support.7,55 Therefore, BZD use should be targeted 
with relatively quick and cheap methods that have been developed (e.g., 
computer-tailored education,11 discontinuation letters59) and found to 
increase effectively BZD cessation rates.11,59
The present study has some limitations. The cross-sectional design 
does not allow us to make causal inferences on whether determinants 
preceded BZD use or vice versa. Although participants were asked to 
bring drug containers to the interview, one fourth of the subjects did not 
adhere to that and reported medication use from memory leading to a 
potential recall bias. The 84.8% inappropriate user number is probably 
an overestimation, as long-term users were more likely to be included 
in the user group than short-term users due to the cross-sectional 
design. A strong aspect of our study is the conductance of a multivariate 
analysis across a comprehensive set of possible determinants of BZD 
use. Furthermore, we included all aspects of inappropriate BZD use in a 
large sample composed of subjects with a range of psychopathology. 
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In conclusion, this study revealed three major points: 1) the vast majority 
of NESDA subjects displayed inappropriate BZD use, mainly due to 
exceeding the maximum duration of recommended use; 2) it is primarily 
the physically or mentally vulnerable subjects who use BZDs, and 3) the 
most physically ill of the BZD users are at highest risk for inappropriate 
use. Without further evidence for the effectiveness of BZDs in long-term 
use, caution in initiating BZD prescriptions is recommended, particularly 
when patients are chronically ill and old, as these subjects are most likely 
to display inappropriate use. 
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ABstrAct
Background: Longitudinal research on determinants of initiated and 
continued benzodiazepine (BZD) use is inconsistent and has identified 
many possible determinants. It is unclear which of those are most 
important in the prediction of BZD use. We aimed to identify the most 
important predictors of initiated and continued BZD use. Therefore, we 
analyzed the most consistently identified determinants from previous 
research plus some new determinants. 
Method: We identified baseline and 2-year longitudinal predictors of 
initiated BZD use (vs nonuse) among 2205 baseline BZD nonusers, 
and of continued use (vs discontinued use) among 369 baseline BZD 
users in the Netherlands Study of Depression and Anxiety using logistic 
regression analyses. 
results: During follow-up, BZD use was initiated by 4.9% of BZD 
nonusers at baseline. Initiated use was predicted by insomnia (odds ratio 
[OR]=1.60), enduring anxiety symptoms (OR=2.02), entering secondary 
care during follow-up (OR=2.85), and past BZD use (OR=3.57). Positive 
life events during follow-up reduced the likelihood of BZD initiation 
(OR=0.76). Of BZD users at baseline, 54.2% continued use during the 
entire follow-up period. Continuation of BZD use was predicted by higher 
age (OR=1.03), severe anxiety (OR=1.85), and a long duration of BZD use 
(OR=1.54). Leaving secondary care was associated with less continued 
BZD use (OR=0.29).
conclusion: Insomnia and anxiety were the main risk factors of initiated 
use, whereas advanced age and anxiety severity were the main risk 
factors of continued use. Gender, education, pain, and physical health 
seemed to be less important. 
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iNtroDUctioN
Benzodiazepines (BZDs) are an effective short-term treatment option 
for symptoms of anxiety and insomnia.1-3 Although BZDs are often the 
indicated treatment,4 they are also inappropriately used for psychosocial 
problems,5 pain,6 and somatic complaints.3,7 As BZDs are associated 
with dose- and concentration related side effects and physiological 
dependence,1,3,8 guidelines advise short-term use.4,9,10 Still, many BZD 
users are long-term users.6 The existence of chronic and inappropriate 
BZD prescriptions call for the identification of risk factors of initiation 
and continuation of BZD use. 
Cross-sectional research has identified many correlates of BZD 
use, but could not establish the temporal order of events.11 Longitudinal 
analyses permit to establish the order of events and to identify true risk 
factors of BZD use. In longitudinal studies, initiated BZD use was predicted 
by female gender,12 older age,12 divorce,12 psychopathology,13 insomnia,14 
alcohol abuse,13 antidepressant use,13 smoking,14 poor physical health,14 
and joint pain.14 Continued BZD use was predicted by older age,14 female 
gender,15 divorce,15 psychopathology,16 poor health,17 pain,14 number of 
GP contacts,15 insomnia,15 a history of BZD use,17 daily BZD use,18 use of 
higher potency BZDs,19 long duration of BZD use,20 high BZD dosage,20 
and hypnotic use.20 Living alone was associated with a decreased risk of 
continued BZD use.14 However, findings are inconsistent across studies, 
possibly due to the investigation of only a few determinants per study,12 
distinct definitions of the outcome variable (psychotropic use,12 BZD 
use,18 onset of use,16 onset of chronic use14), dissimilar data collection 
(pharmacy databases,18 self-report 21), differing study samples (all ages,22 
old subjects 5) and included determinants. Thus, it remains unclear which 
of the above mentioned predictors are most important in the prediction of 
BZD use. Additionally, the associations of course of psychopathology and 
life events with BZD use have not been studied in longitudinal research 
yet.
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We aimed to identify the (most important) independent risk factors of 
initiated BZD use and continued BZD use during a 2-year follow-
up period. Therefore, we included the above described previously 
investigated predictors of BZD use and several not previously investigated 
determinants (e.g., course of psychopathology and life events) in order to 
investigate which variables would fall off (and thus be less relevant) and 
which would remain significant in the a multivariate model.
MAteriALs AND MetHoDs
subjects
Subjects participated in the baseline and 2-year assessment of the 
Netherlands Study of Depression and Anxiety (NESDA), an ongoing 
8-year longitudinal cohort study of 2981 respondents aged 18 through 
65 years.23 NESDA was designed to be representative of individuals with 
depressive and/or anxiety disorders in different health care settings and 
developmental stages of illness. Therefore, subjects with no symptoms 
(“controls”), those with earlier episodes or at risk, and those with a 
depressive or anxiety disorder were recruited from the community, general 
practices and specialized mental health care institutions throughout the 
Netherlands.23 The baseline assessment included a medical exam, an in-
person interview, and self-report questionnaires.23 The study protocol was 
approved by the Ethical Review Board of each participating center and all 
subjects signed an informed consent at the baseline assessment.23 After 
2 years, a face-to-face follow-up was conducted.24 Data from baseline and 
follow-up were used in this analysis. We excluded subjects with lacking 
follow-up data (n=385) and those with epilepsy (n=22), as epilepsy can 
be an indication for long-term BZD use.25 Missing data were imputed by 
the mean for 4.2 % of data points. Imputation did not importantly change 
our results. After exclusion, 2574 subjects remained and comprised the 
sample of the following analyses. 
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To identify the determinants of initiated BZD use, only subjects who did 
not use BZDs at baseline were included (n=2205). They were divided into 
subjects who initiated BZD use in the time interval between baseline 
and follow-up (“initiated use”, n=103) and those who did not (“nonuse”, 
n=2102). For the investigation of continued BZD use, only subjects who 
used BZDs at baseline were included (n=369) and divided into subjects 
who still reported BZD use at follow-up (“continued use”, n=200) and 
subjects who had discontinued use between baseline and follow-up 
(“discontinued use”, n=169). 
MeAsUres
BZD Use
BZD use at baseline/follow-up (including z-drugs; Anatomical Therapeutic 
Codes [ATC codes] N05BA, N05CD, N03AE01 and N05CF26) was defined 
as having used BZDs (daily or less often) in the month before the baseline/
follow-up interview. It was registered by observation of drug containers 
brought to the interview (in 74.3% of cases) or self-report. Information was 
collected about name, dose, number of tablets, frequency and duration 
of BZD use.11
Possible Determinants of initiated and continued BZD Use
To extract a set of the most important determinants of initiated and 
continued BZD use, the following variables were selected:
1) baseline characteristics (sociodemographic, physical, and 
psychological characteristics),
2) characteristics of BZD use (daily use, dosage, duration, half-life, 
number of different BZDs, and dependence), and
3) longitudinal characteristics (duration of psychopathology 
symptoms during follow-up, life events during follow-up, changes 
in treatment setting, insomnia, and chronic illnesses).
72  |  CHAPTER 3
Baseline characteristics and characteristics of BZD use had been 
investigated in the past whereas no previous research has studied the 
above mentioned longitudinal characteristics of BZD use. 
Baseline Characteristics
Sociodemographic characteristics. Gender, age, education level (in years), 
work status (employed, retired/working in household, unemployed/sick 
leave/disabled), partner status (partner, single, widowed/divorced), and 
living status (living together with at least 1 person versus living alone) 
were reported in the baseline interview.
Psychological characteristics. Six-months depressive and anxiety 
disorders were measured by the Composite International Diagnostic 
Interview (life time version 2.1) at baseline, which classifies diagnoses 
according to the Diagnostic and Statistical Manual of Mental Disorders, 
Fourth Edition criteria. Severity of anxiety symptoms was assessed with 
the Beck Anxiety Inventory.27 The presence of insomnia was determined 
using the Insomnia Rating Scale.28 The severity of depressive symptoms 
was measured by the cognitive/mood scale of the Inventory of Depressive 
Symptomatology Self Report.29 Locus of control was assessed by a 5-item 
mastery scale.30 Personality traits were assessed with the Neuroticism 
Extraversion Openness-Five Factor Inventory.31 Antidepressant use 
(with ATC codes N06AA, N06AB, N06AF, N06AX or N06AG) was reported 
during the interview. 
Physical characteristics. An inventory of somatic diseases was 
made by counting the number of chronic illnesses a subject experienced 
at the baseline assessment.11 The number of GP consultations in the 
6 months before baseline assessment was assessed with the trimbos/
iMTA questionnaire for costs associated with psychiatric illness.32 
Pain complaints were measured with the Chronic Graded Pain Scale.33 
Smoking was reported during the interview. Alcohol dependence was 
assessed with the corresponding Composite International Diagnostic 
Interview section.34 
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Characteristics of BZD Use at Baseline
As characteristics of use were associated with continued use in previous 
research,18,19 mean daily dose, frequency of use, half-life, number of 
different types of BZDs used, and BZD dependency were included as 
possible predictors of continued BZD use.11 
Longitudinal Characteristics (Measured During the 2-year Follow-Up)
Duration of psychopathology symptoms. The percentage of time during 
follow-up with symptoms of at least mild severity was calculated using 
the Life Chart Interview.35 Three categories were established: 1) no 
anxiety/depressive symptoms during follow-up, 2) less than half of 
follow-up anxiety/depressive symptoms, and 3) more than half of follow-
up anxiety/depressive symptoms.
Life events. The incidence of 12 negative life events during follow-
up was assessed with the List of Threatening Events Questionnaire.36 
The List of Threatening Events Questionnaire was extended by 7 items 
referring to positive life events: (1) “immediate family member recovered 
from serious illness”, (2) “met a new partner”, (3) “became friends”, (4) “have 
been on holiday”, (5) “new job or important promotion”, (6) “education 
completed”, and (7) “be better off financially”. Numbers of negative and 
positive life events during the follow-up period were summed separately 
in order to derive separate measures for the number of negative and 
positive life events.
Other longitudinal measures. Severity of insomnia and number of 
chronic illnesses at follow-up were assessed using similar methods as at 
baseline. For insomnia severity and chronic illnesses a change score was 
calculated by subtracting the baseline value from the follow-up value. 
A higher score indicated worsening of illnesses/insomnia from baseline 
to follow-up and vice versa. Treatment setting (primary vs secondary 
care) was established at baseline and follow-up. Transitions in treatment 
setting were divided in 4 categories: 1) primary care only, 2) entry of 
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secondary care during follow-up, 3) exit of secondary care during follow-
up, and 4) secondary care only. 
stAtisticAL ANALYses
Sample characteristics were expressed by frequencies or means and 
compared using c2 statistics and analysis of variance (ANOVA). Univariate 
logistic regression analyses were carried out to identify predictors of 
initiated BZD use (vs nonuse [reference]) among baseline BZD nonusers 
and continued use (vs discontinued use [reference]) among baseline 
BZD users. Variables with P < 0.10 in univariate analyses were entered 
in the multivariate regression models. In these analyses, baseline 
characteristics, longitudinal characteristics and characteristics of BZD 
use (only for analysis of continued use, except of history of BZD use 
which was only entered in the analysis of initiated use) were considered. 
All analyses were adjusted for gender and age. Analyses were conducted 
with SPSS 16.0 for Windows. Significance was inferred at P < 0.05. 
resULts
BZD Use
The prevalence rates of BZD use at baseline and follow-up were 14.3% 
and 11.8%, respectively. During follow-up, 4.9% of nonusers initiated 
BZD use. Of the BZD (n=369) users at baseline, 54.2% continued use 
during the entire follow-up period. At baseline, there were 135 daily BZD 
users and 234 infrequent users, of whom 49.1% used BZDs as needed. At 
follow-up, there were 89 daily users and 214 infrequent users, of whom 
59.3% used as needed. Short-acting BZDs were most often used, with on 
average 20.7% using long-acting BZDs at baseline and follow-up. 
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Predictors of initiated BZD Use 
Table 1 shows the baseline and longitudinal characteristics of baseline 
nonusers who initiated BZD use in the follow-up period (4.6%) or remained 
nonusers. In multivariate analyses, higher baseline insomnia (OR=1.60), 
anxiety symptoms for more than half of the follow-up time (OR=2.02), 
entering secondary care during follow-up (OR=2.85), and past BZD use 
(OR=3.57) were independent predictors of initiated BZD use. A higher 
number of positive life events experienced during follow-up decreased the 
probability of BZD use initiation (OR per positive life event=0.76). 
Predictors of continued BZD Use
In Table 2, we present the characteristics of subjects who continued BZD 
use (n=200) as compared with those who discontinued BZD use (n=169) 
as investigated in subjects who were using BZDs at baseline (n=369). 
In multivariate analyses, older age (OR per year=1.03), higher anxiety 
severity (OR per Beck Anxiety Inventory point=1.85), and a longer duration 
of BZD use at baseline (OR per month=1.54) predicted the continuation 
of BZD use. Leaving secondary care treatment during the follow-up time 
was associated with a lower OR of continued BZD use (OR=0.29). 
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tABLe 1. Baseline and Longitudinal Characteristics of Nonusers (at Baseline) 










Sex (% female) 65.9 64.1 0.71 0.81 (0.51-1.27) 0.35
Age (years) 41.2 (40.6-41.7) 44.3 (41.8-46.9) 0.02 1.01 (0.99-1.03) 0.50
Partner status (%)
Current partner 70.6 62.1 0.12
No current partner 21.3 25.2
Widowed / divorced 8.0 12.6
Living status (% alone) 27.2 33.0 0.20
Employment status (%) 0.005
Employed 64.6 49.5
Pension/housewife 3.6 6.8 2.25 (0.88-5.78) 0.09
Unemployed / sick 31.8 43.7 1.23 (0.78-1.96) 0.38
Education level (years) 14.1 (14.0-14.2) 13.3 (12.8-14.0) 0.02 0.73 (0.29-1.84) 0.51
Physical health
Medical consumption 3.9 (3.8-3.9) 4.3 (4.0-4.7) 0.02 0.85 (0.54-1.33) 0.47
Chronic illnesses 3.5 (3.4-3.6) 3.9 (3.6-4.2) 0.005 1.12 (0.60-2.06) 0.73
Pain 3.4 (3.3-3.4) 3.8 (3.6-4.0) <0.001 1.79 (0.75-4.29) 0.19
Smoking (%) 29.6 28.2 0.75
Alcohol dependence (%) 26.2 32.0 0.19
Psychological Characteristics 
Six months diagnosis (%) <0.001
No diagnosis 53.3 27.2
MDD only 14.1 12.6 0.81 (0.36-1.84) 0.61
Anxiety only 15.0 26.2 1.56 (0.79-3.09) 0.20
Comorbid disorder 17.6 34.0 1.01 (0.40-2.56) 0.98
Insomnia rating scale 8.3 (8.1-8.5) 11.3 (10.2-12.5) <0.001 1.60 (1.17-2.18) 0.003
Beck Anxiety Inventory 8.8 (8.5-9.1) 14.0 (12.0-16.5) <0.001 1.07 (0.74-1.54) 0.72
IDS Mood/Cognition 
Scale 
6.5 (6.3-6.8) 9.2 (8.0-10.6) <0.001 0.87 (0.59-1.29) 0.49
Locus of control 17.9 (17.7-18.0) 16.1 (15.3-16.9) <0.001 1.16 (0.87-1.55) 0.31
Antidepressant use (%) 17.2 32.0 <0.001 1.43 (0.87-2.37) 0.16
Past BZD use (%) 12.6 44.7 <0.001 3.57 (2.26-5.63) <0.001
Personality Characteristics
Neuroticism 22.6 (22.2-23.0) 27.1 (25.2-28.9) <0.001 1.11 (0.79-1.55) 0.56
Extraversion 25.5 (25.2-25.8) 22.7 (21.2-24.3) <0.001 1.01 (0.76-1.35) 0.92
Openness 26.3 (26.1-26.6) 26.4 (25.1-27.6) 0.98
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Agreeableness 31.7 (31.4-31.9) 31.9 (30.7-33.0) 0.78
Conscientiousness 30.3 (30.0-30.6) 28.8 (27.5-30.1) 0.03 0.97 (0.76-1.24) 0.79
Longitudinal characteristics
Follow-up time anxiety symptoms (%) <0.001
No anxiety symptoms 55.8 29.1
(Less than) half of 
time symptoms
18.7 18.4 1.23 (0.64-2.38) 0.53
More than half of 
time symptoms
25.5 52.4 2.02 (1.14-3.56) 0.02




(Less than) half of 
time symptoms
4.6 5.8 1.74 (0.66-4.56) 0.26
More than half of 
time symptoms
38.3 56.3 0.94 (0.55-1.62) 0.83
Life Events
Number positive life 
events
2.0 (2.0-2.1) 1.6 (1.3-1.8) <0.001 0.76 (0.61-0.95) 0.01
Number negative life 
events 
2.2 (2.1-2.3) 2.4 (2.1-2.7) 0.15
Switch of treatment setting (%) <0.001
Always primary care 72.8 46.6
Exit secondary care 7.2 8.7 1.23 (0.53-2.85)) 0.64
Entry secondary care 5.0 13.6 2.85 (1.38-5.90) 0.005
Always secondary 
care
15.0 31.1 1.70 (0.92-3.16) 0.09
Change number chronic 
illnesses
-0.4 (-0.4- -0.3) -0.5 (-0.7 - -0.3) 0.30
Change Insomnia Rat-
ing scale
-1.4 (-1.6 – 1.2) -2.4 (-3.3 - -1.5) 0.04 1.02 (0.97-1.07) 0.53
BZD indicates benzodiazepine; IDS indicates Inventory of Depressive Symptomatology; MDD 
indicates Major Depressive Disorder; OR indicates odds ratio, CI indicates confidence interval. 
Means (95% confidence intervals) are given for age, personality traits, negative life events, positive 
life events, change in chronic illnesses, and change in insomnia rating scale. Geometric means 
(95% CI) based on estimated marginal means and calculated by analysis of variance (ANOVA), 
are presented for education, medical consumption, chronic illnesses, pain, Insomnia Rating 
Scale, Beck Anxiety Inventory, and IDS Mood / Cognition Scale as these values are not normally 
distributed. Percentages are given for categorical variables. *P is derived by ANOVA for quantitative 
variables or χ² statistics for categorical variables. ** P is derived by multivariate logistic regression. 
All variables with P < 0.10 in univariate analyses are entered into the multivariate regression 
model. The analysis is corrected for sex, age and previous BZD use. Significance is inferred at P 
< 0.05
table 1. continued
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tABLe 2. Baseline and Longitudinal Characteristics of Users (at Baseline) Who 





P * Multivariate or 





Sex (% female) 63.3 71.0 0.12 1.28 (0.75-2.18) 0.37
Age (years) 43.2 (41.5-44.9) 49.0 (47.4-50.5) <0.001 1.03 (1.01-1.06) 0.02
Partner status (%)
Current Partner 66.9 61.0 0.07
No current partner 23.1 20.5 1.53 (0.81-2.89) 0.19
Widowed/divorced 10.1 18.5 1.76 (0.83-3.69) 0.14
Living status (% alone) 32.0 36.5 0.36
Employment status (%) 0.03
Employed 49.1 35.5
Pension/housewife 4.1 4.5 1.14 (0.33-3.90) 0.83
Unemployed/sick 46.7 60.0 1.45 (0.86-2.45) 0.16
Education level (years) 13.5 (13.0-14.1) 12.5 (12.1-13.0) 0.003 0.62 (0.23-1.67) 0.35
Physical health
Medical consumption 5.2 (4.8-5.7) 5.5 (5.1-6.0) 0.43
Chronic illnesses 4.0 (3.7-4.2) 4.3 (4.1-4.6) 0.03 0.70 (0.35-1.39) 0.31
Pain 3.8 (3.7-4.0) 4.0 (3.8-4.1) 0.19
Smoking (%) 27.8 22.0 0.20
Alcohol dependence (%) 26.0 28.5 0.60
Psychological Characteristics 
Six months diagnosis (%) 0.61
No diagnosis 20.1 18.0
MDD only 18.9 16.0
Anxiety only 21.3 19.5
Comorbid disorder 39.6 46.5
Insomnia rating scale 11.4 (10.6-12.3) 12.2 (11.4-13.0) 0.21
Beck Anxiety Inventory 15.2 (13.7-16.8) 19.0 (17.2-20.9) 0.002 1.85 (1.28-2.69) 0.001
IDS Mood/Cognition 
Scale 
10.4 (9.4-11.5) 11.5 (10.5-12.6) 0.14
Locus of control 15.6 (14.9-16.2) 15.0 (14.4-15.6) 0.19
Antidepressant use (%) 45.0 45.5 0.92
Personality Characteristics
Neuroticism 28.0 (26.7-29.2) 28.7 (27.6-29.9) 0.37
Extraversion 22.1 (21.1-23.2) 21.7 (20.7-22.6) 0.50
Openness  25.6 (24.6-26.6) 25.0 (24.0-25.9) 0.34
Agreeableness 31.1 (30.2-31.9) 31.7 (30.9-32.5) 0.31
Conscientiousness 29.0 (28.0-30.0) 29.0 (28.1-29.9) 0.95
Characteristics of BZD use
Long half-life (%) 17.8 20.0 0.58
Mean daily dose 
(mg/day)1
4.4 (3.9-4.9) 5.6 (5.0-6.2) 0.001 1.04 (0.63-1.71) 0.89
Duration of use 
(months)
16.3 (13.3-20.1) 40.9 (33.9-49.4) <0.001 1.54 (1.26-1.87) <0.001
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Daily BZD use (%) 28.7 44.0 0.001 1.83 (0.89-3.74) 0.10
Number of different 
types of BZDs used 
concomitantly
3.1 (3.1-3.2) 3.1 (3.1-3.2) 0.42
Benzodiazepine Dependence
Problematic Use 9.0 (8.6-9.4) 9.7 (9.3-10.1) 0.02 1.09 (0.96-1.24) 0.20
Preoccupation 12.0 (11.5-12.6) 13.4 (12.9-13.9) 0.001 1.04 (0.90-1.19) 0.53
Lack of Compliance 8.7 (8.9.0) 9.4 (9.1-9.6) 0.003 1.05 (0.94-1.18) 0.40
Longitudinal characteristics




(Less than) half of 
time symptoms
17.8 19.5 1.39 (0.69-2.80) 0.36
More than half of 
time symptoms
39.6 50.5 1.21 (0.66-2.21) 0.54




(Less than) half of 
time symptoms
2.4 4.0




Number of positive 
life events
1.8 (1.7-2.0) 1.7 (1.5-1.8) 0.17
Number of negative 
life events 
2.4 (2.1-2.6) 2.6 (2.4-2.9) 0.21
Switch of treatment setting (%) 0.03
Always primary care 37.9 50.5
Exit secondary care 16.0 9.0 0.29 (0.13-0.66) 0.003
Entry secondary 
care
5.3 7.0 0.73 (0.26-2.09) 0.56
Always secondary 
care
40.8 33.5 0.65 (0.34-1.23) 0.19
Change number  
chronic illnesses
-0.4 (-0.6 - -0.2) -0.4 (-0.6 - -0.2) 0.82
Change Insomnia  
Rating scale
-3.8 (-4.7 - -2.9) -2.2 (-3.0 - -1.3) 0.009 1.03 (0.99 – 1.08) 0.14
BZD indicates benzodiazepine; IDS indicates Inventory of Depressive Symptomatology; MDD indicates 
Major Depressive Disorder; OR indicates odds ratio; CI indicates confidence interval. Means (95% 
CIs) are given for age, personality characteristics chronic illnesses, pain, personality traits, change in 
number of chronic illnesses, and change in insomnia rating scale, problematic use, and preoccupation. 
Geometric means (95% confidence intervals) based on estimated marginal means, calculated by analysis 
of variance, are presented for education, medical  consumption, chronic illnesses, pain, Insomnia Rating 
Scale, Beck Anxiety Inventory, IDS, daily dosage, duration of  use, number of different types of BZDs, 
and lack of compliance as these values are not normally distributed. Percentages are given for categorical 
variables. *P is derived by analysis of variance for quantitative variables or χ² statistics for categorical 
variables. ** P is derived by multivariate logistic regression. All variables with P < 0.10 in univariate 
analyses are entered into the multivariate regression model. The analysis is corrected for sex, age and 
previous BZD use. Significance is inferred at P < 0.05.
table 2. continued
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DiscUssioN
This longitudinal cohort study aimed to identify the most important 
predictors of initiated and continued BZD use. In the multivariate model, 
which included the most consistently identified predictors of BZD use 
from previous research plus a number of not previously investigated 
determinants, the following variables appeared to be most important. 
Initiated BZD use (in nonusers at baseline) was more likely in subjects with 
insomnia, who had enduring anxiety symptoms, who entered secondary 
care, and who had used BZDs in the past. It was less likely in subjects 
who experienced a higher number of positive life events. Continued BZD 
use (among baseline BZD users) was more likely in older subjects with 
more severe anxiety and a long baseline duration of BZD use, but less 
likely in subjects who left secondary care during follow-up. 
Regarding the initiation of BZD use, we confirmed previous 
research, which found that subjects with a history of BZD use were more 
likely to re-start BZD use due to withdrawal symptoms or a new episode of 
psychopathology.37 Furthermore, it was consistent with earlier studies21 
that anxiety and insomnia predicted initiated BZD use and were probably 
the main reasons to issue new BZD prescriptions. However, the following 
4 insights were new: 1) Mainly, subjects who were anxious most of the 
2-year follow-up time initiated BZD use, indicating that a short duration 
of anxiety does not necessarily lead to BZD use. 2) Positive life events 
were associated with less initiation of BZD use, possibly by alleviation of 
emotional distress both directly and by buffering the adverse consequences 
of negative life events.38 3) Entry of secondary care increased the likelihood 
that BZDs were initiated. This might be due to the necessity of adding 
BZDs to the treatment regime in patients who were referred to secondary 
care because of unsuccessful primary care treatment. 4) Gender, age, 
marital status, alcohol abuse, antidepressant use, smoking, physical 
health, and pain were no independent determinants of initiated BZD use 
in the current model, although they were in previous research.12-14 As we 
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corrected for a broad set of important confounders in our multivariate 
model, it seems that insomnia, enduring anxiety symptoms, entry into 
secondary care, and BZD use in the past were more important predictors 
for the initiation of BZD use than these variables were. 
Regarding continuation of BZD use, we confirmed previous 
research that older age,14 more severe anxiety,16 and a longer duration 
of BZD use in the past17 were important predictors. Yet, the following 2 
findings were new: 1) As compared with primary care patients, subjects 
who left secondary care during follow-up were more likely to discontinue 
BZD use, possibly because their mental health status had improved. 
However, secondary care treatment remained an independent predictor 
in our model even after adjustment for severity of psychopathology. 2) 
Continued BZD use was not predicted by gender, marital status, health, 
pain, living status, GP contacts, insomnia, daily BZD use, potency of 
BZD, duration of use, BZD dosage, and hypnotic use in our multivariate 
model, although these variables were important determinants in previous 
research.14,15,17,20 Again, as we corrected for a broad set of important 
confounders in our multivariate model, it seems that severe anxiety, a 
long baseline duration of BZD use and leaving secondary care during 
follow-up were more important in the explanation of continuation of BZD 
use than above described variables were.
Our study had several limitations. Because of the medium sized 
BZD user group and large number of determinants tested, the power of our 
study was limited and we were not able to investigate subgroups of users. 
Furthermore, although participants were asked to bring drug containers 
to the interview, one fourth of the subjects did not do so. This might have 
introduced recall bias and some error. Finally, we could not include all 
previously investigated determinants as some of these were not included 
in the NESDA study (i.e., stress12 and life satisfaction21). This paper is 
limited to subject characteristics and does not include interactions with 
prescribers who also may influence BZD use. There were also several 
strengths to our study. We were able to include the most consistently 
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identified determinants of BZD use from cross-sectional and longitudinal 
research as well as a number of never investigated longitudinal variables 
in a comprehensive multivariate model. That enabled us to identify the 
most important independent determinants of initiated and continued 
BZD use.
In conclusion, this study revealed that insomnia and anxiety were 
the main reasons for initiated BZD use, whereas older age and anxiety 
were the main reason for continued BZD use. Gender, education, pain, 
and physical health appeared to be less important. 
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ABstrAct
Aims: Benzodiazepines (BZDs) are effective on the short-term against 
anxiety and insomnia. However, some BZD users develop BZD dependence 
after a relatively short period of time. Therefore, we aimed to identify the 
risk factors of BZD dependence. 
Design: An observational cohort study. 
setting: The Netherlands. 
Participants: Four hundred one BZD users (13.5%) of the 2,981 
participants of the Netherlands Study of Depression and Anxiety (NESDA) 
were included. 
Measurements: Sociodemographic, physical, psychological, addiction 
related, and BZD use related characteristics were investigated as 
possible correlates of BZD dependence severity. Dependence severity 
was measured by the three subscales of the Benzodiazepine Self-Report 
Questionnaire, which are Problematic Use, Preoccupation, and Lack of 
compliance. 
Findings: In multivariate analyses, Problematic Use was associated with 
more GP contacts in the past six months (β= 0.170, p=0.001) and severity 
of insomnia (β= 0.145, P=0.004). Preoccupation was related with anxiety 
severity (β= 0.194, P=0.001), antidepressant use (β= 0.197, P<0.001), 
alcohol dependence (β= 0.185, P<0.001), and a higher daily dosage of 
BZD (β= 0.160, P=0.001). Lack of compliance was associated with higher 
age (β= 0.122, P=0.03), unemployment (β= 0.105, P=0.04), insomnia (β= 
0.129, P=0.01), antidepressant use (β= 0.148, P=0.002), and alcohol 
dependence (β= 0.108, P=0.02). 
conclusions: Insomnia, antidepressant use and alcohol dependence may 
increase the risk of BZD dependence among individuals who use BZDs. 
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iNtroDUctioN
Benzodiazepines (BZDs) are effective on the short-term against anxiety 
and insomnia.1 Long-term use is associated with the development of 
tolerance2,3 even at therapeutic dosages.4 Interestingly, some subjects 
cease BZD use after a relatively short period of time, while others do not,5 
possibly, due to the development of BZD dependence.6 The identification 
of risk factors of dependence severity would allow physicians to prevent 
BZD dependence in some cases.
BZD dependence was found to be associated with sociodemo-
graphic factors (female sex,7 lower age,8 non-Dutch cultural origin,8 
lower education,8 and retirement8), psychological and psychiatric 
factors (depression,8-11 anxiety,7-10 antidepressant use,12 hostility,8 less 
difficulties to obtain help for emotional problems,7 and lower quality 
of life9), physical factors (somatization11), addiction related factors 
(treatment for dependence,8 drug use10), and BZD use related factors (a 
high daily dosage,8,12 long-term BZD use,8,12 short half-life of BZDs,8 and 
concomitant use of several BZDs8).
However, correlates identified in some studies were not significant 
in others, possibly due to the following reasons. First, previous studies 
reporting on BZD dependence used very different patient samples. The 
included patient samples consisted of community-dwelling seniors 
with a relatively low percentage of psychiatric diagnoses,13 long-
term BZD users who participated in a BZD reduction trial,11 patients 
on buprenorphine maintenance treatment for opiate dependence,9,14 
psychiatric outpatients,8 club drug users who also abused psychoactive 
prescription medication,10 and subjects from addiction centers13. While 
in some studies a large percentage suffered from substance disorder8 or 
psychiatric disorders13, others excluded subjects with a substance abuse 
disorder or those who received treatment for psychiatric disorders11. 
Second, most studies were restricted to sociodemographic, psychological 
and BZD use-related correlates and thus did not include all important 
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variables in one multivariate model.9,13 Third, the studies applied 
different definitions of BZD dependence or just investigated aspects of 
BZD dependence (dependence,7,8,12 abuse or dependence,9 addiction, 
withdrawal, craving11).15 Most of the studies applied dichotomous (yes/
no) definitions of dependence,7,9 while the clinical expression of BZD 
dependence is better modeled using several subscales15 and stages of 
severity14. 
The Benzodiazepine Dependence Self-Report Questionnaire 
(Bendep-SRQ) has been developed to take severity and subscales into 
account. The Bendep-SRQ describes severity of BZD dependence by 
means of three subscales: (awareness of the own) problematic use, 
preoccupation (with the availability of BZDs), and lack of compliance 
(with the therapeutic regime).16 These subscales reflect psychological, 
physiological, and social aspects of BZD dependence and have been 
validated by psychiatrists, general practitioners, and self-help patients.16 
Only one previous study has investigated the correlates of these 
three subscales of dependence severity.8 Lower age, depressive disorder, 
duration and dosage of BZD use were associated with higher scores on 
problematic use.8 Anxiety disorder, a short half-life of the BZD and a 
longer duration of BZD use were associated with more preoccupation.8 
Lower age, retirement, duration of BZD use and a higher dosage were 
associated with more lack of compliance.8 Being an outpatient in a 
substance addiction center was associated with higher scores on all 
three subscales.8 However, this study did not examine the impact of some 
potential physical (chronic illnesses, pain, and GP visits) and addiction-
related (alcohol dependence, and tobacco dependence) variables although 
they might very well be of importance. 
This study aimed to determine the independent cross-sectional 
correlates of BZD dependence severity. We included sociodemographic, 
psychological, physical, addiction-related, and BZD use-related factors in 
an extensive multivariate model. We used three subscales of the Bendep-
SRQ to measure severity of BZD dependence.16-18 
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MAteriALs AND MetHoDs
subjects
Subjects participated in the baseline assessment of the Netherlands 
Study of Depression and Anxiety (NESDA), a longitudinal cohort study of 
2981 adults aged 18-65 years. NESDA was designed to be representative 
of individuals with depressive and/or anxiety disorders in different 
health care settings and developmental stages of illness. Subjects were 
recruited from the community, general practice and specialized mental 
health care institutions throughout the Netherlands. Primary care 
patients were recruited from 65 general practitioners by a three-stage 
screening procedure. A questionnaire was sent to a random sample of 
23,750 patients to screen for affective and anxiety disorders. The screen-
positives were approached for a phone interview to confirm the diagnoses. 
Finally, 743 participants with a six months diagnosis, 353 participants 
with a remitted diagnosis and 141 subjects with subshreshold symptoms 
were included. Additionally, 373 participants with a screen-negative score 
participated as control group.19,20 Regarding specialized mental health 
care, each newly enrolled patient at the participating outpatient clinics 
participated in a standardized intake. The clinic staff submitted 1,597 
patients with primary depressive or anxiety disorder for inclusion. After 
exclusion of subjects who did not fulfill inclusion criteria, could not be 
reached or refused participation, a final sample of 807 subjects remained. 
At the baseline assessment, all subjects completed a medical exam, an 
in-person interview, and several self-report questionnaires. The study 
protocol was approved by the ethical review boards of all participating 
centers, and all subjects gave written informed consent.19 A more detailed 
description can be found in Penninx et al. (2008).19
To determine the independent predictors of BZD dependence 
severity, only BZD users (n=462) were included. As dependence severity 
was the outcome variable of our analyses, BZD users who had not 
completed the Bendep-SRQ were excluded (n=61). BZD users who had 
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filled in the Bendep-SRQ did not differ significantly from those who 
had not filled in the questionnaire in terms of gender, age, education, 
and severity of insomnia, anxiety and depression. After exclusion, 401 
subjects were available for analysis. 
Assessment of BZD Use and BZD Dependence 
BZD use in the month prior to the baseline interview was registered by 
observation of drug-containers brought to the interview (73.6%) or by self-
report. Information was collected about name, dose, frequency, number of 
tablets, and duration of BZD use. The medication was coded according to 
the Anatomical Therapeutic Code/Defined Daily Dose (ATC/DDD) system 
developed by the World Health Organization (WHO) collaborating Centre 
for Drug Statistics Methodology.21 The Mean Daily Dose was calculated 
by dividing individual daily doses (in milligrams) of BZDs by the DDD for 
the particular BZD.22 For BZDs other than diazepam, an equivalent daily 
dose was calculated.23 Dosages were summed when more than one kind 
of BZD was used. Kinds of BZDs were subdivided into short acting and 
long acting types of BZDs. Duration of use was recorded in months.22
In order to assess the severity of dependence on BZDs, the 
Bendep-SRQ was used.18 This questionnaire showed good validity in 
outpatient settings, and has been used to measure BZD dependence in 
many previous research studies.16-18,22 We measured three subscales of the 
Bendep-SRQ reflecting separate subscales of dependence (5 items each): 
1) awareness of problematic use, 2) preoccupation with the availability 
of BZDs, and 3) lack of compliance with the therapeutic regimen. All 
subscales showed good reliability and validity and convincingly met the 
requirements of the Rasch model.18 Each item of the Bendep-SRQ had 5 
possible answers ranging from 1‘this is totally not true for me’ to 5 ‘this 
is totally true for me’. To derive a total score for each 5-item subscale, 
scores for the individual items per subscale were summed yielding a 
score ranging from 5 to 25. 
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Vulnerability Factors of BZD Dependence
Five groups of vulnerability factors were assessed based on previous 
literature concerning BZD dependence: 1) sociodemographic factors, 2) 
psychological factors, 3) physical factors, 4) addiction related factors, and 
5) factors related to the use of BZDs.7-9,11-12 Detailed information about 
these variables and their assessment can be found elsewhere.19
In short, sociodemographic factors were reported during the 
baseline interview and included gender, age, Northern European 
ancestry (yes, no), education (in years), employment status (employed, 
unemployed, pension/housewife), and partner status (current partner, 
no partner, divorced/widowed). 
Psychological factors included the severity of the depression 
and anxiety symptoms, insomnia, personality traits, mastery, and 
antidepressant use (yes/no). Severity of depressive symptoms was 
measured by the cognitive/mood scale of the Inventory of Depressive 
Symptomatology Self Report (IDS-SR), a 30-item self report scale.24 The 
severity of generalized anxiety and panic symptoms at baseline was 
assessed with the Beck Anxiety Inventory (BAI).25 The presence of insomnia 
was determined using the Insomnia Rating Scale (IRS).26 Personality 
traits were assessed with the Neuroticism Extraversion Openness-Five 
Factor Inventory (NEO-FFI).27 Locus of control or mastery was assessed 
with the 5-item version of the Pearlin Mastery Scale.28 Antidepressant 
use was reported during the interview and classified as selective 
serotonin reuptake inhibitors ( SSRIs; ATC codes N06AB02-N06AB10), 
tricyclic antidepressants (TCAs; ATC codes N06AA01-N06AA23), and 
other antidepressants including tetracyclic antidepressants, serotonin-
norepinephrine reuptake inhibitors, and trazodone (ATC codes N06AX05, 
N06AX11, N06AX16, and N06AX21).
Physical factors included the number of chronic somatic 
illnesses, medical consumption in the last 6 months and level of pain. 
An inventory of chronic somatic diseases was made by detailed questions 
on the presence of chronic illnesses such as chronic lung disease and 
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heart condition. Medical consumption was defined as the number of 
GP consultations in the six months prior to the baseline interview, as 
assessed with the Perceived Need for Care Questionnaire (PNCQ).29 Pain 
complaints were measured with the Chronic Graded Pain Scale (consisting 
of pain intensity and disability).30
Addiction related vulnerability factors were the level of dependence 
on nicotine, a life time diagnosis of alcohol abuse or alcohol dependence, 
and illicit drug use. Illicit drug use in the month before the baseline 
interview (cannabis, ecstasy, speed, cocaine, heroin, LSD) was reported 
during the baseline interview. Nicotine dependence among smoking 
subjects was measured with the Fagerström questionnaire.31 Life time 
diagnoses of alcohol abuse and dependence according to DSM-IV criteria 
were assessed by the Composite International Diagnostic Interview (CIDI, 
life time version 2.1).32
statistical Analyses
Sample characteristics and characteristics of BZD use were expressed 
by percentages, means (and standard deviations) for positively skewed 
variables or medians (and interquartile ranges) for non-normally 
distributed variables. 
The non-normally distributed Bendep subscale ‘lack of compliance’ 
was naturally log transformed for regression analyses. Separate univariate 
linear regression analyses were carried out to identify the determinants 
of 1) problematic BZD use 2) preoccupation with availability of BZDs and 
3) lack of compliance to the therapeutic regime. All independent variables 
with P<0.10 in univariate analyses were entered into the multivariate 
regression analyses in order to determine the independent correlates 
of BZD dependence severity as measured with the three subscales. The 
above mentioned sociodemographic, psychological, physical, addiction 
related, and BZD use related vulnerability factors were entered as 
possible correlates of BZD dependence. All variables with P<0.05 in the 
multivariate models were considered statistically significant. The frequent 
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BZD users ( > 50% of all days in the past month, n=201) were analyzed 
separately in sensitivity analyses. All analyses were conducted with SPSS 
17.0 for Windows.
resULts
characteristics of the study Group
Of the investigated 401 BZD users, 158 subjects used BZDs on a 
daily basis (39.4%), 43 (10.7%) used BZDs more than 50% of all days 
in the past month, 88 subjects (21.9%) used BZDs less than 50% of 
all days in the past month, and 112 (27.9%) used BZDs when needed. 
The sociodemographic-, psychological-, physical-, and addiction-related 
characteristics of the 401 BZD users are shown in Table 1. BZD users 
were mainly female (69.6%), had a mean age of 46.0 years, and often 
had a current partner (62.8%). Pure depression disorder (15.5%), pure 
anxiety disorder (18.7%) or comorbid depression and anxiety disorder 
(51.4%) were commonly present and 53.4% of the BZD users also used 
antidepressants. Approximately one fourth of the BZD users had a 
lifetime diagnosis of either alcohol dependence or abuse. As for the three 
subscales of BZD dependence severity, the BZD users scored highest on 
the Bendep-SRQ subscale preoccupation, followed by problematic use 
and lack of compliance. The mean duration of BZD use was 24.0 months 
and the average daily dose was 2.8 mg diazepam equivalents per day. 
Problematic Use
Univariate and multivariate correlates of problematic use are shown 
in Table 2. In multivariate analyses, more GP contacts in the past six 
months (β= 0.170; P=0.001), severity of insomnia (β= 0.145; P=0.004), 
and antidepressant use (β= 0.108; P=0.02) were associated with more 
problematic use. There were no independent sociodemographic and 
addiction related characteristics of problematic use. When analyses 
were repeated in frequent BZD users only (data not shown), the betas of 
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GP contacts in the last six months (β=0.266) and more severe insomnia 
remained comparable (β=0.138). Only the beta of antidepressant use 
decreased in strength in the frequent user group only.
Preoccupation
In multivariate analyses (Table 3), higher scores on the BAI (β= 0.194; 
P=0.001), antidepressant use (β= 0.197; P≤0.001), alcohol dependence 
(β= 0.185; P≤0.001), and a higher daily dosage of BZDs (β= 0.160; 
P=0.001) were associated with higher scores on preoccupation. No 
sociodemographic and physical characteristics were associated with 
preoccupation. When frequent users were analyzed separately, severity of 
anxiety (β =0.250) and alcohol dependence (β =0.217) remained important 
correlates. Antidepressant use (β =0.061) and dosage of BZD use (β 
=0.099) lost relevance in the frequent user group. Severity of depression 
was negatively associated with preoccupation in the frequent users only 
(β =-0.272), but not in the whole group (β =-0.054).
Lack of compliance
In the multivariate model (Table 4), higher age (β= 0.122; P=0.03), 
unemployment due to sickness or disability (β= 0.105; P=0.04), more severe 
insomnia (β= 0.129; P=0.01), antidepressant use (β= 0.148; P=0.002), and 
alcohol dependence (β= 0.108; P=0.02) were associated with more lack 
of compliance. No physical characteristics were associated with of lack 
of compliance. When frequent BZD users were analyzed separately, the 
betas of unemployment (β=0.186), severity of insomnia (β=0.140), alcohol 
dependence (β=0.118), and antidepressant use (β=0.111) remained 
comparable while the beta of age decreased. In contrast, mastery (β=- 
0.240) and pain (β=0.231) had higher betas in the frequent user group 
only than in the whole group.
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tABLe 1. Characteristics of 401 BZD Users and their BZD Use
sociodemographic characteristics
Sex (female, %) 69.6









Education level in years 11.0 (9.0 – 15.0) 
North European ancestry (%) 95.3
Physical vulnerability factors
Number medical contacts 6 months 3.3 (2.0 – 5.0)
Number chronic illnesses 2.0 (1.0 – 4.0)
Severity of pain 2.0 (1.0 – 3.0)
Psychological vulnerability factors 




Mastery Scale 15.0 (12.0 – 18.0)
BAI Questionnaire 20.0 (10.0 – 28.0)
Insomnia Rating Scale 10.0 (8.0 – 15.0)
IDS Questionnaire 12.0 (7.0 – 16.0)








Fagerström Questionnaire 3.0 (0.0 – 3.9)
Alcohol dependence (%) 19.7
Alcohol abuse (%) 9.0
Drug use past month (%) 6.2
Bendep-srQ subscales
Problematic use 9.6 (3.1)
Preoccupation 13.0 (4.2)
Lack of compliance 7.0 (5.0 – 9.0)
characteristics of BZD use 
Type of BZD
Short acting (% t1/2 < 24h)  79.6
Long acting (% t1/2 > 24h)  20.4
Daily BZD use (%) 39.4
Daily dose (mg/day)* 2.8 (0.7 – 6.0)
Duration of use (months) 24.0(5.0 – 96.0)







BZD indicates benzodiazepine; GP indicates general practitioner; IDS indicates Inventory of Depressive 
Symptomatology; BAI indicates Beck Anxiety Questionnaire; MDD indicates Major Depressive Disorder. 
Bendep-SRQ indicates Bendep Self-Report-Questionnaire. Means (standard deviation) are given for age, 
personality characteristics, Problematic Use and Preoccupation. Medians (interquartile range) are given 
for education level, medical consumption, number of chronic illnesses, pain, mastery, IRS, BAI, IDS, 
Fagerström, Lack of Compliance, duration of BZD use, and daily BZD dose as these values are not 
normally distributed. Percentages are given for categorical variables. *Expressed as diazepam equivalents
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β P* β P**
sociodemographic characteristics
Sex (female) 0.010 0.84
Age (years) -0.046 0.36
Partner status
No partner 0.010 0.85
Widowed/divorced 0.050 0.32
Employment status 
Unemployed/sickness/disabled 0.201 <0.001 0.064 0.21
Pension/housewife -0.084 0.09 0.026 0.60
Education level (years) -0.196 <0.001 -0.088 0.07
Northern European ancestry -0.070 0.16
Physical vulnerability factors
GP contacts last 6 months 0.294 <0.001 0.170 0.001
Chronic illnesses 0.145 0.004 0.018 0.72
Pain 0.226 <0.001 0.006 0.91
Psychological vulnerability factors
Mastery Scale -0.199 <0.001 -0.081 0.12
BAI Questionnaire 0.315 <0.001 0.088 0.14
Insomnia Rating Scale 0.227 <0.001 0.145 0.004
IDS Questionnaire 0.311 <0.001 0.062 0.40
Antidepressant use 0.177 <0.001 0.108 0.02
Personality Characteristics 
Neuroticism  0.269 <0.001 0.074 0.27
Extraversion -0.096 0.05 0.107 0.06
Openness -0.105 0.04 -0.028 0.56
Agreeableness -0.106 0.04 -0.004 0.94
Conscientiousness -0.112 0.03 0.025 0.64
Addiction related vulnerability factors
  Fagerström Questionnaire 0.123 0.01 0.032 0.51
  Alcohol dependence 0.108 0.03 0.076 0.10
  Alcohol abuse -0.007 0.89
Drug use past month 0.033 0.51
characteristics of BZD use
Long half life 0.046 0.36
Duration of use (in months) 0.018 0.72
Daily Dosage in diazepam equivalents 0.183 <0.001 0.082 0.09
BZD indicates benzodiazepine; GP indicates general practitioner; BAI indicates Beck Anxiety 
Inventory; IDS indicates Inventory of Depressive Symptomatology. All correlates with P<0.10 
are included in multivariate analyses. Correlates with P<0.05 in multivariate analyses were 
considered as statistically significant. *P values are obtained by univariate regression analyses. ** 
P values are obtained by multivariate regression analyses.
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β P* β P**
sociodemographic characteristics
Sex (female) -0.033 0.51
Age (years) 0.067 0.18
Partner status
No partner -0.030 0.55
Widowed/divorced 0.016 0.74
Employment status 
Unemployed/sickness/disabled 0.148 0.003 0.041 0.41
Pension/housewife -0.065 0.20 0.034 0.48
Education level in years -0.102 0.04 -0.045 0.34
Northern European ancestry -0.009 0.85
Physical vulnerability factors
GP contacts last 6 months 0.151 0.002 0.069 0.16
Chronic illnesses 0.047 0.35
Pain 0.103 0.04 -0.056 0.28
Psychological vulnerability factors
Mastery Scale -0.163 0.001 -0.044 0.38
BAI Questionnaire 0.301 <0.001 0.194 0.001
Insomnia Rating Scale 0.044 0.38
IDS Questionnaire 0.236 <0.001 -0.054 0.45
Antidepressant use 0.272 <0.001 0.197 <0.001
Personality Characteristics 
Neuroticism  0.245 <0.001 0.090 0.17
Extraversion -0.158 0.002 0.004 0.94
Openness -0.035 0.48
Agreeableness -0.054 0.28
Conscientiousness -0.116 0.02 0.035 0.51
Addiction related vulnerability factors
  Fagerström Questionnaire 0.074 0.14
  Alcohol dependence 0.230 <0.001 0.185 <0.001
  Alcohol abuse -0.062 0.22
Drug use past month -0.036 0.47
characteristics of BZD use
Long half life -0.001 0.99
Duration of use (in months) 0.075 0.13
Daily Dosage in diazepam equivalents 0.267 <0.001 0.160 0.001
BZD indicates benzodiazepine; GP indicates general practitioner; BAI indicates Beck Anxiety 
Inventory; IDS indicates Inventory of Depressive Symptomatology. All correlates with P<0.10 
are included in multivariate analyses. Correlates with P<0.05 in multivariate analyses were 
considered as statistically significant. *P values are obtained by univariate regression analyses. ** 
P values are obtained by multivariate regression analyses.
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β P* β P**
sociodemographic characteristics
Sex (female) -0.003 0.95
Age (years) 0.171 0.001 0.122 0.03
Partner status
No partner -0.049 0.32 -0.005 0.92
Widowed/divorced 0.088 0.08 0.023 0.64
Employment status 
Unemployed/sickness/disabled 0.234 <0.001 0.105 0.04
Pension/housewife -0.014 0.78 0.042 0.40
Education level in years -0.204 <0.001 -0.078 0.12
Northern European ancestry 0.059 0.24
Physical vulnerability factors
GP contacts last 6 months 0.149 0.003 0.013 0.80
Chronic illnesses 0.183 <0.001 0.022 0.67
Pain 0.222 0.003 0.104 0.06
Psychological vulnerability factors
Mastery Scale -0.187 <0.001 -0.086 0.10
BAI Questionnaire 0.190 <0.001 -0.064 0.29
Insomnia Rating Scale 0.229 <0.001 0.129 0.01
IDS Questionnaire 0.298 <0.001 0.136 0.07
Antidepressant use 0.199 <0.001 0.148 0.002
Personality Characteristics 
Neuroticism  0.205 <0.001 0.047 0.50
Extraversion -0.170 0.001 0.052 0.36
Openness -0.153 0.002 -0.077 0.11
Agreeableness -0.099 0.048 0.022 0.66
Conscientiousness -0.137 0.006 0.002 0.97
Addiction related vulnerability factors
  Fagerström Questionnaire 0.108 0.03 0.028 0.56
  Alcohol dependence 0.143 0.004 0.108 0.02
  Alcohol abuse -0.057 0.26
Drug use past month 0.041 0.42
characteristics of BZD use
Long half life 0.120 0.02 0.055 0.24
Duration of use (in months) 0.131 0.009 0.069 0.17
Daily Dosage in diazepam equivalents 0.205 <0.001 0.054 0.28
BZD indicates benzodiazepine; GP indicates general practitioner; BAI indicates Beck Anxiety 
Inventory; IDS indicates Inventory of Depressive Symptomatology. All correlates with P<0.10 
are included in multivariate analyses. Correlates with P<0.05 in multivariate analyses were 
considered as statistically significant. *P values are obtained by univariate regression analyses. ** 
P values are obtained by multivariate regression analyses.
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DiscUssioN
This study investigated a large set of potential correlates of problematic 
use, preoccupation, and lack of compliance as indicators of BZD 
dependence in 401 BZD users. Problematic use was independently 
associated with more GP contacts, antidepressant use and higher 
severity of insomnia. Preoccupation was independently associated with 
anxiety severity, antidepressant use, alcohol dependence, and a higher 
daily dosage of BZDs. Lack of compliance was independently associated 
with higher age, unemployment, insomnia, antidepressant use, and 
alcohol dependence. The following paragraphs will discuss each of the 
three subscales separately.
High scores on problematic use implied that users were aware of the 
negative impact of BZDs on their lives, thought about discontinuing, and 
felt BZDs became less effective in symptom reduction.16 It is noteworthy 
that severe insomnia was associated with higher scores on problematic 
use although BZDs are actually prescribed to lessen insomnia. Further, it 
is remarkable that subjects were aware of the apparent ineffectiveness of 
BZDs as well as of their problematic use, but were unable to discontinue 
BZDs, possibly due to the fear that symptoms might worsen.4,33-34 GP 
visits as a correlate of problematic use is in line with previous research 
reporting a negative association between embarrassment to obtain help 
and BZD dependence.13 Subjects who visit their GPs more often may be 
more likely to become dependent on BZDs (as more BZD prescriptions 
are issued). With respect to awareness of problematic use, it may also 
indicate that GPs call their patients’ attention on the problems associated 
with their BZD use. Alternatively, subjects may have been sicker, more in 
need of GP consultations, and thus more vulnerable to problematic use. 
Subjects with high scores on preoccupation with BZDs became 
nervous when they did not carry their drugs with them and were 
generally very concerned with BZDs.16 The association between anxiety 
and preoccupation was in line with previous research8,35 and may be due 
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to a partial conceptual overlap between these constructs. Additionally, 
subjects with mental disorders were previously shown to self-medicate 
their problems and subsequently become dependent.36 The association 
between preoccupation and antidepressant use is in line with an earlier 
reported association between depression and BZD craving.11 It supports 
the assumption that the presence of negative mood states appears 
sufficient to elicit the desire for substance (ab)use of e.g. alcohol.37 
Alcohol dependence was also an expected correlate of BZD dependence8,38 
as both substances influence the same gamma-aminobutric acid alpha 
receptor and cause a dampening of nervous system activity. Subjects 
may use either substance prior to stressful situations in order to feel 
calmer. Alternatively, BZDs might have been administered to relieve the 
withdrawal effects of alcohol and vice versa39,40 or to increase sedation41.
Subjects who scored high on lack of compliance with the 
therapeutic regime took more BZDs than prescribed, tried to renew 
prescriptions earlier than agreed on, and sometimes even falsified 
prescriptions.16 Unemployed and older subjects, who form a vulnerable 
group in general, had higher scores on lack of compliance. This was 
roughly in line with previous research.8,42 It may indicate that for these 
vulnerable subjects adhering to social norms such as a therapeutic 
regime become less important. Insomnia being a correlate of lack of 
compliance possibly pointed toward tolerance development and the 
resulting perceived need to administer more BZDs (than prescribed) to 
relieve the insomnia. The concomitant use of antidepressants, BZDs, 
and alcohol possibly indicated more severe psychopathology and stress 
vulnerability. Polydrug use might have reduced the threshold to take 
medication so that prescription constraints were taken less seriously and 
lack of compliance to therapeutic regimes becomes more likely.41
Kan et al. identified a number of correlates of BZD dependence 
which did not appear to be of importance in the NESDA sample (e.g. 
duration of BZD use and half-life of BZD).8 These inconsistencies may be 
due to the inclusion of different correlates of BZD dependence. Further, 
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Kan et al. included part of their sample from outpatient addiction centers 
and the average daily dosage of BZDs in his sample was much higher 
than in NESDA (10mg vs. 2.8mg of diazepam equivalents, respectively) 
which might put subjects at increased risk to develop BZD dependence.8
In general, it is interesting that mainly psychological, addiction- 
and BZD use related characteristics predicted BZD dependence. 
Insomnia, antidepressant use and alcohol dependence predicted BZD 
dependence severity on two or more severity subscales. Other risk factors 
which were significant on one subscale (i.e., BAI, alcohol dependence, 
daily dosage) were borderline significant on other subscales. Therefore, 
most of the found risk factors seemed to be rather general predictors 
of BZD dependence. However, there were small disparities across the 
three subscales. For example, only preoccupation was related to anxiety, 
only lack of compliance was related to age and unemployment, and only 
problematic use to GP contacts. Frequency of use by itself seems to be 
an important predictor of dependence development. This finding is not 
surprising and in line with previous research reporting that a high daily 
dosage increases the risk of BZD dependence.8,12
Subjects at risk of BZD dependence are in need of close monitoring 
as they are also vulnerable to the development of concomitant mental 
disorders and substance abuse. They may benefit from psychotherapy 
and counseling to make them more resilient and possibly prevent BZD 
dependence. Further, the therapeutic effectiveness of BZDs should be 
monitored closely and weighted against the disadvantages, especially in 
those at risk of BZD dependence. If psychopathology does not improve 
with treatment, it is recommended to discontinue BZD use and switch 
to alternative ([non-] pharmacological) treatment options to prevent 
ineffective long term BZD use. 
The present study had some limitations. The observational and 
cross-sectional design did not allow causal inferences on whether the 
correlates preceded severity of BZD dependence or vice versa. Our results 
cannot be generalized to very specific BZD user populations (such as 
106  |  CHAPTER 4
drug addicts and mentally healthy subjects who only receive BZDs for 
non-psychiatric disorders such as pain) but only to outpatients using 
relatively low-dosage of BZDs who mostly suffer from anxiety and 
insomnia (which are the main indications for BZD use). Further, in 
the light of the number of correlates tested, multiple testing may have 
caused type I errors. Despite these limitations, our study had important 
strengths. We conducted a multivariate analysis across a comprehensive 
set of possible determinants of BZD dependence so that we were able 
to identify the independent correlates of BZD dependence severity. In 
addition, we investigated a large study sample composed of subjects with 
a wide range of psychopathology representative of the average BZD user. 
The use of continuous Bendep-SRQ sumscores instead of dichotomous 
ones allowed us to measure the full variability of the phenotype and detect 
small differences between subjects and the more subtle associations. 
In conclusion, subjects with insomnia, antidepressant use, and 
alcohol dependence were at highest risk to develop more severe BZD 
dependence. As concomitant psychopathology and substance dependence 
may severely compromise these subjects’ quality of life, close monitoring 
and more appropriate symptom treatment is needed. 
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ABstrAct
Background: The patient correlates of benzodiazepine (BZD) use have 
received much attention in the past. Less attention has been paid to the 
contribution of general practitioners’ (GP) attitudes and characteristics 
to patient BZD use.
Aim: We aimed to investigate GP attitudes and characteristics as possible 
correlates of patient BZD use and inappropriate use.
Design: Cross-sectional cohort study.
setting: The Netherlands.
Method: A total of 1433 GP patients of the Netherlands Study of 
Depression and Anxiety (NESDA) and 62 general practitioners (GPs) 
participated. Physician- and patient characteristics were measured 
through questionnaires and interviews. Logistic multilevel regression 
analyses were used to identify GP characteristics as possible correlates 
of patient BZD use and inappropriate use.
results: Patient BZD use and inappropriate use did not vary 
significantly between GPs and were only associated with few attitudes 
and characteristics of GPs (after correction for patient correlates of BZD 
use). Only the GP’s perceived ‘disability to differentiate unhappiness from 
depression’ was weakly associated with less patient BZD use (OR = 0.98, 
P = 0.048) and higher ‘professional comfort and competence with mental 
health care’ of the GPs correlated with less inappropriate patient BZD use 
(OR=0.29, P = 0.03).
conclusions: Our results indicate that the attitudes and characteristics 
of GPs barely affect patient BZD use. Instead, patient characteristics 
seem to be decisive in whether BZDs are used (inappropriately) or not. 
Interventions should target patients at risk of inappropriate use to educate 
them about the downsides of BZD use, and the prescribing physicians to 
teach them alternative treatments for their patients. 
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iNtroDUctioN
Benzodiazepines (BZDs) are an effective short-term treatment of anxiety 
and insomnia,1,2 but guidelines advise against longer-term use,3,4 as the 
risk of side effects5 and dependence development is high.1,6 Regardless, 
(inappropriate) BZD use is common.7,8 In the past, many studies focused 
on user characteristics 9-12 and identified old age, severe psychopathology 
and chronic illnesses as important correlates of (inappropriate) BZD 
use.9-13 Less attention has been paid to the contribution of physician 
characteristics to patient BZD use.14
Qualitative research on physician characteristics showed that 
the majority of physicians were aware of the treatment guidelines.15-17 
Yet, BZDs were inappropriately prescribed due to 1) a presumed lack 
of time,18-22 alternatives16,19,20,23 and skills,19-22 2) the idea that BZDs are 
appropriate for vulnerable patients,17,19,23 and 3) the wish to maintain a 
good-doctor patient relationship.15,20-22
Quantitative studies identified male gender,24,25 personal usage 
of BZDs,26 being a general practitioner (GP) versus a psychiatrist,24,26 
allowing patients to influence prescription decisions,25 prolongation of 
prescriptions without direct doctor-patient contact,25 and multiple drug 
prescribing27 as important correlates of patient BZD use. A substantial 
number of studies did not identify any significant physician related factors 
in the fully adjusted model28,29 or found inconsistent results.24-27,30 Most 
of these studies did not correct for patient characteristics24-26 so that it is 
unclear if the found differences were due to variation between physicians 
or due to differences between the treated patients. The attitudes of 
physicians towards depression and anxiety, guideline implementation, 
and collaboration with health care specialists have received little attention 
in previous research.24,28,30,31 
This study aims to investigate the GP attitudes and characteristics 
as possible correlates of (aim 1) patient BZD use and (aim 2) inappropriate 
patient BZD use. 
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MAteriALs AND MetHoDs
subjects
Subjects participated in the baseline assessment of the Netherlands 
Study of Depression and Anxiety (NESDA), a longitudinal cohort study of 
2981 respondents at different stages of depressive or anxiety disorder.32 
Details on objectives, recruitment, and methods of NESDA have been 
described elsewhere.32 The study protocol was approved by the Ethical 
Review Board of each participating center and all subjects signed an 
informed consent at the baseline assessment.32
Of the 2981 respondents, 1610 were recruited via their 67 general 
practitioners (GPs).32,33 GPs who did not return the NESDA self-report 
questionnaires (n=5), the patients registered with those GPs (n=164) as 
well as patients with epilepsy (n=13)34 were excluded. Accordingly, 1433 
patients and 62 GPs remained for analyses. 
To identify the GP correlates of patient BZD use, (aim [1]), two 
groups were defined: GP patients who reported BZD use in the month prior 
to the baseline interview (‘BZD users’, n=173) and those who reported no 
use of BZDs during the month before the baseline interview (‘non-users’, 
n=1260). For the investigation of GP correlates of inappropriate patient 
BZD use (aim [2]), non-users were excluded and the BZD user group was 
defined into appropriate BZD users (n=18) and inappropriate BZD users 
(n=155).
Patient BZD Use
Two indicators of patient BZD use were investigated:35 patient BZD use 
and inappropriate patient BZD use. Patient BZD use was registered by 
self-report or observation of drug containers. It was defined as daily or 
infrequent BZD use in the month prior to the baseline interview. BZD 
using patients reported the type and dosage of BZD taken on an average 
day of use. The daily BZD dose was computed according to the coding 
system of the Anatomical Therapeutic Code (ATC) and Defined Daily 
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Dose (DDD) system.36 The Mean Daily Dose was calculated by division 
of the individual daily doses (in milligrams) of BZDs by the DDD for the 
particular BZD.35 BZDs were classified as ATC-coded groups N05BA, 
N05CD, and N03AE01. The non-BZD hypnotics zopiclone and zolpidem 
(ATC code N05CF), were also included.35 For GP patients who used BZDs 
other than diazepam, conversion tables were used to calculate equivalent 
daily doses.37,35 If more than one BZD was used, dosages were summed. 
The duration of BZD use was reported in months. The number of 
different types of BZDs used concomitantly was recorded. Inappropriate 
patient BZD use criteria were derived from Dutch and British treatment 
guidelines.4,38,39 The following criteria for appropriate use were derived: 1) 
mean daily dosage ≤ DDD, 2) duration of benzodiazepine use ≤ 3 months 
in case of no concomitant antidepressant (AD) use and ≤ 2 months in 
case of concomitant AD use, and 3) only one type of BZDs is used at a 
time. Patients who met all 3 appropriateness criteria were categorized 
as appropriate users and patients who did not meet one or more criteria 
were categorized as inappropriate users. 
Physician characteristics
Physician characteristics were measured by questionnaires. The first part 
of the questionnaire contained demographic data including age, gender, 
clinical experience (in years), employment status of the GP (in full-time 
equivalents [fte]), the trainer status of the GP (i.e., approved clinical 
supervisor and mentor of GP registrars yes/no),33 the type of practice 
the GP belonged to (i.e., solo vs. group practice), access to health care 
personnel, and the number of patients per GP. These characteristics were 
measured by the ‘Visit instrument to assess practice management’,40 which 
was filled in by the practice assistants or practice nurses of the GPs. In 
part two, the GP’s interest and attitudes towards depressive and anxiety 
disorders were assessed with the Depression Attitude Questionnaire 
(DAQ)41 and a questionnaire to measure GPs’ attitudes to their role in the 
management of patients with depression and anxiety.33,42 In part three, 
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the collaboration of GPs with professionals and institutions specialized 
in mental health care was investigated.33 In part four, the GPs’ perceived 
workload and level of burnout were measured.33 The Utrecht Burn-Out 
Scale (UBOS-C) investigated the GPs’ perceived level of burn-out.43 An 
additional item measured to what extent time limitations were perceived 
as barriers to the provision of mental health care on a 6 point Likert scale 
(from ‘not at all’ to ‘very much’).33 The self-report questionnaires of parts 
two, three and four were filled in by the GPs personally.
covariates: Patient characteristics
The patient characteristics older age, singleness, unemployment, severity 
of anxiety, depression, comorbidity, and insomnia were associated with 
BZD use in previous research of this study group.13 Inappropriate patient 
BZD use was associated with higher age and chronic illnesses.13 These 
characteristics were corrected for in the regression analyses in order 
to identify the GP attitutes and characteristics, which were associated 
with patient BZD use independent of the characteristics of the patients 
themselves.
Patients reported gender, age, work status, and partner status in 
the baseline interview. Depressive and anxiety disorders were measured 
by the Composite International Diagnostic Interview (CIDI, life time version 
2.1).44 For the present analysis, 1 year CIDI diagnoses of anxiety only, 
depression only or comorbidity at baseline were established. The severity 
of generalized anxiety and panic symptoms at baseline was assessed with 
the Beck Anxiety Inventory (BAI).45 The severity of insomnia at baseline 
was determined using the Insomnia Rating Scale (IRS).46 The presence 
of chronic illnesses such as chronic lung disease, heart condition, and 
diabetes mellitus was recorded during the interview and the number of 
chronic illnesses a person suffered from were counted. 
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statistical Analysis
Sample characteristics were expressed by frequencies, means or medians. 
Because of the hierarchical structure of the study (patients nested within 
GPs) and the dichotomous outcome variables (BZD use and inappropriate 
use) univariable and multivariable multilevel logistic models (Proc Glimmix; 
SAS 9.2; SAS Institute Inc., Cary, NC, USA) were conducted. We started 
with two separate models that did not contain any GP characteristics 
yet, but only one of the dependent variables ‘BZD use’ or ‘inappropriate 
BZD use’ and the above mentioned patient characteristics as covariates. 
As a next step, all above described GP characteristics were considered 
as potential correlates of BZD use and inappropriate use in separate 
univariable analyses. Univariable analyses were corrected for the patient 
characteristics age, sex and employment status. Further, the analyses 
of BZD use were corrected for the patient characteristics partner status, 
1 year diagnosis of depression and/or anxiety, Beck Anxiety Inventory, 
and Insomnia Rating Scale.13 The analyses of inappropriate use were 
additionally corrected for the patient characteristic number of chronic 
illnesses.13 GP characteristics with P < 0.10 in univariable analyses and 
above mentioned covariates were entered in the multivariable model. All 
independent variables were entered as fixed factors. We added a random 
intercept at the GP level. Two-sided P-values equal or smaller than 0.05 
were considered as significant in the multivariable model.
resULts
Table 1 shows the characteristics of the 62 GPs. GPs were more 
often male (54.8%), had an average age of 49.2 years and an average 
clinical experience of 17.8 years. At least half of the GPs reported good 
collaboration with social workers, psychologists and social psychiatric 
nurses, but not with mental health care institutions. Most GPs worked 
in group practices (93.5%). All GPs had a practice assistant and most 
GPs had access to mental and non-mental health care professionals. The 
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GPs were responsible for a median number of 1500 patients, of whom a 
median of 20 patients were NESDA participants in the current analysis. 
GP correlates of BZD Use
The patient group consisted of 1260 non-users (87.9%) and 173 BZD 
users. BZD use of patients did not differ between GPs (data not shown, 
P>0.05). In the multivariable analysis, only the perceived ‘disability 
to differentiate depression from unhappiness’ remained a significant 
correlate of less patient BZD use (Odds ratio [OR]=0.98, P=0.048, Table 
2), independent of the included patient characteristics.
GP correlates of inappropriate BZD Use
Inappropriate BZD use of patients did not differ between GPs (P>0.05, data 
not shown). In the multivariable analysis, higher ‘professional comfort 
and competence with mental health care’ (OR = 0.29, P=0.03) remained 
the only GP characteristic that was associated with less inappropriate 
BZD use, independent of the included patient characteristics.
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tABLe 1. Characteristics and Attitudes of GPs (n=62)
sociodemographic characteristics
Gender (female, %) 45.2
Age (years), mean (sd) 49.2 (8.5)
Clinical experience (in years), mean (sd) 17.8 (10.1)
Employment status (in fte), median (IQR) 0.7 (0.6-0.8)
Approved clinical supervisor of GP registrars (%) 54.8
Employed in a group practice (vs. solo, %) 93.5
Access to health care professionals (%)
(Non-mental) health care professionals (except practice 
assistant)
83.9
Mental health care professionals 87.1
Number of patients per GP (per 100), median (IQR) 15.0 (14.6 – 16.3)
GPs interests & attitudes towards depression and anxiety
Depression Attitude Questionnaire (mean score), mean (sd)
Preference for drug therapy 44.1 (9.1)
Uncomfortable feeling dealing with depressed patients 44.2 (11.1)
Belief in the inevitability of depression 35.1 (13.2)
Perceived disability to identify depression 39.0 (12.8)
GPs’ attitudes on depressive and anxiety disorder management
Professional comfort and competence with mental health care, 
mean (sd)
4.5 (1.0)
GPs concerns about difficulties with the health care system, 
median (IQR)
3.0 (2.6-3.5)
collaboration with mental health care professionals / institutions
Good collaboration with social workers (%) 53.2
Good collaboration with primary care psychologists (%) 50.0
Good collaboration with social psychiatrist nurses (%) 67.7
Good collaboration with mental health care institutions (%) 6.5
Perceived workload and level of burn-out
Perceived time limitations, mean (sd) 3.5 (1.3)
Utrecht Burnout Scale
Emotional Exhaustion, mean (sd) 1.4 (0.8)
Depersonalisation, mean (sd) 0.9 (0.6)
Personal Accomplishment, median (IQR) 4.5 (4.0 -4.9)
sd indicates standard deviation; IQR indicates interquartile range, BZD indicates benzodiazepine, 
GP indicates general practitioner, fte indicates full-time equivalent. Mean (sd) is provided for 
normally distributed variabels. Median (IQR) is provided for skewed variabels.
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Gender (female) 0.91 (0.62 – 1.33) 0.62
Age (years) 1.00 (1.00 – 1.02) 0.78
Clinical experience (in years) 1.00 (0.98 – 1.02) 0.94
Employment status (in fte), median 
(IQR)
0.88 (0.31 – 2.53) 0.82
Approved clinical supervisor of GP 
registrars
0.98 (0.68 – 1.41) 0.90
Employed in a group practice (vs. 
solo)
1.06 (0.53 – 2.09) 0.88
Access to professionals
(Non-mental) Health care 
professionals (except practice 
assistant)
1.45 (0.86 – 2.45) 0.16
Mental health care professionals 1.28 (0.78 – 2.11) 0.32
Number of patients per GP (per 100) 1.03 (0.98 – 1.08) 0.23
GPs interests & attitudes towards depression and anxiety
Depression Attitude Questionnaire 
Preference for drug therapy 0.99 (0.97 – 1.01) 0.37
Uncomfortable feeling dealing with 
depressed patients 
1.00 (0.98 – 1.02) 0.81
Belief in the inevitability of 
depression
1.00 (0.99 – 1.02) 0.66
Perceived disability to identify 
depression
0.99 (0.97 – 1.00) 0.07 0.98 (0.97 – 1.00) 0.048
GPs’ attitudes on depressive and 
anxiety disorder management
Professional comfort and 
competence with mental health care
1.21 (0.95 – 1.55) 0.13
GPs concerns about difficulties with 
the health care system
0.90 (0.74 – 1.08) 0.26
collaboration with mental health care professionals 
Good collaboration with social 
workers 
1.30 (0.90 – 1.88) 0.16
Good collaboration with primary care 
psychologists
1.37 (0.96 – 1.95) 0.08 0.92 (0.63 – 1.35) 0.67
Good collaboration with social 
psychiatrist nurses
1.37 (0.92 – 2.05) 0.12
Good collaboration with mental 
health care institutions
0.91 (0.46 – 1.78) 0.78
Perceived workload and level of burn-out
Perceived time limitations 1.09 (0.95 – 1.26) 0.21
Utrecht Burnout Scale
Emotional Exhaustion 1.20 (0.95 – 1.52) 0.12
Depersonalisation 1.26 (0.97 – 1.64) 0.08 1.25 (0.95 – 1.64) 0.11
Personal Accomplishment 0.80 (0.61 – 1.06) 0.12
BZD indicates benzodiazepine; GP indicates general practitioner; CI indicates confidence interval.
ORs are calculated by univariable and multivariable logistic multilevel regression analyses (SAS 
glimmix). P Multilevel is derived by univariable and multivariable logistic multilevel analysis with 
two levels (doctors, patients). Univariable and multivariable analyses were corrected for patient’s 
age, sex and employment status, partner status, 1 year diagnosis of anxiety and / or depression, 
Beck Anxiety Inventory, Insomnia rating scale. All GP characteristics with P < 0.1 in univariable 
analyses were included into the multivariable model
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Gender (female) 1.81 (0.48-6.75) 0.38
Age (years) 0.98 (0.91-1.05) 0.50
Clinical experience (in years) 0.99 (0.93-1.05) 0.67
Employment status (in fte) 0.32 (0.01-9.26) 0.51
Approved clinical supervisor of GP 
registrars 
0.84 (0.26-2.72) 0.77
Employed in a group practice (vs. solo) 0.66 (0.06-7.06) 0.73
Access to health care professionals 
(Non-mental) Health care professionals 
(except practice assistant)
0.32 (0.10-1.02) 0.43
Mental health care professionals 0.87 (0.17-4.45) 0.87
Number of patients per GP 0.87 (0.17-4.45) 0.49
GPs interests & attitudes towards depression and anxiety
Depression Attitude Questionnaire 
Preference for drug therapy 1.03 (0.98-1.09) 0.22
Uncomfortable feeling dealing with 
depressed patients 
0.93 (0.88-0.97) 0.003 0.97 (0.91-1.03) 0.31
Belief in the inevitability of depression 0.97 (0.92-1.02) 0.25
Perceived disability to identify 
depression
0.95 (0.90-1.00) 0.07 0.94 (0.88-1.00) 0.07
GPs’ attitudes on depressive and anxiety disorder management 
Professional comfort and competence 
with mental health care
0.41 (0.23-0.76) 0.005 0.29 (0.10-0.88) 0.03
GPs concerns about difficulties with the 
health care system
1.73 (1.03-2.90) 0.04 0.89 (0.37-2.17) 0.81
collaboration with mental health care professionals / institutions
Good collaboration with social workers 0.67 (0.19-2.38) 0.67
Good collaboration with primary care 
psychologists 
1.17 (0.36-3.76) 0.80
Good collaboration with social 
psychiatrist nurses
1.65 (0.45-6.05) 0.45
Good collaboration with mental health 
care institutions
0.56 (0.09-3.66) 0.54
Perceived workload and level of burn-out
Perceived time limitations 0.76 (0.50-1.17) 0.21
Utrecht Burnout Scale
Emotional Exhaustion 0.77 (0.35-1.69) 0.51
Depersonalisation 0.72 (0.31-1.69) 0.46
Personal Accomplishment 1.41 (0.53-3.76) 0.50
BZD indicates benzodiazepine; GP indicates general practitioner; OR indicates odds ratio. 
Appropriate use was defined as mean daily dosage ≤ DDD, duration of benzodiazepine use ≤ 3 
months in case of no concomitant antidepressant (AD) use and ≤ 2 months in case of concomitant 
AD use and use of only one type of BZDs at a time. Use was defined as inappropriate when at 
least one of these criteria was not met. ORs were calculated by univariable and multivariable 
logistic multilevel regression analyses (SAS glimmix). P Multilevel was derived by univariable 
and multivariable logistic multilevel analysis with two levels (doctors, patients). Univariable and 
multivariable analyses were corrected for patient’s age, sex and employment status, and number 
of chronic illnesses.  All GP characteristics with p < 0.1 in univariable analyses were included into 
the multivariable model.
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summary
In this cross-sectional multilevel study amongst 1433 GP patients of 62 
GPs, we investigated possible GP correlates of (inappropriate) patient 
BZD use and corrected for previously identified patient characteristics. 
Patient BZD use and inappropriate use did not vary significantly among 
GPs. Most GP characteristics were not associated with patient BZD use 
and inappropriate BZD use in the multivariable model. Only the GP’s 
perceived ‘disability to differentiate unhappiness from depression’ was 
associated with less patient BZD use and the GP’s ‘professional comfort 
and competence with the mental health care system’ was a correlate 
of lower inappropriate patient BZD use. This indicates that patient 
characteristics rather than GP characteristics determine patient BZD use 
and inappropriate use. 
strengths and Limitations of the study
Our study had several limitations. In the light of the number of tests 
conducted, multiple testing may have caused a type I error, indicating 
that the two significant associations we found might be a chance finding. 
Further, patient BZD use was established via self-report of the GP patients 
and might not perfectly reflect GP prescriptions or the actual BZD use. 
The GP characteristics used in NESDA mainly included attitudes on 
anxiety and depression and not on the prescription of BZDs. Possibly, 
more specific GP attitudes towards BZD use need to be investigated in 
order to be able to detect differences in GPs’ BZD prescription behaviour. 
However, this is unlikely, as there was little variance of BZD use and 
inappropriate use between GPs. Despite these limitations, we feel that 
our study is a valuable addition to the existing literature as it is the first 
study to investigate a large number of potentially important physician 
characteristics and attitudes in concert as possible correlates of BZD use 
and inappropriate use. Additionally, we corrected for previously identified 
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patient characteristics to find out whether GP characteristics could add 
information on top of already known predicting patient characteristics. 
comparison with existing Literature
The GP’s perceived ‘disability to differentiate unhappiness from depression’ 
was the only weak correlate of less patient BZD use in the fully corrected 
model. This was a rather unexpected finding. These GPs had expressed 
the assumption that depression develops as a consequence of personal 
misfortune and felt that they could do little to help. Possibly, these GPs 
were less likely to prescribe BZDs as they felt they could do nothing 
to improve the mental health of their patients. However, in general, GP 
characteristics provided little additional information in the prediction 
of patient BZD use on top of the patient characteristics identified as 
predictors in previous research. The small number of significant GP 
characteristics is largely in line with some earlier studies that did not 
identify any significant GP correlates.28,29 Other research identified GP 
correlates of BZD use (e.g. male GP gender24,25) which were not significant 
in our research. These studies differed from our own as they did not correct 
for patient characteristics.24,25 Thus, the found differences between GPs 
in those studies might actually be explained by the variability in patient 
characteristics (instead of by differences between GPs). 
Inappropriate patient BZD use was also hardly associated with 
the GP characteristics. Only the GPs’ comfort with mental health care 
correlated with less inappropriate patient BZD use. This indicates 
that GPs who issued less inappropriate BZD prescriptions felt more 
comfortable in dealing with anxious and depressed patients. This may 
be in line with earlier qualitative research which reported that BZDs are 
often prescribed due to a presumed lack of (psychotherapeutic) skills.19,20 
Our findings are also in accord with the earlier finding that subject 
characteristics are more important for the prediction of long-term BZD 
use than GP characteristics.31
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implications for future research and clinical Practice
In general, it is striking that GP characteristics added little information 
on top of the patient characteristics which were shown to be significant 
correlates of BZD use and inappropriate BZD use in previous research.13 
This refutes the previous notion that some physicians are particularly 
responsible for the (inappropriate) BZD use of their patients.16 
Interventions to reduce chronic BZD use should target patients at risk and 
the prescribing physicians alike, with a focus on patient characteristics 
rather than physician characteristics. Physicians should receive training 
to improve their knowledge on alternative treatment strategies and 
interaction skills with subjects at high risk of inappropriate use. Future 
research will have to show which kind of trainings are most helpful 
for the GPs to do so. Patients at risk should receive information about 
the unfavourable consequences of (inappropriate) BZD use, as already 
minimal intervention was shown to reduce chronic BZD use.17,47,48 
conclusion
In conclusion, this study revealed that GP characteristics had little value 
in the prediction of patient BZD use and inappropriate BZD use on top 
of the patient characteristics. Apparently, it is primarily dependent on 
patient characteristics whether BZDs are used (inappropriately) or not. 
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ABstrAct 
Background: As benzodiazepines (BZDs) have anxiolytic effects, it 
is expected that they influence the stress system. During short-term 
treatment, BZD use was found to suppress cortisol levels. However, little 
research has been done on the effects of long-term BZD administration 
on the hypothalamic-pituitary-adrenal (HPA) axis. 
Methods: The association between long-term BZD use and cortisol levels 
was investigated in subjects of the Netherlands Study of Depression 
and Anxiety with a lifetime diagnosis of anxiety or depression (n=1531). 
Subjects were categorized as “daily BZD users” (n=96), “infrequent BZD 
users” (n=172) and “nonusers” (n=1263). Possible associations between 
characteristics of BZD use (dose, duration, and dependence) and salivary 
cortisol levels were analyzed. 
Main outcome measure: Subjects provided 7 saliva samples, from which 
4 cortisol indicators were calculated: the cortisol awakening response, 
diurnal slope, evening cortisol, and cortisol suppression after ingestion 
of 0.5 mg dexamethasone. 
results: Daily users used BZDs for a median duration of 26.5 months 
and had a median daily dosage of 6.0 mg as measured in diazepam 
equivalents. Evening cortisol levels were significantly lower in daily users 
(P=0.004, effect size: d=0.24) and infrequent users (P=0.04, effect size: 
d=0.12) as compared to nonusers. We did not find significant differences 
in the cortisol awakening response, diurnal slope or in the dexamethasone 
suppression test. 
conclusions: Despite the finding of slightly lower evening cortisol levels 
in daily and infrequent BZD users as compared to nonusers, results 
indicate that long-term BZD use is not convincingly associated with HPA 
axis alterations. 
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iNtroDUctioN
As benzodiazepines (BZDs) have anxiolytic and sedating effects, it is 
expected that they influence the stress system. Most studies on the effects 
of short-term BZD treatment (maximum of 3 months) on the hypothalamic-
pituitary-adrenal (HPA) axis in human subjects reported a decrease in 
cortisol levels,1-11 although some studies reported mixed results.12,13 These 
inconsistencies may be explained by differences in dosages and half-lives 
of the BZDs used13 and by disparities in the measurement time points 
used in the assessments (only predrug and postdrug measurements,13 at 
certain time intervals,6,8,10-12,14 or for a full circadian cycle1,2,5). Differences 
in patient groups,12,13 and measurements of basal versus stress-provoked 
cortisol levels may also influence the results.3,13 In general, the studies 
measured plasma cortisol levels1-3,5,6,9,11,13 or urinary free cortisol as 
measures of HPA axis activity.4 Associations between BZD use and 
dexamethasone suppression have only been investigated in 1 study and 
no clear effect of BZD use on dexamethasone suppression was observed.14 
A few studies found that the cortisol decrease in response to BZD 
treatment was followed by a return to baseline cortisol levels within only 
a few hours, despite persisting high plasma drug levels,15-17 suggesting 
fast development of tolerance to the stress-axis-suppressing effects of 
BZDs. In contrast, other studies did report significant cortisol reductions 
in 24h, overnight and daytime means,1 suggesting that tolerance does 
not develop as rapidly. 
Tolerance to the effects of BZDs as a consequence of chronic 
use (>3 months) has been extensively discussed in previous studies.18,19 
In related research on the therapeutic effects of BZDs, several authors 
reported that tolerance was developed to only the cognitive and 
psychomotor effects and not to the anxiolytic effects of chronic BZD 
treatment,19 whereas others found decreasing anxiolytic efficacy as well 
when treatment exceeded a few weeks.18 Most studies on the effects of 
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BZDs on cortisol levels found that cortisol suppression was maintained 
for up to 3 months of use.1,2,4,9,12
There was only 1 small cross-sectional study investigating long-
term BZD use (> 3 months).20 The authors found that long-term users 
have similar baseline cortisol levels as nonusers, indicating that BZDs do 
not maintain their cortisol-suppressing effects during longer-term use. 
In contrast, an additional dosage of BZDs (on top of the BZD dosage that 
chronic users took daily) still affected the HPA axis after chronic use. 
However, comparison groups were small, no measurement of the whole 
circadian rhythm was conducted, and no dexamethasone challenge test 
was applied.20
In this paper, we examine the effects of chronic BZD use on 
various salivary cortisol measures (cortisol awakening response, diurnal 
slope, evening cortisol level and suppression after oral dexamethasone 
administration). In addition, we explore the effects of dosage, duration 
of use, and level of dependence. The study was carried out on data from 
1531 subjects with a lifetime diagnosis of anxiety and / or depression 




Subjects participated in the baseline assessment of NESDA, an 8-year 
longitudinal cohort study of 2981 respondents aged 18 to 65 years.21 
Subjects were recruited from the community, general practice and 
specialized mental health care institutions throughout the Netherlands. 
Subjects completed a medical exam, an in-person interview, saliva 
collection and several questionnaires. The study protocol was approved 
by the Ethical Review Board of each participating center and all subjects 
signed an informed consent at the baseline assessment. 
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To investigate the associations between BZD use and salivary cortisol 
indicators, 3 groups were defined: subjects who reported daily BZD use 
in the month prior to the baseline interview (“daily BZD users”, n=176), 
subjects who used BZDs on an infrequent basis in the previous month 
(“infrequent BZD users”, n=264) and those reporting no use of BZDs in 
the last month (“nonusers”, n=1854). All subjects reported a current or 
past diagnosis of a depressive or anxiety disorder (referred to as a lifetime 
disorder), defined as an anxiety disorder (panic disorder with or without 
agoraphobia, generalized anxiety disorder or social phobia) or depressive 
disorder (dysthymia or Major Depressive Disorder, MDD) as assessed 
by the Composite International Diagnostic Interview (WHO version 2.1) 
which classifies diagnoses according to the criteria of the Diagnostic 
and Statistic Manual of Mental Disorders IV-TR (American Psychiatric 
Association, 2001). From these 3 groups, 1664 (72.5%) subjects returned 
saliva samples. Responders on saliva collection did not differ from non-
responders in gender (67.7% vs 68.3% women, P = 0.79) but were older 
(43.6 ± 12.5 years vs 37.9 ± 11.9 years, P<0.001), more educated (12.2 ± 
3.3 years vs 11.5 ± 3.2 years, P<0.001) and less likely to have a lifetime 
diagnosis of comorbid disorder (55.5% vs 64.0%, P<0.001). Furthermore, 
responders had marginally significantly lower rates of BZD use (18.2% 
vs 21.7%, P=0.06). Of the responders, 1658 provided sufficient cortisol 
samples of high quality from which at least one usable salivary cortisol 
indicator (cortisol awakening response [CAR], diurnal slope, evening 
cortisol or dexamethasone suppression test [DST], see later section) 
could be calculated. 
Because of known associations with cortisol or use of BZDs, 
pregnant or breastfeeding women (n=10), subjects using corticosteroids 
(n=104), and patients with epilepsy (n=13) were excluded, leaving a final 
sample of 1531 subjects (1263 nonusers, 172 infrequent BZD users and 
96 daily BZD users).
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MeAsUres
Benzodiazepine Use
Four indicators of BZD use were investigated: type of BZD, daily BZD 
dose, duration of BZD use, and BZD dependence severity. BZD use during 
the month before the baseline interview was registered by observation of 
drug containers brought to the interview (73.4%) or self-report (26.6%). 
Daily and infrequent BZD users reported the type and dosage of BZD 
taken on an average day of use. Frequency of use for infrequent users 
was taken into account when calculating the average daily dose. The 
daily BZD dose was computed according to the coding system of the 
Anatomical Therapeutic Code (ATC) and Defined Daily Dose (DDD) 
system.22 The mean daily dose was calculated by dividing individual daily 
doses (in milligrams) of BZDs by the DDD for the particular BZD. BZDs 
were classified as ATC-coded groups N05BA, N05CD, and N03AE01. The 
non-BZD hypnotics zopiclone and zolpidem (ATC code N05CF), were also 
included. Similar to BZDs, these hypnotics act on the central omega I 
gamma aminobutyric acid receptor. For patients using BZDs other than 
diazepam, an equivalent daily dose was calculated with conversion 
tables,23,24 and 10 mg of diazepam were regarded equivalent to 1 mg 
alprazolam, 10 mg bromazepam, 0.25 mg brotizolam, 20mg clobazam, 
20 mg chlordiazepoxide, 13.3 mg clorazepate, 8 mg clonazepam, 30 mg 
flurazepam, 1 mg loprazolam, 2 mg lorazepam, 1 mg lormetazepam, 7.5 mg 
midazolam, 10 mg nitrazepam, 33 mg oxazepam, 20 mg prazepam, 20 mg 
temazepam, 20 mg zolpidem and 13 mg zopiclone. Dosages were summed 
when more than 1 BZD was used. The duration of BZD use was reported 
in months. BZD users completed the Benzodiazepine Dependence Self-
Report Questionnaire (Bendep-SRQ), a 15-item self-report questionnaire, 
as a measure of dependence severity. Each item was rated on a 5- point 
scale. Three dependence dimensions were derived: 1) awareness of 
problematic use, 2) preoccupation with the availability of BZDs, and 3) 
lack of compliance with the therapeutic regimen.25 The Bendep-SRQ has 
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good scalability, reliability and validity in general practice patients,26 and 
psychiatric outpatients.27
salivary cortisol 
The respondents were asked to collect saliva samples at home on a 
regular, preferably working day, shortly after the baseline interview by 
using Salivettes (Sarstedt AG und Co, Nürmbrecht, Germany).28 The 
median time between the interview and saliva sampling was 9 days 
(25th – 75th percentile: 4-22). Eating, smoking, drinking tea or coffee, or 
brushing teeth was prohibited within 15 minutes of sampling. Saliva was 
measured at seven time points (Ts): upon awakening (T1), 30 minutes 
(T2), 45 minutes (T3) and 60 minutes (T4) after awakening and in the 
evening at 10PM (T5) and 11PM (T6). Immediately after saliva sampling at 
T6, the cortisol suppression test was carried out by oral administration of 
a 0.5-mg dexamethasone pill and assessed by cortisol sampling the next 
morning directly after awakening (T7). All samples were refrigerated and 
returned by mail. During laboratory analysis, Salivettes were centrifuged 
at 2000g for 10 minutes, aliquoted, and stored at -80°C. Competitive 
electrochemiluminescence immunoassay (E170 Roche, Basel, 
Switzerland) was used to measure cortisol levels at a functional detection 
limit of 2.0 nmol/l.29 Intraassay and interassay variability coefficients in 
the measuring range were less than 10%. Assays were repeated if cortisol 
levels were very high (> 80 nmol/L) or very low (< 1 nmol/L) (n=128). 
All very high samples remained high in the second measurement, and 
the mean of the 2 measured values was used in further analyses. In 
80% of the very low samples, the repeated cortisol value was within the 
reference range and was used for analysis. In cases where the second 
measurement was also very low, the mean of the samples was used. Data 
cleaning was performed by excluding cortisol values more than 2 SDs 
above the mean.28 
Four cortisol measures were derived: the CAR, diurnal slope, 
evening cortisol and cortisol suppression on the DST.28 
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Cortisol Awakening Response (CAR)
The CAR was calculated from 4 sampling points: T1, T2, T3, and T4. In 
our study, it was calculated by analysis of T1 to T4 with Linear Mixed 
Models (LMM) and 2 aggregate indicators: area under the curve with 
respect to the ground (AUCg) and with respect to the increase (AUCi) 
according to Pruessner’s formulas.30 The AUCg is an estimate of the total 
cortisol secretion and predicts mean cortisol levels throughout the day, 
and the AUCi is a measure of the dynamics of the CAR, related to the 
sensitivity of the system and emphasizing changes over time.28,30 For the 
AUC analyses, a minimum of 3 samples were required. For those with 
1 missing cortisol value (n=84), the fourth was imputed using linear 
regression analyses with information on the other available 3 cortisol 
values, gender, age, awakening time and smoking status. 
Diurnal Slope and Evening Cortisol
As cortisol levels at 10PM (T5) and 11PM (T6) were correlated (r=0.73, P 
< 0.01), evening cortisol was defined as the average of the 2 values (T5 
and T6) or by one of the 2 if only one was available. Diurnal slope was 
calculated by subtracting the evening cortisol level (as calculated earlier) 
from the cortisol level at T1 and dividing it by the time in hours between 
the 2 samples, resulting in the change over time of cortisol throughout 
the day, calculated per hour.28,31 
Dexamethasone Suppression Test (DST)
In addition to the cortisol level at awakening after dexamethasone ingestion 
(T7), a cortisol suppression ratio was calculated by dividing the cortisol 
value at awakening on day 1 (T1) by the post-dexamethasone cortisol 
value at awakening on day 2 (T7). Lower post-dexamethasone cortisol 
levels (T7) and higher DST ratios (ie, a larger difference between T1 and 
T7) indicate a greater cortisol-suppressing effect of dexamethasone.
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Covariates 
As associations between sociodemographics (gender, age, education, 
and North-European ancestry), sampling factors (awakening time, work 
status, weekday, season, and sleep duration) and health indicators 
(smoking, physical activity) on salivary cortisol variables have been 
described previously,32 these identified determinants were considered as 
covariates. 
Comorbidity of anxiety and depression as well as antidepressant 
use have been found to be associated with salivary cortisol levels in 
previous research in this study sample,28 and numbers of antidepressant 
use and comorbidity differed between BZD groups (Table 1). Therefore, 
comorbidity and antidepressant use were also included as covariates. 
Depression and anxiety disorders were established with the Composite 
International Diagnostic Interview (WHO version 2.1) which classifies 
diagnoses according to the criteria of the Diagnostic and Statistic Manual 
of Mental Disorders Fourth Edition-Text Revision (American Psychiatric 
Association, 2001). The use of antidepressants in the past month was 
determined by observation of drug containers brought to the baseline 
interview. Antidepressants were subdivided into selective serotonin re-
uptake inhibitors (SSRI, ATC code N06AB), tricyclic antidepressants 
(TCA, ATC code N06AA), and other antidepressants (monoamine oxidase 
inhibitors N06AG, non-selective N06AF, and antidepressants classified 
as N06AX). 
Respondents were asked to report time of awakening, and 
working status on the sampling day. Sampling date information was 
used to categorize weekday versus weekend day and season categorized 
in less daylight (October through February) and more daylight (March 
through September) months. Average sleep duration during the last 
week was dichotomized as ≤6 or >6 hours/night, and smoking status 
as current versus non-smoker. Physical activity was assessed using the 
International Physical Activity Questionnaire and expressed as activity 
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per 1000 MET-minutes (metabolic equivalent of number of calories spent 
by a person per minute) a week.28
statistical Analyses
Characteristics of study groups were expressed by frequencies, means 
or medians, and compared using c2 statistics (categorical variables), 
analysis of variance (continuous variables, normally distributed), and 
the Kruskal-Wallis-test (continuous variables, non-normally distributed). 
Area under the curve with respect to the increase and diurnal slope were 
normally distributed, which allowed data analysis with nontransformed 
values. T1-T4, AUCg, evening cortisol, T7, and DST were naturally log 
transformed because of their positively skewed distributions. Back-
transformed values are given in Table 2. 
Differences in AUCg, AUCi, diurnal slope, evening cortisol, T7, and 
DST across groups were analyzed using analysis of covariance (ANCOVA), 
adjusting for basic sociodemographic variables, sampling factors, health 
indicators, comorbidity, and antidepressant use. Cohen’s d (the difference 
in group means, divided by their pooled SD) was calculated as a measure 
of effect size. Further analysis of the CAR was carried out with random 
coefficient analysis of the 4 morning cortisol data points by using LMM. 
This analysis keeps original values on all 4 data points, accommodates 
for missing data, and takes correlations between repeated measurements 
within subjects into account.33 
Linear regression analyses were used to assess associations 
between characteristics of BZD use (ie, duration, dose and dependence 
as separate independent variables) and salivary cortisol indicators 
as continuous dependent variables after full adjustment in daily and 
infrequent BZD users.
Differences across the 4 most commonly used BZD types, 
that is, oxazepam (n=115), diazepam (n=33), alprazolam (n=16), and 
temazepam (n=45) on salivary cortisol indicators were analyzed in 
pairwise comparisons using ANCOVA, adjusting for aforementioned 
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covariates. The other BZDs were not included in these analyses as group 
numbers were to small (n<15). Oxazepam was used as reference group. 
Statistical significance was inferred at P < 0.05. All statistical analyses 
were conducted using SPSS for Windows, version 16.0 (SPSS, Chicago, 
Ill).
resULts
Characteristics of the 3 BZD user groups are presented in Table 1. BZD 
users were older, less educated, more often diagnosed with a comorbid 
disorder, and more likely to use antidepressants as compared to 
nonusers. Only 17.9% of subjects were short-term users (≤3 months), 
and the remaining 82.1% were long-term users (> 3 months). The median 
duration of use was 35.5 months (25th – 75th percentile: 5-96). Although 
the group of short-term users was too small (n = 48) to be analyzed 
separately, exclusion of these subjects did not affect our main results 
(data not shown). The median daily dosage of BZDs used was 1.0 mg (25th 
– 75th percentile: 0.2 – 2.0) of diazepam equivalents for infrequent users 
and 6.0 mg (25th – 75th percentile: 3.2 – 13.9) of diazepam equivalents 




Overall, 71.5 % of respondents showed an increase in cortisol in the first 
hour after awakening, with a mean increase of 6.6 nmol/L (or 53.5%). No 
significant effects were found for any of the crude CAR analyses (Table 2). 
Adjusted CAR results showed that daily users and infrequent users did 
not differ on overall cortisol levels from nonusers, reflected by analysis of 
AUCg (P=0.09 for daily users vs nonusers and P=0.74 or infrequent users 
vs nonusers; Table 2) and LMM analysis (daily users vs non-users, F(1329, 
.097)=3,07, P=0.08; and infrequent users vs nonusers, F(1413, 642)=0.11, 
P=0.74). A nonsignificant effect on AUCi (daily users vs nonusers, P=0.99 
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and infrequent users vs nonusers, P=0.99, Table 2) and no significant 
group by time interaction in the LMM analysis (daily users vs nonusers, F 
(3947, 327)=0.49, P=0.69 and infrequent users vs nonusers, F(4171, 422)=0.92, 
P=0.43) were found, indicating a similar time course between groups. 
Diurnal slope
No significant effects were found for crude or adjusted diurnal slope 
analyses (daily users vs non users: P=0.79).
evening cortisol Level
Unadjusted evening cortisol levels did not differ between groups (Table 
2). After adjustment, evening cortisol was significantly lower in daily 
BZD users (P=0.004, effect size [Cohen’s d], 0.24) and infrequent users 
(P=0.04, effect size, 0.12) compared to nonusers. Age and SSRI use were 
the most important confounders in the fully adjusted model.
Dexamethasone suppression test
The unadjusted cortisol suppression ratio was significantly lower in daily 
users as compared to nonusers (P=0.049, effect size, 0.08, Table 2) which 
indicates increased nonsuppression after dexamethasone ingestion in the 
daily user group. After adjustment, however, cortisol suppression ratios 
(P=0.71) and T7 levels (P=0.46) did not differ between groups. Infrequent 
users also did not differ from nonusers on either of the cortisol indicators 
(P=0.46 for cortisol suppression ratio and P=0.31 for T7). 
characteristics of BZD Use
Table 3 reports the results of additional analyses on specific associations 
between salivary cortisol levels and characteristics of BZD use (duration, 
dose and severity of BZD dependence as measured by the Bendep-SRQ) 
among the combined BZD user groups (infrequent and daily). For the 
duration of use, no effect on any cortisol indicator was found except 
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for a weak negative association with adjusted T7 cortisol levels after 
dexamethasone ingestion (β=-0.15, P=0.03), indicating that a longer 
duration of BZD use was associated with a somewhat lower cortisol 
level after dexamethasone ingestion, that is stronger suppression. The 
daily BZD dose and the 3 subscales of the Bendep-SRQ (problematic 
use, preoccupation and lack of compliance) were not associated with any 
salivary cortisol indicator. 
Pairwise comparisons of the most common BZD types showed 
that the temazepam group did not differ from the oxazepam group on any 
of the cortisol indicators. However, the diazepam group had lower diurnal 
slope levels (P=0.01) and a decreased dexamethasone suppression ratio 
(P=0.01) as compared to oxazepam users. The alprazolam group had a 
lower AUCg than the oxazepam group (P=0.007, data not shown). 
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DiscUssioN
In this study, the relationship between BZD use and various salivary 
cortisol measures was studied in NESDA subjects with a lifetime diagnosis 
of depression and/or anxiety. With the exception of slightly lower evening 
cortisol levels in daily and infrequent BZD users compared with non-
users, the user groups did not differ on any cortisol indicators after 
adjustment for covariates. Dose, frequency of use, and dependence were 
not associated with salivary cortisol levels except of a correlation of longer 
duration of use with stronger cortisol suppression after dexamethasone 
ingestion. As the found effect sizes were small, the clinical relevance of 
the statistically significant findings is limited. Further, in the light of the 
number of tests conducted, multiple testing may have caused a type 1 
error for evening cortisol in BZD users.
An explanation for the lack of consistent associations could be 
that BZDs inhibit the HPA axis during short-term use and that tolerance 
to the cortisol-suppressing effect of BZDs develops after long-term BZD 
treatment. Correspondingly, intervention studies that found lower cortisol 
levels in response to BZD administration mainly looked at short-term 
effects during a time period ranging from 1 day to 1 month,3,5,6,9,13,34-37 
except for a few studies with a duration of 2-3 months.1,2,4 In contrast, 
chronic users were found to have similar baseline cortisol levels as 
nonusers, also indicating that BZDs do not maintain their cortisol-
suppressing effects in long-term use.20 As our study mainly consists of 
chronic users (3-year median duration of use), the lack of association 
between BZD use and baseline cortisol levels agrees with results from 
the latter study.20 
Although tolerance is likely to develop during long-term use, an 
additional dosage of BZDs (on top of a regular daily dosage) still induces 
HPA axis inhibition. Indeed, Cowley et al.20 found that long-term users 
showed similar decreases in plasma cortisol after an extra dosage of BZDs 
as treatment-naïve patients.20 In related research on the therapeutic 
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effects of BZDs, an increased dosage of BZDs was found to increase 
anxiolytic effects even after more than 10 years of daily use.38 
Along with the hypothesis of tolerance development to the cortisol 
suppressing effects of long-term BZD use, there are several alternative 
explanations that may account for discrepancies in findings. First, 
BZD users may have had enhanced HPA axis activity prior to the start 
of BZD treatment which was subsequently normalized by long-term 
BZD treatment. Indeed, a significantly higher percentage of daily users 
compared to nonusers had comorbid disorder, which has been found to 
be associated with increased cortisol levels in this study population.28 
Second, it might be that the joint investigation of a number of different 
types of BZDs with possibly opposing effects on the HPA axis has covered 
effects on cortisol levels.39 We found lower diurnal slope levels and a 
decreased dexamethasone suppression ratio in the diazepam group and 
a lower AUCg in the alprazolam group compared to the oxazepam group. 
This may be evidence for the possibly opposing effects of the different 
BZDs. This corresponds to a former study that reported BZDs to have 
either a stimulating or an inhibiting effect on the HPA axis conditional 
on the alpha subunit of the GABA receptor modulated by the drugs.39 
However, as comparison groups were small in NESDA, results have to be 
replicated in future research. Third, stronger effects on cortisol levels may 
be due to higher dosages. In intervention studies higher average dosages 
were used than in the current study (ie, 12 mg of diazepam equivalents 
in intervention studies versus 6 mg in NESDA). Another explanation for 
basal cortisol being the only cortisol measurement differing significantly 
between BZD user groups might be that hippocampal mineralocorticoid 
receptors (MRs) are more affected by central acting BZDs than 
glucocorticoid receptors (GRs). Because MRs are more occupied at 
intermediate cortisol concentrations while GRs are not,40 basal evening 
cortisol might be a probe of MR activity.41 However, because research 
on GR, MR and BZDs is still limited, this assumption deserves further 
confirmation in future research. 
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Our study has some limitations. A cross-sectional analysis was done, 
which precludes causal inferences or differentiation between the potential 
explanations of the lack of group differences in salivary cortisol. Because 
we had to rely on subjects’ self-report on BZD intake, we cannot be 
completely sure whether subjects were actually using the medications 
as prescribed and as they themselves indicated. Noncompliance with 
instructions of saliva collection due to the ambulatory setting could 
have resulted in measurement error. In addition, because time of 
drug intake was not recorded, acute effects of BZD use could not be 
assessed. Despite these limitations, our study had many strong aspects, 
including a large sample size with clearly distinct BZD groups primarily 
composed of long-term users, the inclusion of multiple cortisol measures 
indicative of different aspects of HPA axis activity, the investigation of 
various characteristics of use and the adjustment for various potential 
confounders. 
In conclusion, we found no consistent associations between BZD 
use and salivary cortisol indicators within a sample primarily composed 
of long-term users. This finding is in line with the hypothesis that the 
HPA axis develops tolerance to the cortisol-suppressing effect of BZDs 
during chronic BZD use.
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ABstrAct
Background: As benzodiazepines (BZDs) are used for the treatment of 
stress, they may affect the autonomic nervous system (ANS) which is 
aroused in stressful situations. Studies on the short-term effects of BZDs 
on the ANS are inconsistent and the effects of long-term use have hardly 
been studied. 
Materials and Methods: In 2838 participants of the Netherlands Study 
of Depression and Anxiety, we examined the associations between 
baseline characteristics of BZD use (frequency, type, dosage, duration) 
and ANS measures. BZD initiators (n=85), BZD discontinuers (n=145), 
and chronic users (n=158) were also compared to non-users (n=1726) on 
absolute changes of the following ANS measures over a two-year period: 
heart rate [HR], respiratory sinus arrhythmia [RSA, as an indicator of 
PNS], and pre-ejection period [PEP, as an indicator of SNS]. 
results: BZDs were used–for a median duration of two years by 442 
(15.6%) of NESDA participants at baseline. At follow-up, 243 (11.5%) used 
BZDs. In adjusted cross-sectional analyses no associations between BZD 
use and ANS measures were found. During follow-up, PEP increased in 
BZD initiators (Cohen’s d=0.23; P=0.04), but decreased in chronic users 
(d=0.19; P=0.03) versus non-users. No association between HR (P=0.21) 
and RSA (P=0.99) with BZD use was found.
conclusion: In general, long-term BZD use does not seem to negatively 
affect ANS activity. The only observations were slightly increased 
sympathetic activity in chronic BZD users and slightly decreased 
sympathetic activity in new BZD users. The clinical relevance of these 
findings needs to be established in future research.
INITIATED AND DISCONTINUED BENZODIAZEPINE USE IN RELATION 
TO AUTONOMIC NERVOUS SYSTEM ACTIVITY  |  161
iNtroDUctioN
The autonomic nervous system (ANS) is part of the peripheral nervous 
system and controls functions that are engaged in physiological 
homeostasis. It consists of the sympathetic (SNS) and the parasympathetic 
nervous system (PNS). The SNS mobilizes the fight-or-flight response; it 
enhances energy release and increases heart rate to prepare the body for 
action. The PNS stimulates “rest-and-digest” activities that occur when 
the body is at rest, such as digestion and salivation. In research, SNS 
activity can be measured through the pre-ejection period (PEP) which is 
a widely used, valid index of sympathetic effects on cardiac contractility.1 
PNS activity is often measured through respiratory sinus arrhythmia 
(RSA) which is an index of heart rate variability (HRV). Heart rate (HR) 
reflects both the inhibitory and augmenting control of PNS and SNS on 
the heart.2
It was recently described with cross-sectional and longitudinal 
data of the Netherlands Study of Depression and Anxiety (NESDA) 
that antidepressant medication use is associated with unfavourable 
effects on SNS and PNS activity.2-4 The use of tricyclic antidepressants 
(TCAs), selective serotonin reuptake inhibitors (SSRI) and serotonin–
norepinephrine reuptake inhibitors (SNRI) was associated with decreased 
HRV, the use of SNRI and TCAs was associated with decreased PEP, and 
the use of SSRIs was associated with increased PEP.2-4 Consequently, it 
raises the important question, whether BZDs could have similar effects. 
Based on animal research, two theories about the effects of BZDs 
on the ANS were put forward. BZDs were suggested to suppress (stress-
induced) sympathetic activation by enhancing the sympathoinhibitory 
effects of GABA on presympathetic neurons in the paraventricular 
nucleus (PVN) of the hypothalamus.5,6 These neurons are critically 
involved in the forebrain regulation of sympathetic outflow5 and project 
to the rostral ventrolateral medulla and the spinal cord to modulate the 
excitability of sympathetic preganglionic neurons.7 As GABA is localized in 
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discrete autonomic centers of the brain, BZDs might enhance GABAergic 
inhibition of sympathetic outflow by other brain structures than the PVN 
as well (such as nucleus ambiguous,8 caudal ventrolateral medulla,8 
rostral ventrolateral medulla, 8 medullary raphe nuclei9). BZDs were also 
hypothesized to have vagolytic effects, meaning that they enhance the 
direct GABAergic inhibition of cardiac vagal neurons and the GABAergic 
inhibition in the nucleus tractus solitarii.10 
Both hypotheses have been investigated in short-term intervention 
studies in humans with the following results. In line with the hypothesis 
that BZDs affect SNS activity, BZDs were generally found to suppress 
stress-induced increases of sympathetic activity, 11-13 except for one study 
where BZDs seemed to heighten sympathetic outflow10 and another one 
which did not detect any SNS related effects of BZDs.14 During rest, 
BZDs were either reported to decrease sympathetic tone15-17 or not to 
have any effect at all. 14,18-20 Corresponding to the hypothesis that BZDs 
have a vagolytic effect, BZDs were commonly found to attenuate heart 
rate variability10,19,21-25 and to increase HR10,19,21,24-26. In contrast, two 
studies reported heightened heart rate variability17,27 and HR14 after BZD 
administration. Thus, based on these results of experimental studies, the 
effects of BZDs remained unclear.
Opposite to intervention studies, observational research on the 
effects of BZDs on the ANS is less common. While BZDs’ effects on SNS 
activity have not been investigated yet, cross-sectional research of our 
own group did not find significant differences in HRV and HR between 
BZD users and non-users.2 There are several possible explanations for 
the discrepancy of this finding with previous experimental research that 
reported an attenuation of HRV caused by BZDs. As dissimilar effects 
of lorazepam and alprazolam on the ANS have been reported,17 the joint 
investigation of different types of BZDs with possibly opposing effects 
might have cancelled each other out, resulting in no overall effects of 
BZDs on the ANS in long-term users. An alternative explanation is that 
only frequent BZD use and/or high BZD dosages lead to alterations of 
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ANS activity. Consistently, several intervention studies only found ANS 
alternating effects at higher dosages of BZDs22,28 and a dose-response 
effect of BZDs was reported.21,27 Finally, long-term users might develop 
tolerance to the effects of BZDs on the ANS so that they no longer differ 
from non-users. As most studies were limited to one day of testing, little 
can be said about this hypothesis. Only one study reported that BZDs 
still increases HR after seven nights of use,28 indicating that at least for 
this duration of use no tolerance develops.
As the potential effects of type of BZD, dosage, duration and 
frequency of BZD use on the ANS have not been studied previously, 
additional research is needed. The current study examined the associations 
between several characteristics of BZD use (frequency, type of BZD, 
daily dosage, duration of use) and SNS and PNS measures at baseline 
in 2838 subjects participating in the Netherlands Study of Depression 
and Anxiety (NESDA). Additionally, we compared BZD initiators, BZD 
discontinuers and chronic users to non-users (n=2114) over a two-year 
period on changes in several SNS and PNS functioning parameters in 
order to confirm or refute our previous cross-sectional results.2 
MAteriALs AND MetHoDs
subjects
Subjects participated in the baseline assessment of the Netherlands 
Study of Depression and Anxiety (NESDA), a longitudinal cohort study 
of 2981 respondents aged 18 to 65 years.29 Subjects were recruited from 
the community, general practice and specialized mental health care 
institutions throughout the Netherlands. The baseline interview consisted 
of a blood draw, a medical examination, supine rest with blood pressure 
recordings, psychiatric interviews, a cognitive computer task, and saliva 
sampling. The study protocol was approved by the Ethical Review Board 
of each participating center and all subjects signed an informed consent 
at the baseline assessment. 
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For the cross-sectional analyses, we excluded subjects with lacking 
data on ANS measures (n=143). For prospective analyses, additionally, 
subjects who did not participate in the follow-up assessment (n=385) or 
those with lacking follow-up data on BZD or ANS measures were excluded 
(n=482). Consequently, our final sample consisted of 2838 subjects 
at baseline and 2114 subjects at follow-up. At baseline and follow-up 
subjects who reported daily or less regular BZD use in the month prior 
to the baseline interview were defined as “BZD users” (baseline: n=442, 
follow-up: n=243) and those reporting no use of BZDs in the month before 
the baseline interview were defined as “non-users” (baseline: n=2396, 
follow-up: n=1871). For the follow-up measurement, we divided subjects 
into “non-users” (subjects who did not use BZDs during the whole follow-
up period, n=1726), “BZD initiators” (subjects who did not use BZDs 
at baseline, but initiated use during follow-up, n=85), “chronic users” 
(subjects who used BZDs at baseline and follow-up, n=158), and “BZD 
discontinuers” (subjects who used at baseline, but discontinued during 
follow-up, n=145) independent of dose and frequency of use in order to 
maximize group sizes. 
BZD Use
As characteristics of BZD use might be associated with ANS function,27 
four indicators of BZD use were investigated at baseline: frequency of 
BZD use, type of BZD, daily BZD dose, and duration of BZD use. BZD 
use during the month prior to baseline interview was registered by 
observation of drug containers brought to the interview (approximately 
70% of cases) or self-report. Daily and infrequent BZD users reported the 
type and dosage of BZD taken on an average day of use.30 The daily BZD 
dose was computed according to the coding system of the Anatomical 
Therapeutic Code (ATC) and Defined Daily Dose (DDD) system.31 The 
Mean Daily Dose was calculated by dividing individual daily doses (in 
milligrams) of BZDs by the DDD for the particular BZD. Frequency of 
use for infrequent users was taken into account when calculating the 
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average daily dose.30 BZDs were classified as ATC-coded groups N05BA, 
N05CD, and N03AE01. The non-BZD hypnotics zopiclone and zolpidem 
(ATC code N05CF), were also included. For patients using BZDs other 
than diazepam, equivalent daily doses were calculated with conversion 
tables.30,32,33 Dosages were summed when more than one BZD was used. 
The duration of BZD use was reported in months.
Physiological Measurements of the Autonomic Nervous system
Physiological recording was performed using the Vrije Universiteit 
Ambulatory Monitoring System (VU-AMS; Vrije Universiteit, Amsterdam, 
the Netherlands). The VU-AMS is a lightweight portable device that 
records electrocardiograms (ECG) and the impedance cardiogram (ICG) 
from 6 electrodes placed on the chests and backs of participants.34,35 
Recording was unobtrusive, and participants, who maintained full 
freedom of movement, tended to adjust very rapidly to this type of 
recording. Details on the VU-AMS recording can be found elsewhere.2,36 
In short, NESDA participants wore the VU-AMS device during most of 
the baseline assessments. The start of the various assessments was 
indicated by an event marker to divide the total recording into fixed 
periods (resting baseline, breaks, and test periods [interview 1, computer 
task, and interview 2]). Movement registration by a vertical accelerometer 
was used to excise periods in which participants were not stationary. 
Removal of breaks and non-stationary moments (about 15 minutes) left 
an average registration of 99.9 minutes (standard deviation [SD], 23.0 
minutes). The ANS controls several aspects of cardiac function, and is 
therefore reflected by the following indices: HR (controlled by the balance 
between the PNS and SNS), respiratory sinus arrhythmia (RSA, an 
indicator for heart rate variability [HRV], solely controlled by the PNS), 
and pre-ejection period (PEP, as a measure of sympathetic control).2 
From the ECG and the ICG, interbeat interval time series and respiration 
signal were extracted as described elsewhere.34,35,37 HR was derived 
from the interval between R-R waves in the ECG. RSA was obtained 
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by directly combining the electrocardiogram data with the respiration 
signal to obtain the variation in the interbeat intervals restricted to the 
typical respiratory frequency range (0.15-0.40 Hz), as described in detail 
elsewhere.38 High RSA reflects high parasympathetic activity. From the 
ICG PEP was derived, as described in detail elsewhere.39 Under conditions 
of unchanged preload and after load, the PEP is a pure measure of SNS 
control on the contractility of the heart, with high PEP signaling low SNS 
activity.36 The mean HR, PEP, and RSA were computed for rest and test 
conditions at baseline and follow-up separately. As rest and test scores 
for HR and RSA were not significantly different, they were collapsed to 
a single ‘test’ condition for each ANS indicator to simplify analyses.40 As 
PEP data during the computer task and the two interview conditions was 
also found to be very comparable, these data were combined to create one 
single PEP value per subject.3 
covariates 
As respiration rate has often been identified as possible confounder 
of HRV,41 we adjusted RSA analyses for respiration rate. Further 
important covariates in analyses of ANS have been identified in previous 
research in our study group.47,48 Those relevant for analyses on BZDs 
were sociodemographic characteristics (age, gender, education), health 
indicators (body mass index (BMI), physical activity, alcohol use, smoking, 
presence of a heart disease, number of chronic illnesses, and medication 
(use of heart medication, frequent use of antidepressant medication 
including selective serotonin reuptake inhibitors [SSRIs, ATC code 
N06AB], tricyclic antidepressants [TCAs, ATC code N06AA], and selective 
serotonin and noradrenalin reuptake inhibitors [including monoamine 
oxidase inhibitors, nonselective N06AF, and antidepressants classified 
as N06AX].
Sociodemographic characteristics included age, gender, and 
education in years and were reported during the baseline interview. 
Health indicators were measured at baseline and follow-up. BMI was 
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calculated as weight in kilograms divided by the square of height in 
meters. Physical activity was measured using the International Physical 
Activity Questionnaire42 and expressed as MET-minutes per week (the 
multiple of one’s resting metabolic rate times minutes of physical activity 
per week). Smoking was categorized as non-smoker versus smoker. For 
regular alcohol use, a continuous variable was computed as mean number 
of alcoholic consumptions per day. Self reports were used to ascertain 
the presence of heart disease (including coronary disease, cardiac 
arrhythmia, angina pectoris, heart failure, and myocardial infarction). 
The number of other chronic conditions such as diabetes, stroke, and 
cancer was ascertained by self-report and summed into a count variable. 
The presence of insomnia was determined using the Insomnia Rating 
Scale (IRS).43 Medication use was recorded at baseline and follow-up. 
Dichotomous variables for the use of heart medication were computed at 
both time points, scoring ‘yes’ if subjects frequently (daily or>50% of the 
time) used a medication with the following ATC codes: cardiac therapy, 
C01; antihypertensive drugs, C02; diuretic drugs, C03; peripheral 
vasodilator drugs, C04; vasoprotective drugs, C05; β-blocking agents, 
C07; and calcium channel blockers, C08. In addition, frequent use (daily 
or >50% of the time) of selective serotonin reuptake inhibitors (SSRIs, 
ATC code N06AB), tricyclic antidepressants (TCAs, ATC code N06AA), 
and serotonin and noradrenalin reuptake inhibitors (SNRI; including 
monoamine oxidase inhibitors, nonselective N06AF, and antidepressants 
classified as N06AX) was defined at either of the time points. 
statistical Analyses
Characteristics of study groups at baseline and follow-up were expressed 
by frequencies, means or medians, and compared using c2 statistics 
(categorical variables), analyses of variance (continuous variables, 
normal distribution), and Kruskal-Wallis tests (continuous variables, 
non-Gaussian distribution). 
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Analyses of variance (ANOVAs) were conducted to compare non-users, 
infrequent users and daily users as well as the different types of BZDs 
at baseline on RSA, PEP, and HR. Linear regression analyses were used 
to assess associations between baseline characteristics of BZD use (i.e., 
duration of BZD use and BZD dose) and ANS indicators as continuous 
dependent variables. All analyses were conducted unadjusted as well as 
after adjustment for sociodemographic characteristics in model 1 and 
additional adjustment for health indicators and used medication in 
model 2. We did not adjust for diagnosis and severity of depression and/
or anxiety, as these diagnoses were not associated with ANS variables 
in previous research of our study group. Analyses of variance (ANOVAs) 
were conducted to compare BZD initiators, BZD discontinuers and 
chronic users to non users on absolute changes of RSA, PEP, and HR 
between baseline and follow-up in order to confirm or refute cross-
sectional results by prospective data. In order to investigate changes 
of ANS indices between the baseline and the follow-up measurement, a 
change score was calculated by subtracting the baseline RSA, PEP and 
HR value from the follow-up value. A higher score indicated higher values 
at follow-up, as compared to baseline. These analyses were adjusted for 
above mentioned covariates in model 1 as well as for health indicators 
and medication use as measured at follow-up in model 2. We additionally 
performed sensitivity analyses after separate exclusion of the different 
antidepressant groups (TCA, SSRI, and SNRI users at baseline and 
/ or follow-up), in order to make sure that our findings would not be 
confounded by the strong effects of antidepressant use on the ANS. 
Cohen’s d (i.e., the difference in group means, divided by their pooled 
standard deviation) was calculated as a measure of effect size. Post-hoc 
tests on individual group differences were performed using the Fisher’s 
Least Significant Difference test. Statistical significance was inferred at P 
< 0.05. All statistical analyses were conducted using SPSS version 16.0 
for Windows.
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resULts
Characteristics of the three user groups as defined at baseline are 
presented in Table 1. Daily and infrequent users were older than non-
users (P<0.001) and had a lower education level (P<0.001). They had a 
higher BMI (P<0.001), more often suffered from heart disease (P<0.001) 
and more often had comorbid anxiety and depression (P<0.001). They 
also used more antidepressants (P<0.001). Daily BZD users used a higher 
daily BZD dosage than infrequent users (P<0.001). 
Baseline Associations between BZD Use and ANs Measures
Table 2 presents group differences between daily users, infrequent users, 
and non-users on the PNS measure RSA, the SNS measure PEP, and HR. 
In the fully adjusted models, daily and infrequent users did not differ 
from non-users on HR (P=0.27), RSA (P=0.96), and PEP (P=0.08). 
Table 3 shows associations between the ANS variables and the 
duration as well as the daily dosage of BZD use. In the fully adjusted 
models, neither duration nor dosage of BZD use was associated with 
any of the SNS and PNS measures. Further, we compared oxazepam, 
diazepam, alprazolam, temazepam, lorazepam and zopiclone users on the 
different ANS measures. Neither in unadjusted nor in adjusted analyses 
groups differed on HR, HRV and PEP (data not shown). 
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Gender, % female 66.4 70.7 64.8 0.32
Age, years 40.9 (40.4 – 41.4) 45.0 (43.4 – 46.5) 48.3 (46.4 – 46.5) <0.001
Education level, years 12.0 (10.0 – 15.0) 11.0 (9.0 – 15.0) 10.0 (9.0 – 15.0) <0.001
Lifestyle factors
Body Mass Index, kg/m2 25.4 (25.2 – 25.6) 26.2 (25.7 – 26.8) 26.7 (26.0 – 27.4) <0.001
Physical Actvity, 1000 
MET-min/week 
3.1 (1.4 – 5.0) 2.8 (1.4 – 4.6) 2.6 (0.7 – 4.8) 0.01
Current smoker, % 28.9 26.7 21.6 0.10
Alcohol use, # drinks/day 0.4 (0.02 – 1.2) 0.3 (0.02 – 1.2) 0.02 (0.0 – 0.8) <0.001
Physical and psychological health
Heart disease, % 5.1 7.1 12.5 <0.001
Respiration rate, breaths/
min
17.1 (17.0 – 17.1) 16.9 (16.8 – 17.1) 17.0 (16.8 – 17.2) 0.07
Number of chronic 
illnesses
1.0 (0.0 – 1.0) 1.0 (0.0 – 2.0) 1.0 (0.0 – 2.0) <0.001
One year diagnosis, % <0.001
Anxiety disorder only 14.7 20.3 15.9
Depressive disorder only 15.2 18.0 16.5
Comorbid disorder 23.3 44.4 55.1
BAI Questionnaire 8.0 (3.0 – 16.0) 19.0 (9.0 – 25.0) 22.0 (11.0 – 31.0) <0.001
IDS-SR Mood/Cognition 
Scale
6.0 (2.0 – 11.0) 10.5 (5.0 – 15.0) 13.0 (7.6 – 19.0) <0.001
Medication Use
Use of heart medication, 
%




TCA 2.0 4.5 8.5
SSRI 13.6 30.5 40.9
SNRI 4.0 9.4 16.5
Characteristics of BZD Use
Duration of Use, months NA 24.0 (5.0 – 84.0) 24.0 (5.0 – 96.0) 0.84
Dosage of BZD, mg NA 1.0 (0.3 – 2.0) 6.3 (5.0 – 13.1) <0.001
Long half-life, % NA 17.3 19.9 0.49
MDD indicates Major Depressive Disorder; SSRI indicates Selective Serotonin Reuptake Inhibitor; 
TCA indicates Tricyclic Antidepressant; NA indicates not applicable. Means (95% confidence 
intervals) are given for continuous, normally distributed variables. Medians (interquartile ranges) 
are given for continuous, non-normally distributed variables (education, physical activity, alcohol 
use, number of chronic illnesses, BAI, IDS-SR, duration of BZD use, and daily dosage of BZD 
use). Percentages are given for categorical variables. P is derived by analysis of variance (ANOVA) 
for quantitative, normally distributed variables, Kruskal Wallis test for continuous, non-normally 
distributed variables, or χ² statistics for categorical variables.
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tABLe 2. Association Between ANS Measures and Frequency of BZD Use 
(n=2838)









Unadjusted 72.0 (71.6 – 72.4) 71.2 (70.1 – 72.4) 72.7 (71.3 – 74.1) 0.35
Model 1 71.9 (71.6 – 72.3) 71.4 (70.3 – 72.5) 73.3 (71.9 – 74.7) 0.07
Model 2 72.0 (71.6 – 72.4) 71.2 (70.1 – 72.4) 72.8 (71.4 – 74.3) 0.27
rsA, ms
Unadjusted 45.8 (44.8 – 46.9) 39.7 (36.6 – 42.8)* 33.5 (29.7 – 37.3)* <0.001
Model 1 45.0 (44.2 – 45.9) 42.4 (39.9 – 45.0) 40.5 (37.3 – 43.7)* 0.007
Model 2 44.5 (43.7 – 45.4) 44.3 (41.7 – 46.8) 44.6 (41.4 – 47.8) 0.96
PeP, ms
Unadjusted 119.3 (118.6 – 120.0) 121.4 (119.2 – 123.6) 122.8 (120.1 – 125.5)* 0.02
Model 1 119.3 (118.5 – 120.0) 121.6 (119.4 – 123.8)* 123.2 (120.5 – 126.0)* 0.007
Model 2 119.4 (118.7 – 120.1) 120.9 (118.8 – 123.1) 122.0 (119.2 – 124.7) 0.08
HR indicates heart rate; RSA indicates respiratory sinus arrhythmia; PEP indicates pre-ejection 
period; BZD indicates benzodiazepine; CI indicates confidence interval. Model 1 was adjusted 
for age, gender, and education. Model 2 was additionally adjusted for physical activity, BMI, 
smoking, alcohol/day, number of chronic diseases, presence of heart disease, TCA, SSRI, SNRI, 
heart medication. The analyses of RSA were additionally adjusted for respiration rate. P-value was 
calculated by analysis of variance (ANOVA, P for linear trend). Significance was inferred at P<0.05. 
* indicates that the group differs significantly from the non-user group (post-hoc test,P <0.05).
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tABLe 3. Associations Between BZD Dose and Duration of BZD Use and Various 
ANS  Indicators in 442 BZD Users
ANs measures Duration of Use Daily BZD Dose
N β P N β P
Hr, beats/min
Unadjusted 439 -0.075 0.12 436 0.025 0.60
Model 1 439 -0.062 0.22 436 0.046 0.34
Model 2 439 -0.077 0.14 436 0.047 0.35
rsA, ms
Unadjusted 439 -0.119 0.01 436 -0.141 0.003
Model 1 439 0.028 0.54 436 -0.086 0.04
Model 2 439 0.053 0.22 436 -0.026 0.53
PeP, ms
Unadjusted 439 -0.054 0.26 436 0.044 0.36
Model 1 439 -0.053 0.30 436 0.041 0.41
Model 2 439 -0.051 0.32 436 0.012 0.80
HR indicates heart rate; RSA indicates respiratory sinus arrhythmia; PEP indicates pre-ejection 
period; BZD indicates benzodiazepine;. Model 1 was adjusted for age, gender, and education. 
Model 2 was additionally adjusted for physical activity, BMI, smoking, alcohol/day, number of 
chronic diseases, presence of heart disease, TCA, SSRI, SNRI, heart medication. The analyses of 
RSA were additionally adjusted for respiration rate. P was calculated by linear regression analysis. 
Significance was inferred at P<0.05.
Prospective Associations between BZD Use and ANs Measures
Chronic users were older (P<0.001) and had more chronic diseases 
(P<0.001) than non-users, BZD initiators and BZD discontinuers. 
Chronic users had more severe anxiety than all other groups (P<0.001) 
and more severe depression than non-users and initiated users, but not 
than discontinued users. Further they had a lower education (P<0.001) 
than non- users and BZD discontinuers. All BZD user groups more 
often used antidepressants than non-users (P<0.001). At follow-up, the 
average HR across the whole sample was 72.7 beats/minute, the mean 
RSA 41.7 milliseconds and the mean PEP 119.2 milliseconds. Paired 
sampled t-tests showed a significant mean increase in HR (P<0.001) and 
a significant decrease in RSA (P<0.001), but no significant changes in 
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PEP (P = 0.88) over time within participants. The Spearman’s correlation 
coefficients between baseline and follow-up measurements were 0.72 for 
HR, 0.81 for RSA, and 0.59 for PEP (all Ps<0.001). The mean HR was 72.6 
for non-users, 73.8 for BZD initiators, 71.7 for BZD discontinuers and 
73.5 for chronic users. The mean RSA was 41.7 for non-users, 41.7 for 
BZD initiators, 42.3 for BZD discontinuers and 41.3 for chronic users. 
Mean PEP was 119.1 for non-users, 121.8 for BZD initiators, 120.6 for 
BZD discontinuers and 117.4 for chronic users.
In fully adjusted analyses, BZD user groups did not differ on HR 
(P=0.21) and RSA (P=0.99). However, groups showed significant differences 
on PEP, even after adjustment for all covariates (P=0.009). BZD initiators 
displayed a higher increase of PEP between baseline and follow-up than 
non-users (Cohen’s d=0.23; P=0.04). As higher PEP represents lower SNS 
activity, this indicates that BZD initiators have a higher decrease in SNS 
activity than non-users. Chronic users displayed a higher decrease in 
PEP than non-users (d=0.19: P=0.03), indicating that chronic users had 
higher increase in SNS activity than non-users. When TCA users (n=74) 
and SNRI users (n=168) were excluded in separate sensitivity analyses, 
these results did not change. When the SSRI users were excluded 
(n=441), group differences on PEP were not significant anymore (P=0.13) 
while the effect sizes of the difference between initiated users and non-
users decreased (d=0.18) and the effect size of chronic users vs. non-
users increased (d=0.20).
Figure 1 shows the prospective group differences of BZD initiators, 
BZD discontinuers, and chronic users compared to non-users on HR, 
RSA, and PEP after adjustment for all covariates at baseline and follow-
up. Over the follow-up period, BZD initiators displayed a significantly 
higher increase in PEP while chronic users showed a significantly higher 
decrease in PEP versus non-users in post-hoc analyses.
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∆ (95% CI) ∆ (95% CI) ∆ (95% CI) ∆ (95% CI) P 
HR, beats/min
Unadjusted 0.5 (0.1 – 0.8) 1.1 (-0.5 – 2.7) 1.2 (-0.0 – 2.4) 2.6 (1.5 – 3.8)* 0.005
Model 1 0.5 (0.2 – 0.9) 0.8 (-0.8 –2.4) 1.0 (-0.2 –2.3) 2.4 (1.2 –3.6)* 0.04
Model 2 0.6 (0.3 – 1.0) 0.3 (-1.2 –1.9) 1.0 (-0.2 – 2.2) 1.9 (0.7 – 3.1) 0.21
RSA, ms
Unadjusted -2.1 (-2.8 – -1.3) -4.0 (-7.3 – -0.6) -1.4 (-3.9 – 1.2) -2.3 (-4.7 – 0.1) 0.67
Model 1 -1.9 (-2.6 – -1.2) -3.9 (-7.1 – -0.6) -2.6 (-5.1 – - 0.0) -3.2 (-5.7 – - 0.8) 0.52
Model 2 -2.1 (-2.8 – -1.4) -2.7 (-5.9 – -0.6) -2.2 (-4.7 – -0.3) -2.3 (-4.7 – 0.2) 0.99
PEP, ms
Unadjusted 0.7 (-0.1 – 1.4) 2.0 (-1.5 – 5.5) -2.9 (-5.5 – -0.2)* -5.0 (-7.5 – -2.4)* <0.001
Model 1 0.4 (-0.4 – 1.1) 2.8 (-0.6 – 6.3) -1.3 (-4.0 – 1.4) -3.6 (-6.2 – -1.0)* 0.008
Model 2 0.3 (-0.5 – 1.0) 3.8 (0.5 – 7.1)* -1.6 (-4.2 –1.0) -2.7 (-5.2 – -0.2)* 0.009
HR indicates heart rate; RSA indicates respiratory sinus arrhythmia; PEP indicates pre-ejection 
period; BZD indicates benzodiazepine.
Model 1 was adjusted for baseline age, gender, education, physical activity, BMI, smoking, 
alcohol/day, number of chronic diseases, presence of heart disease, TCA, SSRI, SNRI, and 
heart medication. The analyses of RSA were additionally adjusted for respiration rate. Model 2 
was additionally adjusted for physical activity, BMI, smoking, alcohol/day, number of chronic 
diseases, presence of heart disease, TCA, SSRI, SNRI, and heart medication at follow-up. 
P was calculated by analysis of variance (ANOVA). Significance was inferred at P<0.05. * indicates 
that the group differs significantly from the non-user group (post-hoc test, P <0.05)
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FiGUre 1. Prospective 
Associations Between 
Transitions in BZD Use and 
Changes in ANS Measures 
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DiscUssioN
In this study, possible associations between BZD use and various 
measures of the autonomic nervous system (ANS) were studied over a two-
year follow-up period. In cross-sectional analyses, BZD use in general and 
characteristics of use (type, dose, frequency, and duration of use) were 
not associated with any of the ANS indicators. In contrast to previous 
research,17 alprazolam did not have different effects on the ANS than 
other BZDs. In prospective analyses, BZD initiators displayed slightly 
lower SNS activity while BZD chronic users displayed slightly higher SNS 
activity. No associations between BZD use and PNS function were found. 
As effect sizes of the found group differences were relatively small, the 
clinical relevance of these findings is questionable. As the increase in PEP 
in BZD initiators opposed that of the decrease found in chronic users, the 
significant results might be chance findings considering the number of 
tests conducted in this study. The absence of strong effects on the ANS 
by BZDs is in contrast with our earlier observations for antidepressants, 
for which we found unfavourable effects on SNS and PNS activity.
In our cross-sectional analyses, we did not detect associations 
between SNS functioning and BZD use. In prospective analyses, BZD 
initiators showed a decrease in SNS activity versus non-users, indicating 
that BZD use may slightly suppress SNS functioning. This finding is in 
line with a number of studies that found a suppression of SNS activity (as 
measured by spectral power analysis,11,12,15 norepinephrine,16 and muscle 
sympathetic nerve activity15) after BZD administration,11-13,15-17 but in 
contrast with those that reported heightened SNS activity10 or HR10,19,21,24-26 
upon BZD intake. As in NESDA most subjects initiated BZD use longer 
than two months ago, the slight, sustained reduction in SNS activity in 
BZD initiators suggests that tolerance to BZDs SNS decreasing effect has 
not developed, at least not within several months. However, a suppression 
of SNS activity should also be reflected in a decrease of HR which was not 
present in our study. This complicates the interpretation of our results. 
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Further, chronic users displayed a higher increase in SNS activity between 
baseline and follow-up than non-users and also had higher absolute SNS 
activity values than the non-user group. This might be explained by the 
development of tolerance to the SNS decreasing effects of BZDs in chronic 
use. However, as the majority of chronic BZD users were already using 
for a long duration of time when the baseline measurement took place, 
tolerance development would have been expected much earlier. Therefore, 
these explanations are unlikely. As the cross-sectional and longitudinal 
results of the PEP analyses were quite inconsistent and the decrease of 
PEP was not accompanied by a decrease in HR, the group differences are 
difficult to explain and further research is needed to clarify the clinical 
relevance of our findings. When the sizeable group of SSRI users was 
excluded in a sensitivity analysis, the effect size of the difference between 
BZD initiators and non-users decreased by 20%, but the effect size of 
the difference between chronic users and non-users increased by 5%. As 
SSRIs were found to decrease sympathetic activity in previous research,3 
a small part of the SNS decrease found in BZD initiators may have been 
driven by concomitant SSRI use. 
The absence of group differences on PNS activity in our 
cross-sectional and prospective analyses contrasts with the BZD 
induced lowered HRV and elevated HR values found in experimental 
research.10,19,21-26 There are several possible explanations for these 
discrepancies. Tolerance may have developed to the effects of BZDs on 
the ANS, so that BZDs do not affect PNS activity in chronic BZD users 
as they do in short-term users.21,22,24 This hypothesis is not supported by 
previous research which did not report tolerance development to BZDs 
effects on HR after a duration of seven days.28 However, other research 
indicated that BZD induced HR increases went back to baseline after 
approximately 30 minutes, suggesting that this effect might be transient 
in nature.10,24 Alternatively, NESDA mainly consists of participants using 
relatively low dosages of BZDs (median daily dosage of 6.0 mg diazepam 
equivalents) and previous research mainly found alternated ANS activity 
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with higher dosages.22,28 However, some studies also found ANS effects 
with comparably low dosages of BZDs.27 Further, low dosage BZD use 
presents the daily treatment practice so that the NESDA BZD user sample 
is representative of the average BZD user. 
A dysregulation of the ANS can manifest itself as a reduction in 
HRV, an increase in HR, and heightened SNS activity. These alterations 
of the ANS are established risk factors for cardiovascular disease (CVD) 
such as coronary heart disease and acute myocardial infarction.44-46 As 
BZDs are often used for long periods of time, adverse effects on the ANS 
may put users at a higher risk to develop CVD. This is especially true 
when BZDs are used in the treatment of anxiety caused by chest pain 
and myocardial ischemia.47 Therefore it is reassuring that BZDs - unlike 
antidepressants - do not seem to affect PNS functioning in long-term 
users.2 Furthermore, BZDs may even modestly decrease SNS activity. 
In contrast, chronic BZD use was associated with a slight increase in 
SNS activity and might thus be harmful, especially for patients with 
established CVD. 
Our study has some limitations. We were not able to investigate 
the effects of high dosages of BZDs as the median daily dosage in NESDA 
was relatively low. As we had to rely on subjects’ self-report on BZD intake, 
we cannot be sure whether subjects were actually using the medications 
as prescribed and as they themselves indicated. In addition, as the time 
of the most recent drug intake was not recorded we could not know if and 
how long ago the most recent BZD intake had taken place. This might have 
reduced the reported effects. Despite these limitations, our study had 
also several strengths. We were the first study to investigate the potential 
effects of type of BZD, dosage, duration and frequency of BZD use on 
the ANS. Further, we were able to investigate the effects of transitions of 
BZD use on the ANS over a two-year follow-up while correcting for the 
most important confounders. Finally, we included several aspects of ANS 
activity and investigated a user group representative of the average BZD 
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user. Therefore, our results may reflect the actual effects of BZDs on the 
ANS in the average BZD user. 
In conclusion, long-term BZD use does not appear to have strong 
adverse effects on SNS or PNS activity as earlier described for some 
antidepressants.2,3 Longitudinal analyses seem to suggest that relatively 
recent BZD initiation might slightly suppress SNS activity while chronic 
BZD use might slightly increase SNS activity. Whether this finding has 
clinical relevance needs to be established. 
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ABstrAct
Aim: Short-term administration of benzodiazepines (BZD) was found to 
prolong reaction time (RT) in experimental studies. However, studies on 
long-term BZD use did not always adjust for important confounders and 
showed inconsistent results. We aimed to identify a possible relationship 
between long-term BZD use and RT in BZD users of this large cross-
sectional, observational study.
Methods: The RT of non-users (n=2404) were compared to low- (n=288), 
intermediate- (n=74), and high dose BZD users (n=57) of the Netherlands 
Study of Depression and Anxiety. RTs were obtained from the Implicit 
Association Test. Analyses were adjusted for sociodemographic 
characteristics, health indicators, severity of psychopathology, and 
antidepressant use. 
results: Of the NESDA participants, 419 subjects (14.8%) used BZDs. A 
higher dose of BZDs was associated with prolonged RTs (P=0.01). When 
comparing the different dose groups, the high dose group, but not the 
low and medium dose groups, had significantly longer RTs than the non-
users. 
conclusions: Tolerance for the RT prolonging effect of relatively high 
doses of BZDs does not seem to develop. As prolonged RTs can have severe 
consequences in daily life, BZDs should be prescribed conservatively at 
the lowest possible dose.
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iNtroDUctioN
As the prevalence of long-term benzodiazepine (BZD) use is high,1 the 
accompanying side effects are an important research topic. Reaction 
time (RT) impairments are common in short-term BZD use2 and even 
seem to remain in chronic use3. Choice RT tasks (CRTTs), where different 
responses are to be sorted to one of several stimuli as fast as possible, are 
an objective means to detect RT impairments due to the use of BZDs.4,5 
Previous research on the association between BZD use and RT (as 
measured by CRTTs) mainly consisted of small randomized trials, which 
compared the effects of short term BZD administration to placebo. In 
most of these studies, BZD administration prolonged RTs for a duration 
up to six weeks.6-11 Only two small studies did not find prolonged RTs 
after BZD intake.12,13 
The few studies on the association between longer-term BZD use 
and RTs reported inconsistent results. One cross-sectional, observational 
study found longer RTs in chronic users than in non-users, but did not 
investigate if this effect was confounded by psychopathology.14 Two studies 
did not report differential RTs among BZD users and non-users.15,16 When 
an extra dose of 20mg oxazepam was administered, RT increased in 18 
BZD-naive participants, but not in 18 long-term BZD users, suggesting 
that tolerance to BZDs effects on RT may have developed.16
The inconsistent results regarding chronic BZD use may be 
caused by the lack of correction for established confounders such as 
psychopathology,14,16 physical health,14,15 and antidepressant use14. 
Further, differences in sample selection (healthy subjects versus subjects 
with psychopathology) may have led to the discrepancies. In order to 
determine whether the effects of BZD on RT remain in long term BZD 
use, we analyzed the association between BZD use and RT as measured 
by the Implicit Association Test (IAT) in 2823 participants of the NESDA 
study and corrected for important confounders.
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MetHoDs
subjects
Subjects participated in the baseline assessment of the Netherlands Study 
of Depression and Anxiety (NESDA).17 NESDA recruited 2981 individuals 
aged 18-65 with and without symptoms of depressive and/or anxiety 
disorders from different health care settings.17 Lifetime diagnoses were 
defined as current or past diagnosis of a depressive or anxiety disorder 
as assessed by the DSM-IV Composite International Diagnostic Interview 
(CIDI, WHO version 2.1). The baseline assessment included written 
questionnaires, an oral interview and the IAT computer task.17 The study 
protocol was approved by the ethical review board of each participating 
center, and all subjects signed an informed consent.
Subjects without IAT data (n=129), those with unusual long RTs 
(>10seconds, n=5) or missing values on BZD dose (n=6) or BZD users 
without a lifetime diagnosis of depression or anxiety (n=18) were excluded. 
After exclusion, 2823 subjects (94.7%) remained for our analyses. Of this 
group, 419 (14.8%) subjects used BZDs. Subjects who conducted the 
IAT were not statistically different from those who did not in terms of 
BZD use in general, used dose of BZDs, gender, education, and severity 
of depression and anxiety. However, subjects without IAT data were 
significantly older (P=0.002). 
MeAsUres
BZD Use
BZD use was registered by observation of drug containers brought to 
the interview (73.4%) or self-reports. BZDs were classified as ATC-coded 
groups N05BA, N05CD, and N03AE01 and the non BZD hypnotics 
zopiclone and zolpidem (ATC code N05CF).18 The daily BZD dose was 
computed according to the coding system of the Anatomical Therapeutic 
Code (ATC) and defined daily dose (DDD) system.19 The mean daily 
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dose was calculated by dividing individual daily doses of BZDs by the 
corresponding DDD. For subjects using BZDs other than diazepam, an 
equivalent dose was calculated.20 The DDD was categorized into three 
groups: 1) daily dose below 0.5 DDD (low dose), 2) daily dose between 0.5 
and 1 DDD (intermediate dose), and 3) daily dose > 1 DDD (high dose). 
BZD users completed the BZD Dependence Self-Report Questionnaire 
(Bendep-SRQ) as a measure of dependence severity.21,22 
implicit Association test
The Implicit Association Test (IAT) is a computerized RT task which 
measures the strength of implicit associations.23 However, we did not use 
the IAT to measure implicit associations, but solely to measure RTs in 
a CRTT. To avoid the interference of implicit associations, we only used 
four single concept blocks of the IAT (Supplement 1). Stimulus words 
from two categories (e.g., anxious or calm) appeared in mixed order in 
the middle of a computer screen. Participants were instructed to sort 
the stimulus words as fast as possible to one of the two categories by 
pressing either a left response key (‘Q’) or a right response key (‘P’) on the 
keyboard. The RT of a trial was defined as the time from the appearance 
of a stimulus word until the correct response key was pressed.24 In the 
NESDA study, two IATs were included, a ‘depression IAT’ and an ‘anxiety 
IAT’.25 In the anxiety IAT, subjects needed to sort words (such as nervous 
or relaxed) into the categories ‘anxious’ and ‘calm’. In the depression IAT, 
subjects needed to sort words (such as meaningless or valuable) in the 
categories ‘depressed’ and ‘elated’.25 
covariates
As sociodemographic characteristics (sex, age, education), health 
indicators (alcohol use, chronic disease), psychopathology (severity 
of anxiety and depression), and antidepressant use were found to be 
associated with RTs and BZD use,5,26,27 these variables were included as 
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covariates in our analyses. Additionally, the total number of mistakes 
made during the analyzed IAT blocks was taken into account. 
Sociodemographic characteristics were reported during the 
baseline interview. For regular alcohol use, the mean number of alcoholic 
consumptions per day was computed. The number of chronic somatic 
conditions was ascertained by self-report and dichotomized into presence 
of one or more chronic somatic conditions (yes/no). The severity of 
generalized anxiety and panic symptoms was assessed with the Beck 
Anxiety Inventory (BAI).28 The severity of depressive symptoms was 
measured by the cognitive/mood scale of the Inventory of Depressive 
Symptomatology Self Report (IDS-SR).29 Antidepressant use was 
subdivided into selective serotonin reuptake inhibitors (SSRIs, ATC code 
N06AB), tricyclic antidepressants (TCAs, N06AA), and selective serotonin 
and noradrenalin reuptake inhibitors (N06AF, N06AX). The mean daily 




Sample characteristics were expressed by percentages for categorical 
variables, by means for continuous, normally-distributed variables 
and by medians for continuous, non-normally distributed variables. 
RTs were transformed into their negative inverse (-1/RT) due to their 
positively skewed distributions, yielding a normal distribution.30 The 
negative inverse of the blocks 2, 5, 8, and 11 of the IAT were averaged to 
diminish the influence of a preference for responses with the dominant 
hand. To correct for the learning effect, z-scores were calculated for each 
block (using -1/RTs transformed values). These were averaged into one 
single score per subject. A higher z-score indicates a longer RT, thus 
a prolonged response. Group differences between non-users, low dose 
users, intermediate dose users and high dose users on RTs were analyzed 
by analysis of covariance. Post-hoc tests on individual group differences 
were performed using the Fisher Least Significant Difference test. The 
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analysis was corrected for sociodemographic characteristics, duration 
of BZD use, health indicators, severity of psychopathology, duration 
of BZD use, daily dose of antidepressant use, and number of mistakes 
made in the IAT. Analysis for trend was conducted. Linear regression 
analyses were used to examine associations between characteristics of 
BZD use as separate independent variables and RT in BZD users only 
after adjustment for all covariates. 
resULts
characteristics of the study Population
Table 1 shows the sample characteristics of the 2823 included participants, 
of which 419 subjects (14.8%) had used BZDs in the past month. Subjects 
with a low daily dose were more often female (72.2%) than the non users, 
intermediate-, and high dose groups. The average age was lower in the 
non-users (40.9 years) and increased with each BZD dose. Non-users 
had lower BAI (median=8.0) and IDS (median=6.0) scores than all BZD 
user groups. The mean RT for the group as a whole was 0.96 seconds 
(s). It was shortest in the non users group and increased with each dose 
group. All groups had a median number of three mistakes in the four 
included blocks.
Associations Between BZD use and rt
Table 2 shows group differences between non-users and low-, 
intermediate- and high dose users on RT. In unadjusted (P for linear 
trend <0.001) and adjusted analyses (P=0.01) groups differed significantly 
on RT. Gender (F=16.69), age (F=521.32), education (F=108.03), number 
of alcoholic drinks consumed (F=5.27), severity of depression (F=15.88) 
and anxiety (F=14.38) had much higher F values than dose of BZD use 
(F=2.35). In contrast, daily dose of TCA (F=0.008), SSRI (F=0.05), and 
other antidepressants (F=0.13) had much lower F values than daily 
dose of BZDs. In post-hoc tests, high dose BZD users had significantly 
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longer RTs than non-users, while the other dose groups did not differ 
significantly from non-users. Figure 1 shows the adjusted mean RTs per 
user group as obtained by multivariate regression analysis. Higher BZD 
doses were significantly associated with longer RTs (P=0.01).
FiGUre 1. The adjusted mean values of reaction time (in milliseconds) obtained from 
the Implicit Association Test (IAT) according to the dose of BZDs used in 2823 NESDA 
participants. The size of each square is proportional to the number of participants. Vertical 
lines indicate standard errors. Analyses were adjusted for sociodemographic variables 
(i.e., gender, age, education), health indicators (i.e., daily alcohol use, presence of somatic 
disease), psychopathology (i.e., IDS-mc, BAI), and antidepressant use (in 4 categories). Low 
dose was defined as <5 mg diazepam equivalents/day, intermediate dose as 5-10 mg/
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tABLe 2. Differences of Non-users, Low Dose Users, Intermediate Dose Users, 
and High Dose Users on RT as Analyzed in 2823 NESDA Participants
No Use Low Dose Intermediate 
Dose
High Dose
n=2404 n=288 n=74 n=57
Mean (95% CI) Mean (95% CI) Mean (95% CI) Mean (95% CI) P
Unadjusted 0.95 (0.94–0.96) 1.03 (1.00-1.06) 1.11 (1.04-1.18) 1.19 (1.11-1.29) <0.001
Adjusted 0.96 (0.95-0.97) 0.97 (0.95-0.99) 0.99 (0.95-1.05) 1.03 (0.97-1.10) 0.01
RT, reaction time; BZD, benzodiazepines; DDD, defined daily dose; CI, confidence interval. 1 DDD was 
defined as 10 mg diazepam equivalents per day. The adjusted analysis was adjusted for sociodemographic 
characteristics (gender, age, education level), health indicators (alcohol intake and presence of a somatic 
disease), severity of psychopathology (BAI and IDS-mc), daily dose of used antidepressants, and number 
of mistakes made in the IAT. Low dose was defined as <5 mg diazepam equivalents/day, intermediate 
dose as 5-10 mg/day, and high dose as > 10 mg/day. P was obtained by ANCOVA (analysis for linear 
trend). Significance was inferred at P < 0.05. 
Associations Between characteristics of BZD use and rt 
Table 3 reports the results of additional regression analyses on specific 
associations between the characteristics of BZD use and RT among 
the BZD users only. After adjustment, a higher daily dose of BZDs was 
associated with longer RTs (β=0.096, P=0.03). This indicates a possible 
dose-response effect of BZDs on RTs. Further, problematic use showed 
a positive association (β=0.118, P=0.02) with RT. Figure 2 shows the 
adjusted mean values of reaction time according to problematic use on the 
Bendep-SRQ in BZD users only (n=366). Beta-coefficients and P-values 
were obtained by multivariate linear regression analysis. A higher score on 
the Bendep-SRQ subscale Problematic Use was significantly associated 
with longer RTs (P=0.02). 
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tABLe 3. Associations between Characteristics of BZD use and RT in 419 BZD 
Users
Univariate analysis Adjusted model§
characteristics of BZD use n β P β P
Dose$ 419 0.167 0.001 0.096 0.03
Duration of BZD use 419 0.114 0.02 0.036 0.40
Type of BZD 419 0.115 0.02 -0.013 0.77
Problematic use# 366 0.190 <0.001 0.118 0.02
Preoccupation# 366 0.110 0.04 0.023 0.64
Lack of Compliance# 366 0.210 <0.001 0.070 0.17
BZD; benzodiazepines, β; standardized beta coefficient by linear regression analyses. $ Daily 
dose is entered as a continuous variable. # Subscales of the Benzodiazepine Dependence Self 
Report Questionnaire. § The adjusted models were adjusted for sociodemographics (gender, 
age, education), health indicators (daily alcohol use, presence of somatic disease), severity of 
psychopathology (IDS-mc, BAI), and antidepressant use (SSRI, TCA, other antidepressants).
FiGUre 2. The adjusted mean values of reaction time (in milliseconds) obtained from the 
Implicit Association Test (IAT) according to problematic use on the Bendep-SRQ in BZD users 
only (n=366). The size of each square is proportional to the number of participants. Vertical 
lines indicate standard errors. Analyses were adjusted for sociodemographic variables (i.e., 
gender, age, education), health indicators (i.e., daily alcohol use, presence of somatic disease), 
psychopathology (i.e., IDS-mc, BAI), and antidepressant use. Beta-coefficients and P-values by 
multivariate linear regression analysis.
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DiscUssioN
In this cross-sectional, observational cohort study, we investigated the 
putative association between long-term BZD use and RT. High doses of 
BZDs (>1DDD), but not lower doses, were associated with prolonged RTs. 
This indicates that tolerance to the RT prolonging effect of BZDs does not 
(completely) develop at higher doses of BZDs. 
The finding of longer RTs in high dose BZD users was in line 
with experimental research on short-term BZD use and RT6-11 as well 
as with an observational study which found longer RTs in anxious, high 
dose BZD users (1.2 - 4 DDD) than in healthy non-users14. However, in 
the latter study it was unclear, whether prolonged RTs were due to BZD 
intake or psychopathology. 
Still, several studies did not find associations between BZD use 
and RT in chronic users.15,16 Possibly, BZDs still affect RTs in chronic 
use, but study design issues led to a lack of significant group differences 
in these studies (small sample size, absence of adequate statistical 
transformations).15,16 Alternatively, the lack of significant associations 
between BZD use and RT may indicate that tolerance to BZDs’ RT 
prolonging effect develops in long-term BZD use so that only relatively 
high doses affect RT. 
Our study has some limitations. The data are limited by 
representing only one outcome composed of six individual RT trials. The 
highest doses in NESDA were still rather moderate doses, so that effects 
of very high doses could not be investigated. The IAT may not be the most 
optimal task to measure RT, because the stimulus words were not neutral 
but related to depression and anxiety and may therefore influence subjects 
suffering from these illnesses. However, as the effects on RT remained 
after adjustment for severity of anxiety and depression, this is unlikely. 
Further, the validity of a CRTT for real life situations such as driving 
or working at a machine is lower than the validity of a simulation task. 
Despite these limitations, our study makes an important contribution to 
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the literature on BZDs and RT due to the following strengths. NESDA is a 
large observational, cohort study and includes a large sample of average 
BZD users with a long duration of use and comorbid psychopathology, so 
that our findings can be generalized to outpatient BZD users in primary 
and secondary care. The study size enabled us to adjust for important 
confounders such as psychopathology. The investigation of various 
characteristics of BZD use enabled us to determine the aspects of long-
term BZD use which are associated with RT.
In conclusion, we found increased RTs in high dose BZD users 
even after adjustment for severity of psychopathology and antidepressant 
use. This indicates that no complete tolerance to the RT prolonging effect 
of high BZD doses develops in long-term BZD users. Medical doctors 
should alert their patients of the prolonged RTs associated with high 
doses of BZDs and possible consequences for everyday tasks where fast 
reaction is required. This study also underlines the directive to prescribe 
and use BZDs conservatively, and at the lowest dose possible.31 
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sUPPLeMeNt 1. Arrangement of the Different Implicit Association Test Blocks
Block Left Label (s) Right Label(s) No. of trials
1 Single concept Me Other 20
2 Single concept* Anxious Calm 20
3 & 4 Combined concepts Me/Anxious Other/Calm 80
5 Single concept* Calm Anxious 20
6 & 7 Combined concepts Me/Calm Other/Anxious 80
8 Single concept* Depressed Elated 20
9 & 10 Combined concepts Me/Depressed Other/Elated 80
11 Single concept* Elated Depressed 20
12 & 13 Combined concepts Me/Elated Other/Depressed 80
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sUMMArY oF resULts
This thesis had three aims. Our first aim was to identify the independent 
correlates of BZD use in general, inappropriate BZD use, and BZD 
dependence. As the prescribers may affect the BZD use of their patients, 
we also established the GP characteristics of patient BZD use. Our 
second aim was to examine whether there is evidence that (chronic) BZD 
use has an impact on the functioning of two human stress systems, 
the hypothalamic-pituitary-adrenal axis (HPA axis) and the autonomic 
nervous system (ANS). Third, we aimed to investigate whether the 
relationship between BZD use and prolonged reaction time (RT) would 
persist in long-term BZD use or whether tolerance to this side effect of 
the BZDs would develop. We conducted these analyses on data from 
the Netherlands Study of Depression and Anxiety (NESDA). NESDA 
is a prospective cohort study on the course of depressive and anxiety 
disorders that comprises a large number of BZD users. 
As the prevalence of BZD use and inappropriate use is high, we 
investigated the correlates of BZD use and inappropriate BZD use in 
cross-sectional regression analyses (chapter two). Of the NESDA sample, 
15.0% (n=429) used BZDs. Of these BZD users, only 15.2% used BZDs 
according to international prescription guidelines. Most users (82.5%) 
exceeded the recommended duration of safe use, but some also surpassed 
the recommended dosages or had prescriptions for more than one type 
of BZD at a time. Older age, being single, unemployment, treatment in 
secondary care, more GP visits in the past six months, (more severe) 
anxiety, depression, comorbidity, insomnia, and use of antidepressants 
were independently associated with BZD use. Older age and chronic 
illnesses were independently associated with inappropriate BZD use. 
We concluded that mentally or physically vulnerable subjects were most 
likely to use BZDs. The most vulnerable (i.e. old and physically ill) BZD 
users were at highest risk of inappropriate BZD use.
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In chapter three, we investigated the prospective determinants of 
initiated and continued BZD use. During follow-up, BZD use was initiated 
by 4.9% of BZD non-users at baseline. Initiated use was predicted by 
insomnia, enduring anxiety symptoms, entering secondary care during 
follow-up and past BZD use. Positive life events during follow-up reduced 
the likelihood of BZD initiation. Of the BZD users at baseline, 54.2% 
continued use during the entire follow-up period. Continuation of BZD 
use was predicted by higher age, severe anxiety, and a long duration 
of BZD use. Leaving secondary care was associated with less continued 
BZD use. We concluded that insomnia and anxiety were the main risk 
factors of initiated use, while advanced age and anxiety severity were the 
main risk factors of continued use. 
As BZD dependence is experienced by many BZD users, but regularly 
remains unrecognized, we investigated the cross-sectional correlates of 
BZD dependence in chapter four. Problematic use was independently 
associated with more GP contacts in the past six months and severity of 
insomnia. Preoccupation was related to anxiety severity, antidepressant 
use, alcohol dependence, and a higher daily dosage of BZDs. Lack of 
compliance was associated with higher age, unemployment, insomnia, 
antidepressant use, and alcohol dependence. We concluded that BZD 
users with insomnia, antidepressant use and alcohol dependence were at 
the highest risk to develop BZD dependence. 
The patient correlates of BZD use have received much attention in 
the past. Less attention has been paid to the contribution of general 
practitioner (GP) characteristics to patient BZD use. Therefore, we 
investigated GP characteristics as possible correlates of patient BZD 
use and inappropriate BZD use in chapter five. Patient BZD use and 
inappropriate use did not vary significantly between GPs. Only few GP 
characteristics were associated with patient BZD use (after correction 
for patient correlates of BZD use). Only the GP’s perceived disability to 
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differentiate unhappiness from depression was weakly associated with 
less patient BZD use. Higher professional comfort and competence with 
mental health care of the GPs correlated with less inappropriate patient 
BZD use. Our results indicate that GP characteristics barely affect patient 
BZD use. Instead, patient characteristics seem to be decisive in whether 
BZDs are used (inappropriately) or not. 
As BZDs are used for the symptomatic treatment of anxiety and stress, 
they may influence the human stress system. Short-term BZD use was 
found to suppress cortisol levels. However, little research has been done 
on the effects of long-term BZD administration on the hypothalamic-
pituitary-adrenal (HPA) axis. The relationship between BZD use and 
various salivary cortisol measures was studied in chapter six. Daily and 
infrequent BZD users displayed slightly lower evening cortisol levels as 
compared to non-users, but did not differ on any other cortisol indicator. 
As BZDs are often taken at night time, the reduced cortisol levels in the 
evening may reflect a transient suppressive effect of BZDs on the HPA 
axis (which could not be detected anymore in the morning). Alternatively, 
tolerance to BZDs cortisol suppressant effects may develop in long-term 
BZD use.
Short-term BZD use was repeatedly found to suppress sympathetic 
nervous system activity and heart rate variability. However, findings 
between studies were inconsistent. Further, it was unclear if BZDs 
maintain their effects on the autonomic nervous system (ANS) in chronic 
use. Therefore, we investigated the prospective association between 
transitions in BZD use and ANS alterations in chapter seven. After 
adjustment of covariates, subjects who had initiated BZD use during 
the follow-up period displayed a decrease in sympathetic activity while 
chronic users showed an increase in sympathetic activity. No effects of 
BZDs on parasympathetic activity were detected. This finding suggests 
that BZDs suppress sympathetic activity in short-term use, and that 
GENERAL DISCUSSION  |  209
these effects remain, but become smaller, in longer term users, potentially 
due to tolerance development. 
Short-term administration of benzodiazepines (BZD) was found to prolong 
reaction time (RT) in experimental studies. However, studies on long-term 
BZD use did not always adjust for important confounders and showed 
inconsistent results. In chapter eight, we investigated the relationship 
between BZD use and RT in mainly chronic BZD users of NESDA. We 
found that high dosage chronic BZD users, but not lower dosage users, 
had longer RTs than non-users. This indicates that tolerance to this 
side effect of the BZDs did not develop (completely). Further, BZD users 
with higher scores on problematic use, a dimension of BZD dependence 
severity, had longer RTs than those who scored lower on problematic use.
GeNerAL DiscUssioN
In this discussion, these findings are discussed. Further, clinical 
implications, methodological considerations, and topics for future 
research will be outlined. 
PArt A) correLAtes oF BZD Use, iNAPProPriAte 
Use AND tHe iNFLUeNce oF PrescriBers
Despite the narrow indication range for BZDs and the growing public 
awareness of the drawbacks of BZD use, many patients use BZDs, also 
for invalid indications.1-4 Against international prescription guidelines, 
high daily dosages are used, though these may increase the risk of 
side effects, dependence, and suicidal ideations.5,6 BZDs are also used 
inappropriately for long periods of time, even though the therapeutic 
effectiveness may decrease.7 Therefore, we aimed to identify patients at 
risk of new BZD use, chronic use, inappropriate use, and dependence. 
Our findings are summarized in Table 1.
210  |  CHAPTER 9
tABLe 1. Risk and Protective Factors in Relation to BZD Use

































































the initiation of BZD Use
During the two year follow-up period, BZD use was initiated by 4.9% of 
the subjects who did not use BZDs at baseline.8 We investigated the risk 
factors of the initiation of BZD use in prospective analyses in the NESDA 
sample.8 Beyond the studies already discussed in chapters two and three 
of this thesis, no other prospective cohort studies have been published 
on this specific topic, so we will restrict this argumentation to our own 
results and the scarce previous literature on new BZD use.
We found that insomnia, enduring anxiety, and entry of secondary 
care were the strongest predictive factors of the initiation of BZD use.8 This 
finding is in line with previous research9,10 and suggests that BZDs are 
primarily prescribed for their main indications. We discovered that BZD use 
GENERAL DISCUSSION  |  211
was initiated for longer rather than shorter episodes of psychopathology.8 
Possibly, GPs and patients try different treatment alternatives before 
they decide to initiate BZDs. This suggests that guidelines11,12 for BZD 
initiation are followed relatively well by most patients and prescribers. 
Albeit, BZDs only suppress symptoms of anxiety and insomnia for the 
duration of use and do not cure the underlying disorder. Consequently, 
relapse rates after BZD discontinuation are high.13 BZD use may even 
interfere with cognitive behavioural therapy due to its impairing effects 
on cognitive functions.14 For these reasons and reasons related to other 
side effects, namely decreasing effectiveness, dependence, and tolerance 
development, BZDs are never the first treatment option.15 Before 
prescribing BZDs, GPs should try the alternative treatment approaches 
suggested by Dutch and international guidelines as summarized in 
Table 2.11,12 The mentioned pharmacological alternatives are mostly 
better suited as first choice treatments of anxiety and insomnia. The 
non-pharmacological treatment options may additionally help to treat 
these disorders, and reduce the need for long-term drug prescriptions. As 
current insomnia treatment guidelines do not include pharmacological 
treatment alternatives to BZDs and so-called z drugs, we have also added 
empirical research evidence regarding psychopharmacological insomnia 
treatment to Table 2.16 
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Female gender,17 older age,17 divorce,17 alcohol problems,9 antidepressant 
use,9 smoking,10 and poor physical health10 were identified as important 
risk factors for BZD initiation in previous research, but not confirmed in 
our study.8 As we corrected for these confounders in one large multivariate 
model, these factors may be less important in the prediction of new BZD 
use than insomnia, anxiety and entry of secondary care. However, as 
older age, divorce, alcohol problems, and physical health problems are 
often accompanied by anxiety and insomnia, it is possible that BZDs 
were prescribed for symptom reduction, (although it would have been 
better to treat the cause of the anxiety and insomnia). Alternatively, the 
discrepancies may be caused by differences in sample selection or the 
inclusion of a different subset of BZD predictors.
An interesting observation was that the risk for BZD initiation 
was reduced by the occurrence of positive life events.8 This indicates that 
patients at risk of BZD use may benefit from the active search for more 
positive life situations, such as making new friends and participating in 
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recreational activities. They may be taught how to do so in counselling or 
psychotherapy. 
chronic BZD Use
At baseline, 82.5% of the 429 BZD users in NESDA were chronic users.18 
Of all BZD users at baseline, 54.2% continued use during the entire 
follow-up period of two years.8 As most of the BZD users in NESDA were 
already long-term users at baseline, we combined the results of our own 
cross-sectional and prospective analyses in this discussion.8,18 Older age, 
severe anxiety and treatment in secondary care were associated with 
chronic BZD use in both analyses and thus formed the most important 
risk factors.8,18 These results are in line with other prospective research 
studies.19,10 
Old patients with severe anxiety seem to form a vulnerable group 
who suffer from the troubles of aging in combination with psychopathology. 
As these patients often have a low quality of life, it is important to reduce 
their symptoms, but even more favourable to treat the underlying 
disorders. Only when other treatment alternatives (see Table 2) have 
been tried without success, long-term BZD use may be considered. Yet, 
BZDs should only be prescribed for the duration of time that they actually 
reduce symptoms of anxiety and insomnia. As there is little evidence for 
BZDs effectiveness in daily, long-term use,20 intermittent use may be a 
pragmatic alternative in order to delay tolerance development.21 However, 
intermittent use is also no optimal solution, as it may also lead to (or even 
be an expression of) BZD dependence.22
The association between BZD use and secondary care treatment18,8 
indicates that BZDs are often initiated at entry of and discontinued at exit 
of specialized mental health care treatment. This finding is not surprising 
as oftentimes all other treatment options are exhausted when subjects 
enter secondary care and immediate symptom reduction is necessary. 
However, it does seem positive that BZD treatment is also discontinued, 
when subjects leave secondary care. Apparently, specialized health care 
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personnel largely adhere to treatment guidelines. Further, subjects seem 
to benefit from secondary care treatment, so that they are no longer in 
need of BZDs when they leave the mental health care institutions. 
Female gender,23 divorce,23 pain,10 general practitioner contacts23 
and several characteristics of BZD use24 were established as important 
risk factors of chronic use in previous research, but not confirmed by the 
thesis on hand. Possible explanations are again the differences in sample 
selection or the inclusion of different putative risk factors in multivariate 
models. However, as mentioned above, insomnia and anxiety may also 
be a consequence of pain complaints and divorce. Thus, GPs may have 
treated symptoms of anxiety and insomnia, although it would have been 
better to treat the cause of these two disorders.
inappropriate BZD Use
Inappropriate BZD use was defined as using a mean daily dose higher 
than the DDD as defined by the World Health Organisation, using BZDs 
for longer than three months, and using more than one type of BZDs 
at a time.18 In NESDA, the prevalence of inappropriate use was high, 
with 84.8% of the 429 BZD users meeting at least one of the mentioned 
criteria.18 In order to find out who was at highest risk, we investigated the 
correlates of inappropriate BZD use in the NESDA sample. In our study, 
older patients who also had chronic, physical illnesses were at highest 
risk of inappropriate BZD use. These patients may insist to receive or 
refuse to discontinue their BZD prescriptions. Alternatively, GPs may 
view BZDs as the only treatment option for the vulnerable patients and 
therefore issue prescriptions despite the treatment guidelines.25-28 Of the 
inappropriate users, the majority exceeded the recommended duration 
of BZD use of three months,18 while only a relatively small percentage 
surpassed the recommended dose or used more than one type of BZDs at 
a time.18 Thus, chronic long-term use presents the most common problem. 
Although the prevalence of exceeded doses was relatively low (14.0%), 
high dose use may have substantial impact on public health due to the 
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increased risk of adverse outcomes such as hip fractures29 and motor 
vehicle accidents.30 Patients using antidepressants were at highest risk of 
inappropriately high BZD doses, possibly due to co-prescription of BZDs 
to reduce the most severe symptoms in the first weeks of antidepressant 
treatment. Even after full effectiveness of the antidepressant treatment 
enfolded, subsequent BZD use was found to be frequent.31 Therefore, it 
is important to ensure that BZD tapering is initiated as soon as patients 
respond to antidepressants.
High scores on agreeableness protected against inappropriate 
BZD use. This is in line with an earlier found association between 
agreeableness and treatment adherence in hypertensive subjects.32 As 
agreeable subjects are generally characterized as empathetic, harmony 
seeking, and trusting,33 they may be more likely to listen to the GPs 
advices when short-term BZD treatment or BZD tapering is recommended. 
They may also trust their GPs more easily on the drawbacks of BZD 
use. This emphasizes the importance of developing a trusting doctor-
patient relationship, so that the patient believes in the competence of the 
GP and is willing to take his/her advice. GPs should also learn how to 
convince less trustful patients of the most appropriate treatment options 
and to refrain from prescribing when they do not consider BZDs justified. 
Future research needs to investigate whether GPs with these skills issue 
less inappropriate prescriptions. If that is the case, more emphasis needs 
to be put on training these skills to GPs.
BZD Dependence
Patients dependent on BZDs commonly initiate use due to anxiety or 
insomnia and continue their prescriptions longer than recommended or 
at doses outside the recommended range.20 As they are partly maintained 
on this inappropriate use by their prescribers, this is occasionally called 
‘involuntary’ dependence. The prevalence of patients seeking BZDs 
for intentional abuse is much lower, and those who do, usually have 
a comorbid diagnosis of substance-abuse and derive their drugs from 
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more than one prescriber or other additional sources such as illicit sales 
and internet sites.34 Nevertheless, dependence development is relatively 
common, even in low-dose BZD users, and especially in subjects with 
comorbid psychopathology.20 As BZD dependence impairs the quality 
of life of the affected subjects and interferes with the treatment of the 
primary disorder,35 its development should be prevented. 
In order to prevent BZD dependence, GPs may identify patients 
at risk with empirically validated correlates of BZD dependence. In the 
thesis on hand, severity of insomnia, antidepressant use and alcohol 
dependence were identified as the most important correlates of the three 
scales of BZD dependence severity. These correlates were significantly 
associated with more than one subscale of dependence severity. Higher 
age, unemployment, more GP contacts, severity of anxiety and a daily 
dosage of BZD use were associated with one subscale of BZD dependence.
As alcohol dependence increases the risk of BZD dependence 
and vice versa, caution is essential in patients with alcohol problems. It 
has been shown that polydrug users often combine high doses of BZDs 
and alcohol in order to increase sedation.20 This can be very dangerous 
as memory impairments are enhanced and the risk of accidents and 
injuries becomes even more pronounced. Therefore, BZDs should not 
be prescribed for mild alcohol withdrawal where supportive care may be 
sufficient.36 Instead, it should be reserved for severe alcohol withdrawal 
and delirium tremens, where short-term BZD administration is considered 
as treatment of choice.36 Regarding insomnia, the above stated may also 
hold true. Subjects often initiate BZD use for the treatment of insomnia 
and continue longer than indicated due to enduring symptoms. Finally, 
they become dependent. This has also been shown for antidepressant 
use, where subjects initiate BZD treatment during the first weeks of 
antidepressant treatment and continue their BZD use thereafter. 
Previous research identified a number of correlates (e.g. female 
gender,37 retirement,38 depressive disorder,38 drug use,39 longer duration 
of BZD use38) which we did not confirm in our own research. However, 
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as most studies on BZD dependence used dichotomous definitions of 
dependence37,40 instead of severity dimensions, results are difficult to 
compare. Additionally, BZD users in previous research were on higher 
dosages of BZDs37 and had more severe alcohol problems, which may 
increase the risk of BZD dependence. 
General Practitioner characteristics, Patient characteristics and 
BZD Use
General practitioners (GP)s have often been blamed for the inappropriate 
BZD use of their patients as they bear at least part of the responsibility 
by maintaining  patients on the prescription drug. Therefore, we aimed 
to investigate whether certain physician characteristics were associated 
with an increased risk of inappropriate patient BZD use, even after the 
correction for patient characteristics. Previous research has identified 
a number of independent physician determinants of patient BZD use 
including male gender,41,42 personal usage of BZDs,43 allowing patients to 
influence prescription decisions,42 prolongation of prescriptions without 
direct doctor-patient contact,42 and multiple drug prescribing44. However, 
these studies did not adjust for patient characteristics, so that it was 
unclear if the found differences were due to variation in the physicians 
or in the treated patients.41-43 The only study which adjusted for patient 
characteristics reported that patient and practice characteristics 
were more important in the prediction of patient BZD use than GP 
characteristics.45 
Our results were very consistent with the latter findings.45 When 
analyses were adjusted for patient characteristics, the majority of GP 
characteristics were no longer associated with patient BZD use. This 
indicates that GP characteristic are not decisive to the inappropriate 
BZD use of patients. Instead, it seems that most GPs prescribe BZDs 
(inappropriately) to a specific group of vulnerable patients (independent 
of their own GP characteristics). This assumption was supported by 
numerous qualitative studies which reported that GPs are commonly 
218  |  CHAPTER 9
aware of the BZD treatment guidelines, but still prescribe BZDs, because 
of the idea that BZD treatment is appropriate for subjects with severe 
mental problems or as they feel incapable of helping these patients by 
any other means.25-28 Less inappropriate BZD prescriptions were issued 
by GPs who reported feeling comfortable in dealing with anxious and 
depressed patients. Possibly, these GPs are more confident to inform 
patients about the risks of BZD use and the need of discontinuation after 
short-term treatment. 
summary and Discussion Part A: BZD use, inappropriate Use and 
the Influence of BZD Prescribers
BZD use was mostly initiated by patients with a diagnosis of insomnia 
or anxiety and those who entered secondary care; while the experience 
of positive life events protected from the initiation of BZD use.8 The most 
vulnerable patients, i.e. the old and psychologically or physically ill, were 
at highest risk of inappropriate (and in particular chronic) BZD use.18 
Patients with a diagnosis of insomnia or alcohol dependence or those also 
using antidepressants were at highest risk of BZD dependence. Patient 
characteristics rather than GP characteristics were associated with the 
different modalities of patient BZD use. Therefore, patients as well as GPs 
should receive education and training on responsible BZD use. Since GPs 
who felt more comfortable in dealing with anxious and depressed patients 
issued less inappropriate BZD prescriptions, GPs need to be trained on 
how to manage this patient group25,46 and acquire good knowledge on 
alternative treatment options.25,28 For example, the Dutch Institute for 
Responsible Drug Use (Instituut voor Verantwoord Medicijngebruik) offers 
education, trainings and improvement trajectories to support health care 
organisations with responsible drug prescriptions.47 
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PArt B) tHe PHYsioLoGicAL coNseQUeNces oF BZD 
Use
In short-term intervention studies, BZDs were found to acutely 
suppress the HPA axis (stress-induced activation) and SNS activity.48-50 
The underlying mechanism of action may be as follows. BZDs bind to 
GABAA receptors, enhance the inhibitory effect of these receptors in 
the paraventricular nucleus (PVN) of the hypothalamus and thereby 
suppress the HPA axis and the SNS. As SNS arousal was found in 
stressful situations51 and HPA axis hyperactivity was detected in anxious 
subjects, these suppressant effects of the BZDs may contribute to their 
anxiolytic and stress reducing actions. Consistent with this hypothesis, 
BZD induced cortisol reductions were found to be accompanied by an 
improvement of anxiety.52,53 Additionally, the alpha 2 subunit of the GABAA 
receptor, which mediates BZDs’ anxiolytic effects, was found to be most 
abundant in the hypothalamus,54,55 which is involved in the regulation 
of ANS and HPA axis effects.48,49 However, findings were inconsistent, in 
particular for the ANS, so that no firm conclusions can yet be drawn.
It is also not known whether BZDs effects on the HPA axis and 
the ANS remain in chronic BZD users or if tolerance develops. Possibly, 
the BZD concentration needed to suppress the HPA axis becomes higher 
with tolerance development so that the daily dose of BZDs does not affect 
the HPA axis activity anymore after a certain period of use. Alternatively, 
BZDs may only suppress the HPA axis activity briefly, so that the activity 
returns to baseline shortly (in a couple of hours) after BZD administration. 
It was oftentimes reported that BZDs lose their anxiolytic and especially 
hypnotic effectiveness in chronic BZD use.56,57 Possibly, once BZDs effects 
on ANS and HPA axis decrease, their anxiolytic and hypnotic effectiveness 
also diminish. 
If BZDs constantly suppressed the SNS and the HPA axis in 
chronic BZD users, a deregulation of these two stress systems was to 
be expected. Constant hyperarousal of the HPA axis was found to be 
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associated with psychiatric and somatic conditions, such as depressive 
and anxiety disorders, osteoporosis, atherosclerosis, and certain 
infectious diseases.58-60 Hypoarousal of the HPA axis was found to be 
associated with fibromyalgia, hypothyroidism, chronic fatigue syndrome, 
and post-traumatic stress disorder.58 Altered ANS activity was found 
to be associated with angina pectoris, myocardial infarction, coronary 
heart disease death, or congestive heart failure.61,62 If these conditions 
were likely to develop, even more caution regarding the (long-term) use of 
BZDs would be warranted.
To find out whether the effects of BZDs on the ANS and the HPA 
axis remain in long-term users, we investigated the cross-sectional 
association between BZD use, the HPA axis and the ANS in mainly long-
term BZD users of the NESDA sample. Additionally, we investigated 
prospective data on BZD use and the ANS.
the Association Between BZD use and the HPA Axis
In the past, the effects of short-term BZD administration on serum, urine 
and salivary cortisol levels as a measure of the HPA axis were studied 
during a time period ranging from one day to one month. In most of 
these studies, BZDs suppressed (stress-induced increases of) cortisol 
levels.50,53,63-68 It was concluded that the suppression of the HPA axis may 
be involved in BZDs’ mechanism of action.53 
Research on the effects of chronic BZD use on the HPA axis 
has been scarce. In one study, chronic BZD users had similar baseline 
plasma cortisol levels as non-users, indicating that these subjects’ daily 
BZD use did not (lastingly) affect the HPA axis.57 In NESDA, long-term 
BZD users did not differ from non-users on most cortisol indicators, 
confirming these findings.69 This suggests tolerance development for the 
HPA axis suppressant effects of BZDs. Only evening cortisol levels of BZD 
users were lower than those of non-users in the NESDA sample.69 As 
BZDs are usually taken at night time, this may indicate the existence 
of an acute, transient, cortisol suppressant effect of BZDs in long-term 
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users. In line with the finding of transient cortisol reductions, a short-
term intervention study reported that a BZD-induced suppression of the 
HPA axis was followed by a rapid return to baseline cortisol levels, despite 
persisting high plasma BZD levels.70,71 Consistently, the morning cortisol 
samples of BZD users in NESDA were only non-significantly lower than 
those of non-users with smaller effect sizes.69 This suggests that cortisol 
levels went back to baseline as the BZD suppressant effect wore off. 
Nonetheless, the lack of strong effects of BZD use on cortisol in 
NESDA does not prove the absence of these effects on the HPA axis. Earlier 
research found significantly decreased ACTH levels, but non-significantly 
reduced cortisol levels upon BZD administration. The authors concluded 
that ACTH and cortisol reductions might be unassociated.72 This 
illustrates the biological complexity of the human stress system which 
we tried to capture by the measurement of salivary cortisol as the single 
biological indicator. 
In summary, BZDs still seem to slightly suppress the HPA axis 
in chronic BZD users. This cortisol suppression seems to occur only 
transiently directly after BZD ingestion. However, the BZD induced 
cortisol reductions are much smaller than in short-term use, probably 
due to the development of tolerance.
the Association Between BZD use and the ANs 
The current body of literature on the effects of BZDs on the ANS is 
inconsistent and largely comprises short-term intervention studies that 
measured the effects of relatively high doses of BZDs on the ANS. The 
majority of studies on SNS activity reported a suppression of (stress-
induced increases of) sympathetic activity.51,73-77 However, one study 
reported that BZDs increased sympathetic outflow78 and a few other 
studies did not detect any SNS related effects of BZDs.79-82 Research on 
PNS activity found that BZD administration attenuated HRV,78,80,83-87 
and heightened HR,78,80,83,86-88 aside from two studies which announced 
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heightened HRV after BZD administration.77,89 Based on these short-term 
results, the effects of BZDs on the ANS remain unclear.
Less research has been conducted on the effects of chronic BZD 
use on the ANS. Cross-sectional analyses of the NESDA study reported 
similar HRV in chronic BZD users and non-users.90 In prospective 
research, this finding was confirmed. On the one hand, this may imply 
that BZDs do not affect PNS activity in chronic use due to tolerance 
development. On the other hand, it may indicate that BZDs have an 
acute, transient effect on the ANS (which could not be detected hours 
after BZD intake when NESDA interviews took place). 
In contrast, the SNS activity of BZD initiators in NESDA was lower 
at the two year measurement than it was at baseline. This may suggest 
that initiating BZDs slightly decreased SNS activity. Yet, a BZD induced 
decrease in SNS activity would also be reflected in a decrease of HR, which 
was not found in NESDA. Further, chronic users displayed an increase in 
SNS activity between the baseline and the follow-up measurement, which 
is difficult to explain. As different group and ANS measure comparisons 
gave conflicting results, we need to be cautious when drawing firm 
conclusions. At this point, is seems that BZDs suppress SNS activity 
in short-term use, and that these effects remain, but become smaller, 
in longer term users due to tolerance development. It is also very likely 
that the effect of BZDs on the ANS is transient in nature so that it can 
be measured directly after BZD intake and decreases with time. As we 
did not record the time of BZD intake, it is very likely that the effect of 
the BZDs on the SNS had already worn off in some subjects, while it was 
still present in others and again others may have shown rebound SNS 
increases (between doses elevations). 
summary and Discussion Part B: the Physiological consequences 
of BZD Use 
We neither detected strong effects of BZDs on the HPA axis nor on the 
ANS in long-term BZD users. This is in contrast with intervention studies 
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which reported a suppression of the HPA axis and either decreased SNS 
or HRV levels directly after the administration of BZDs. The absent or 
weak influences of BZDs on the ANS and the HPA axis in long-term users 
have several implications. On the one hand, it suggests that patients, who 
suffer from anxiety and/or depression, may use BZDs without strong 
adverse effects on these two stress systems. While in the first weeks of 
BZD use minor respiratory and cardiovascular changes may occur, these 
effects should wane relatively fast with the development of tolerance. Most 
importantly, no chronic hypo- or hyperarousal of the two stress systems 
is expected. In this respect, BZDs may be safer than antidepressants 
which were shown to have adverse effects on the ANS and the HPA axis. 
The use of tricyclic antidepressants (TCAs), selective serotonin reuptake 
inhibitors (SSRIs) and serotonin–norepinephrine reuptake inhibitors 
(SNRIs) was associated with decreased HRV, the use of SNRIs and TCAs 
was associated with decreased PEP, and the use of SSRIs was associated 
with increased PEP.90-92 Further, the use of antidepressants was associated 
with less cortisol suppression after dexamethasone,59 which may increase 
the risk to develop hypercortisolemia. 
The absence of strong physiological consequences of BZD use 
in long-term users may also explain why BZDs do not maintain their 
anxiolytic and hypnotic effectiveness in chronic BZD use.56,57 As decreases 
in cortisol levels were found to be associated with decreases in anxiety,53 
tolerance development to the cortisol-suppressant effect might also 
indicate tolerance development to BZDs anxiolytic and hypnotic effects. 
Cautiousness in drawing final conclusions is recommended. As 
GABA is widely spread throughout the human brain, BZDs may affect 
several different brain structures via their direct and indirect effects 
on GABA. The lack of strong alterations of the HPA axis and the ANS 
indicators associated with BZD use reported in this study, are no proof 
for the absence of stress system effects in chronic BZD use. Future 
research needs to confirm if tolerance to BZDs’ suppressant effects on 
the HPA axis and the ANS develops in chronic use. Further, it needs to 
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be established, if tolerance development to these physiological effects of 
BZDs is the reason for the decreasing anxiolytic and hypnotic effects of 
BZDs in long-term use. 
PArt c) seDAtiVe AND AtteNtioN iMPAiriNG 
eFFects oF BZDs
Until the 1970s it was assumed that BZDs did not have any cognitive 
side effects.93 However, it is now common knowledge that clinical doses of 
BZDs induce high levels of sedation, attention impairments, and memory 
deficits in short-term use.93 In long-term use, only some of these effects 
seem to remain, while others are subject to tolerance. Memory deficits 
were found to persist in long-term use (even after five years)94 indicating 
that tolerance to these effects never fully develops. While some research 
studies suggested that sedation and attention impairments improve with 
time,93 others found sustained attention impairments in chronic BZD 
users,95 but no impairments of simple reaction time.95 Another research 
study reported no effect of diazepam on psychomotor speed in a group 
of subjects using BZDs for 5-20 years, pointing to the persistence 
of tolerance.94 From these research studies, it did not become clear, 
whether sedation and attention impairments remain in chronic BZD use. 
Therefore, we aimed to investigate whether BZDs’ effects on attention and 
sedation would persist in chronic BZD use. Daytime sedation (including 
psychomotor speed impairments) and attention deficits can objectively 
be measured by reaction time (RT) tasks such as choice reaction time 
tasks (CRTTs).
the Association between BZD use and reaction time
Previous research on the association between BZD use and RT mainly 
consisted of small randomized trials which compared the effect of short 
term administration of BZDs to the effect of placebo in CRTTs. In these 
studies, the administration of BZDs was generally found to prolong 
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RTs in healthy, BZD-naive subjects.96,97 This increase was reported to 
last for the time measured, which ranged from 0,5 to 36 hours.96,97 One 
intervention study investigated the effects of BZD use on RT during a 
longer period of time and found that six weeks of daily BZD intake still 
increased RTs.98 This finding indicates that at least for this duration of 
time limited or no tolerance for the RT prolonging effect had developed. 
Two small studies did not find prolonged RTs after BZD intake, possibly 
due to a lack of power related to small sample sizes.99,100
Only a few observational studies investigated the association 
between long-term BZD use and RT with inconsistent results. One cross-
sectional, observational study did not detect longer RTs in chronic BZD 
users as compared to healthy controls.101 In contrast, another study 
found longer RTs in chronic BZD users with anxiety than in healthy 
non-users,102 but did not investigate whether the increased RTs were 
due to psychopathology or the use of BZDs.102 As psychopathology was 
found to increase RT in previous research, this may be the reason for the 
increased RT detected in this study. Consistently, a different study found 
longer RTs in depressed subjects (half of whom used BZDs) as compared 
to healthy volunteers.103 When analyses were repeated in the depressed 
group only, RTs did not differ between BZD-users and non-users.103 This 
suggests that the increased RTs were due to psychopathology rather 
than BZD use. 
We wanted to investigate if BZD use prolongs RT independent 
of psychopathology. Therefore, we examined BZDs’ effects on RT 
(as measured by a CRTT) in chronic BZD users. We found a positive 
association between the daily dose of BZDs and RTs. This significant 
effect remained after adjustment for psychopathology, indicating that 
the harmful effects of BZDs on RT are independent of psychopathology 
and remain in chronic BZD use. The found dose-response relationship in 
this thesis was in line with previous short-term research which reported 
that impairments of psychomotor speed and attention increased with the 
administered dose.96
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In this thesis, the awareness of problematic BZD use was associated 
with prolonged RTs, independent of the used dose. High scores on 
problematic use probably reflect the experienced strength of side effects. 
The experienced side effects may differ between individuals, as they are 
influenced by the individual drug metabolism and pharmacokinetics. 
Studies on BZD pharmacokinetics have shown that alterations in 
distribution and elimination of certain compounds occur in old age.104 
In older subjects, half a dosage is sufficient to achieve a comparable 
therapeutic effect to the effect the whole DDD causes in younger patients. 
If the common DDD is used in older patients, side effects become much 
stronger and the risk of accidents, falls, and other consequences of 
cognitive impairments increases.105,106 Yet, younger subjects may also 
show differential reactions to the same dose of BZDs. This may be related 
to the individual genetics. Alternatively, the concomitant use of other 
drugs or substances (cigarettes, certain food, alcohol, opioids, lithium, 
antipsychotics) may enhance or suppress the effects of BZDs.107 For 
example, diazepam and chlordiazepoxide plasma concentrations increase 
in combination with drugs that inhibit cytochrome P (CYP) enzymes 
CYP450 and CYP 343/4, including cimetidine, disulfiram, and isoniazid 
and result in much stronger side effects.107,108 Therefore, GPs should 
closely monitor the drug regime of their patients, consider possible drug 
interactions and regularly ask them about the experienced side effects.
summary and Discussion Part c: sedative and Attention impairing 
effects of BZDs 
We found a dose response relationship between the daily BZD dose and 
RT. This result underlines the importance of limiting BZD use to the 
defined daily dose. Medical doctors should repetitively alert BZD users of 
the prolonged RTs associated with high doses of BZDs and the possible 
consequences for everyday tasks where good concentration, attention, 
and psychomotor speed are required, (such as driving or working with 
machinery), even when they are already using for a long duration of time.
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Interestingly, we did not find strong associations between BZD use and 
the two stress systems, but did detect associations between BZD use 
and RT. A possible explanation for this finding may be that sedation and 
anxiolysis are mediated via two different receptor subunits of the GABAA 
receptor.109 Possibly, BZDs effects on the stress system are related to their 
anxiolytic effects while RT impairments rather reflect daytime sedation 
(including psychomotor slowing) and attention deficits. Anxiolytic effects 
are mediated via the alpha 2 subunit of the GABAA receptor110,111 which 
is dominant in the PVN of the hypothalamus. In contrast, sedation was 
found to be mediated via the alpha 1 subunit of the GABAA receptor110,112 
which is present in most parts of the adult brain, including the PVN 
(although not dominant in this area). Tolerance to BZDs’ anxiolytic 
effects on the alpha 2 subunit may develop earlier than tolerance to the 
sedative effects on the alpha 1 subunit does. This hypothesis contradicts 
previous research which reported fast (2 weeks) tolerance development 
to the sedative effects of BZDs,113,114 and slower tolerance development 
to the anxiolytic effects of BZDs. Yet, the association between dose of 
BZDs and RT indicates that there is no complete tolerance development 
to BZDs sedative effects in chronic BZD use. Most likely, the dose needed 
to impair RT is lower than the dose needed to put a patient to sleep. 
This would explain why studies found decreasing sedative effectiveness 
in insomniac patients with a longer duration of use and why we still 
detected prolonged RT in long-term users (indicating that the sedative 
effects have not yet completely disappeared). 
PArt D) MetHoDoLoGicAL coNsiDerAtioNs
Specific limitations of the studies presented in this thesis have already 
been addressed in the corresponding chapters. In this part of the thesis, 
only the general methodological considerations will be discussed. One 
of the overarching limitations was the limited ability to determine 
causality due to the observational nature of our studies. Therefore, we 
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do not know for sure, if the identified correlates are actually risk factors 
of the modalities of BZD use or otherwise related (due to confounding). 
However, The Medical Ethical Committee (in Dutch: Medisch Ethische 
Toetsingsingscommissie or METc) does not allow long-term trials on BZD 
use to be conducted due to the high risk of BZD dependence. 
Due to attrition and the recruitment of patients in outpatient 
(and not in inpatient) settings, the most severely depressed and anxious 
subjects were not optimally represented within the NESDA study, 
especially at the follow-up measurement. As a result, the findings of 
this thesis cannot be generalized to the most severely ill psychiatric 
patients. Furthermore, the NESDA sample mainly consisted of low-dose 
BZD users, while high dose and severely dependent subjects were not 
included in this study. Therefore, our results cannot be generalized to 
these patients. As NESDA mainly consists of outpatients with previous or 
current psychopathology or a family history of psychopathology, subjects 
who use BZDs (inappropriately) for other than psychiatric indications 
are less present in our studies. A related restriction is that only adults 
aged 18 through 65 were included in NESDA, so we cannot be sure if our 
findings can be generalized to the elderly above 65. This is unfortunate 
as the age of 65 and older is a major part of the BZD user population. 
Additional restrictions were related to the group sizes for the subgroups 
of BZD users. Since the group sizes of most of the different BZD types 
were relatively small (for some analyses the groups were smaller than 
n=20), small group differences could have been missed due to the 
restricted power of these analyses. Moreover, the BZD user sample did 
not comprise many short-term users with less than one month of use. 
Consequently, the correlates of short-term versus long-term use and the 
respective consequences could not be compared. The same problem also 
applied for high dose and low dose BZD use and high and low severity of 
BZD dependence.
Furthermore, certain analyses could not be conducted as the 
necessary variables had not been included in the NESDA study. For 
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example, we could not analyse the attitudes and ideas of GPs regarding 
BZD use (but only more general attitudes regarding depression and 
anxiety) and did not know the reasons for BZD initiation. Other limitations 
of this thesis are related to non-compliance or memory bias. BZD use, 
which was registered by self-report and observation of drug containers, 
may not always represent the actual use. Our studies were also limited 
by the fact that patients took their daily dose of BZDs at home and we did 
not ask them for the most recent time of intake. Therefore, we could not 
be sure whether all patients actually took BZDs on the days of the RT, 
ANS and HPA axis measurements, nor did we know how much time had 
passed since the last administration of BZDs. Several NESDA subjects 
may have used short-acting BZDs at night so that the plasma BZD 
concentration was very low at time of RT, HPA and ANS measurements 
and no acute effects could be established. 
PArt e) iMPLicAtioNs For FUtUre stUDies AND 
cLiNicAL PrActice
Effort should be made for the inclusion of high dose, BZD-dependent 
patients in observational studies to confirm present findings in that 
patient group. Strategies to motivate this group to participate need to be 
developed, as these patients are not only most difficult to motivate, but 
also most in need of professional care. In addition, research should focus 
on old patients (and also include subjects older than 65) with comorbid 
physical and mental diseases, in order to define detailed treatment 
strategies for this patient group who is at high risk of inappropriate 
BZD use. These subjects are often excluded from trials as they suffer 
from more than one disorder. As a consequence, participants of trials 
commonly do not represent the average BZD user and thus the findings 
of these studies might not apply to the actual BZD user group. Therefore, 
research studies with these subjects are needed in order to define 
BZD prevention and reduction strategies for the people most in need. 
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Furthermore, available treatment options should be compared in terms 
of clinical outcome so that the optimal strategies for this high risk group 
can be defined. 
ANS, HPA axis and RT measurements should be taken several times 
prior to and after BZD administration in order to define time-dependent 
changes and distinguish between transient and relatively lasting effects of 
BZDs. Different levels of BZD dependence severity, different BZD types, 
high and low doses users as well as short-term and long-term users 
should be compared on these measurements. Perceived anxiety, sedation, 
and side effect levels should be measured prior and post BZD intake with 
validated self-report questionnaires in order to assess whether the found 
stress system effects are associated with their therapeutic (anxiolytic 
and sedative) and their adverse effects. Cortisol in hair may be a good 
opportunity to assess the effects of chronic BZD use on the HPA axis, as 
changes can be detected relatively easily.116 The time of the last BZD intake 
as well as the reason for BZD use should be reported. Ideally, psychomotor 
speed and attention impairments should not only be measured by RT 
tasks, but also by other tasks that are more similar to real life activities 
(i.e., driving simulation, working at a machine simulation). 
implications for clinical Practice
As BZDs are an effective short-term, symptomatic treatment for stress, 
anxiety and insomnia,11 they should be prescribed for rapid symptom 
relief when needed. More effort should be put into restricting prescriptions 
to the licensed durations of use (typically: 4 weeks anxiolytics, 2 weeks 
hypnotics) by preparing patients beforehand that their BZD use will 
only be short-term.20 Generally, GPs have three options regarding BZD 
prescriptions: 1) Prevent the use of BZDs, 2) Prescribe BZDs for short-
term use only and already invest in discontinuation strategies at the 
start, or 3) Accept BZD use when benefits outweigh risks. 
Option 1: BZD use can be prevented by informing patients about 
the drawbacks of BZDs and offering them a (non-) pharmacological 
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alternative treatment (see table 2). As GPs who felt more comfortable in 
dealing with anxious and depressed patients issued less inappropriate 
BZD prescriptions, GPs need to be trained in how to refuse BZD 
prescriptions when inappropriate 25,46 and acquire good knowledge on 
alternative treatment options.25,28 Trainings are for example offered by 
the Dutch Institute for Responsible Drug Use (Instituut voor Verantwoord 
Medicijngebruik).47
Option 2: If patients suffer from acute severe stress, anxiety or 
insomnia, prevention of short-term BZD treatment for fast symptom 
relief may not always be possible. In these cases, short-term use needs 
to be prevented from becoming long-term use. GPs can use the risk 
factors for inappropriate BZD use (older age, physical and psychological 
comorbidity) to identify patients at risk. All patients and the ‘high risk’ 
group in particular, should be informed right at the start of BZD treatment 
that their BZD treatment will only be short–term, so that expectations 
are clear. If anxiety or insomnia is mild or transient (e.g. related to a 
specific situation), symptoms may improve so that no other treatment is 
needed and BZDs can be discontinued. For subjects who are in need of 
longer-term treatment for anxiety and insomnia, alternative treatments 
should be used from the start. For anxiety disorders, pharmacological 
treatment with SSRIs and TCAs (for patients who do not suffer from ANS 
related comorbidities) should be accompanied by non-pharmacological 
treatment options (i.e., exposure therapy, cognitive therapy, relaxation, 
etc.) so that not only symptom reduction, but also a cure of the underlying 
disorder is targeted. For insomnia, non-pharmacological treatments such 
as information about sleep physiology and hygiene should be attempted 
first. When insomnia is severe and disabling, cognitive therapy directed 
at sleep, as well as tradozon or mitrazapine may be prescribed instead 
of BZDs. As soon as this treatment has built up its full effectiveness, 
BZD discontinuation can be initiated and actively be supported by 
the GP. Minimal intervention such as a discontinuation letter with the 
advice to taper BZD use off gradually is a common strategy to end BZD 
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treatment.22 If this intervention is unsuccessful, the GP should commence 
and actively support gradual dose reduction.20,117,118 For patients, who 
experience severe distress during the discontinuation of BZDs, low-
dose flumazenil infusion may be a potent aid to reduce the severity of 
withdrawal symptoms.20,119 
Option 3: In treatment resistant patients with physical and 
psychological comorbidities and little problem-solving as well as coping 
abilities,120 long-term BZD treatment may not always be avoidable. 
However, research showed that a lack of response to antidepressants is 
often caused by suboptimal prescribing practices (such as prescriptions 
of insufficiently low doses or for too short durations of use).121,122 As a 
consequence, subjects are declared as treatment resistant and longer-
term BZD use is justified according to the treatment protocol, although 
these patients possibly could have been helped by antidepressant 
treatment if the regime had been followed well. This calls for more 
accurate prescribing practices in general and more cautiousness before 
issuing a BZD prescription. For those patients who have been proven 
to be treatment resistant and chronic BZD treatment is indicated, 
treatment must be monitored closely to observe if symptom reduction is 
actually achieved by the use of BZDs as there is little evidence for BZDs 
effectiveness during chronic use. This constitutes a difficult task since 
patients insist on BZDs enduring effectiveness (probably due to memory 
impairments, the fear of symptom recurrence and experienced withdrawal 
effects), although the limited research on this topic does not support this 
view. As use of a high daily dose of BZDs was found to be associated with 
prolonged RTs, this small subgroup of high dose BZD users should enter a 
BZD discontinuation (or at least reduction) program. This goes especially 
for older subjects who are more sensitive to the adverse effects of BZDs 
due to altered drug metabolism and pharmacodynamics. Further, GPs 
should closely monitor the drug regime of their patients to avoid aversive 
drug interactions and question their patients about the perceived side 
effects. Prospective observational studies in long-term BZD users and 
GENERAL DISCUSSION  |  233
clinical trials on BZD discontinuation will have to investigate associations 
between biological indicators, clinical symptoms and side effects, to 
shed more light on this important matter. In the meantime, intermittent 
use may help to maintain the anxiolytic and hypnotic effectiveness of 
BZDs longer than in daily use.21 With these action alternatives, the GP 
is put in the position of a risk manager who weighs the advantages and 
disadvantages of BZD use for certain patients.
PArt F) coNcLUsioNs AND FiNAL reMArKs
In this large research cohort, BZD use was mainly initiated by patients 
with a diagnosis of insomnia or anxiety. The most vulnerable patients, 
i.e. the old and psychologically or physically ill, were at highest risk of 
inappropriate (and especially chronic) BZD use. Patients with a diagnosis 
of insomnia and alcohol dependence or those who used antidepressants 
were at highest risk of BZD dependence. BZD users did not differ from 
non-users on most HPA axis and ANS measures, indicating tolerance 
development. However, a higher dose of BZD use was associated with 
prolonged RTs, suggesting that tolerance to this psychomotor effect of 
BZDs does not seem to develop completely. 
Many chronic BZD users seem to believe in the maintained 
effectiveness of the BZDs, although supportive research evidence is 
missing. Additionally, chronic BZD users are usually those who suffer 
from the most severe anxiety and insomnia. This raises the question, 
if BZDs are actually still effective in reducing symptoms of anxiety and 
insomnia, and if not, if subjects should continue taking BZDs for such 
a long time. Future research should focus on long-term therapeutic 
and side effects of BZDs use, so that a clear risk benefit ratio can be 
established for long-term BZD users. Despite continuing attempts to do 
so, no such risk-benefit ratio could be established yet. A wise man once 
said: “Men love to wonder, and that is the seed of science.”123 So there is 
still hope.
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eNGLisH sUMMArY
Benzodiazepines are a class of psychotropic drugs with anxiolytic, 
sedative, muscle-relaxant and hypnotic properties. In clinical practice, 
they are mainly used to manage the symptoms of anxiety and insomnia. 
There is a broad evidence-based knowledge foundation which showed 
benzodiazepines’ therapeutical effectiveness in short-term use. 
However, as benzodiazepine use is associated with a high risk of side 
effects, tolerance, and dependence development, prescription guidelines 
recommend to limit benzodiazepine prescriptions to short-term treatment 
of two to three months. Still, benzodiazepine users and prescribers do 
not always adhere to these guidelines and long-term benzodiazepine use 
– oftentimes over many years- is a common phenomenon. Furthermore, 
many benzodiazepine users use very high dosages or receive prescriptions 
for more than one type of benzodiazepine, which can easily and 
unnecessarily lead to dose escalation. As many benzodiazepine users are 
long-term users, prescribing decisions for these patients should be based 
on clinical research. Nevertheless, studies in long-term users are scarce. 
This thesis therefore investigated the determinants and consequences of 
long-term BZD use on the data of the Netherlands Study of Depression 
and Anxiety (NESDA), which is a longitudinal, observational cohort study 
of 2981 adults aged 18-65 years.
Our first aim was to identify the independent correlates of 
benzodiazepine use in general, as well as of new, inappropriate and 
chronic benzodiazepine use and of benzodiazepine dependence. Of the 
NESDA sample, 429 subjects (15.0%) used benzodiazepines. Of these 
benzodiazepine users, only 15.2% used benzodiazepines according to 
international prescription guidelines. Most users (82.5%) exceeded 
the recommended duration of safe use, but some also surpassed the 
recommended dosages or had prescriptions for more than one type 
of benzodiazepine at a time. Older age, being single, unemployment, 
treatment in secondary care, more general practitioner contacts in 
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the past six months, (more severe) anxiety, depression, comorbidity, 
insomnia, and use of antidepressants were independently associated 
with benzodiazepine use (chapter two). Older age and chronic illnesses 
were independently associated with inappropriate benzodiazepine use. 
We concluded that mentally or physically vulnerable subjects were 
most likely to use benzodiazepines. The most vulnerable (i.e. old and 
physically ill) benzodiazepine users were at highest risk of inappropriate 
benzodiazepine use and are thus in need of close monitoring, support 
and possibly benzodiazepine reduction programs. 
During the two year follow-up period, benzodiazepine use 
was initiated by 4.9% of the benzodiazepine non-users at baseline 
(chapter three). Initiated use was predicted by insomnia, enduring 
anxiety symptoms, entering secondary care during follow-up and past 
benzodiazepine use. Positive life events during follow-up reduced the 
likelihood of benzodiazepine initiation. Of the BZD users at baseline, 
54.2% continued use during the entire follow-up period. Continuation 
of benzodiazepine use was predicted by higher age, severe anxiety, and a 
long duration of BZD use. Subjects who were discharged from specialized 
health care centres, were more likely to discontinue their benzodiazepine 
use. We concluded that insomnia and anxiety were the main risk factors 
of initiated use, while advanced age and anxiety severity were the main 
risk factors of continued use. 
Benzodiazepine dependence was measured by the three following 
dimensions: awareness of the own problematic benzodiazepine use, 
preoccupation with the use of benzodiazepines and lack of compliance 
with the therapeutic regimen (chapter four). Problematic use was 
independently associated with more general practitioner contacts in the 
past six months and severity of insomnia. Preoccupation was related to 
anxiety severity, antidepressant use, alcohol dependence, and a higher 
daily dosage of BZDs. Lack of compliance was associated with higher age, 
unemployment, insomnia, antidepressant use, and alcohol dependence. 
As benzodiazepine users with insomnia, antidepressant use and alcohol 
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dependence scored high on two out of three benzodiazepine dependence 
dimensions, they were the highest risk group. The concomitant 
psychopathology and substance dependence may severely compromise 
these subjects’ quality of life. Therefore, close monitoring and more 
appropriate symptom treatment is needed. 
As the prescribers may affect the benzodiazepine use of their 
patients, we also established the general practitioner characteristics of 
patient benzodiazepine use (chapter five). Not much research has been 
conducted on this topic and usually the patient characteristics formed 
the focus of previous research, so that there was not much literature 
available which our findings could have been compared to. In the 
NESDA study, patient benzodiazepine use and inappropriate use did not 
vary significantly between general practitioners. Furthermore, patient 
benzodiazepine use and inappropriate use were only associated with a 
minor fraction of the general practitioner characteristics. The general 
practitioners’ perceived disability to differentiate unhappiness from 
depression was weakly associated with less patient benzodiazepine use 
and higher professional comfort and competence with mental health care 
of the general practitioners correlated with less inappropriate patient 
benzodiazepine use. Our results indicate that general practitioner 
characteristics are barely associated with patient benzodiazepine use. 
Instead, patient characteristics seem to be more decisive in whether 
benzodiazepines are used (inappropriately) or not.
Our second aim was to examine whether there is evidence that 
(chronic) benzodiazepine use affects the functioning of two human stress 
systems, the hypothalamic-pituitary-adrenal axis and the autonomic 
nervous system. Most of the previous research on the hypothalamic-
pituitary-adrenal axis was of experimental nature and investigated the 
short-term effects of benzodiazepines on the stress hormone cortisol as 
the end product of the stress axis. Short-term benzodiazepine use was 
found to suppress cortisol levels in these studies. Research on the effects of 
long-term benzodiazepine administration on the hypothalamic-pituitary-
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adrenal axis was hardly existent. In the NESDA study, benzodiazepine 
users displayed slightly lower evening cortisol levels as compared to non-
users, but did not differ on any other cortisol indicator (chapter six). 
As BZDs are often taken at night time before going to bed, the reduced 
cortisol levels in the evening may reflect a transient suppressive effect of 
the benzodiazepines on the hypothalamic-pituitary-adrenal axis. 
Regarding the autonomic nervous system, short-term 
benzodiazepine use was repeatedly found to suppress sympathetic 
nervous system activity and heart rate variability. However, findings 
between studies were inconsistent. Furthermore, it was unclear if 
benzodiazepines maintain their effects on the autonomic nervous system 
in chronic use. Therefore, we investigated the prospective association 
between transitions in benzodiazepine use and autonomic nervous 
system alterations. After adjustment for covariates, subjects who had 
initiated benzodiazepine use during the follow-up period displayed a 
decrease in sympathetic activity while chronic users showed an increase 
in sympathetic activity (chapter seven). No effects of benzodiazepines 
on parasympathetic activity were detected. This finding suggests that 
benzodiazepines suppress sympathetic activity in short-term use, and 
that these effects remain, but become smaller, in longer term users, 
potentially due to tolerance development. 
Our third aim was to investigate whether the relationship 
between benzodiazepine use and increased reaction time would persist 
in long-term benzodiazepine use or whether tolerance to this effect of 
the BZDs would develop (chapter eight). Short-term administration of 
benzodiazepines was found to prolong reaction time in many experimental 
studies. However, studies on long-term benzodiazepine use did not always 
adjust for important confounders and showed inconsistent results. We 
investigated the relationship between benzodiazepine use and reaction 
time in benzodiazepine users of the NESDA study. We found that chronic 
high dosage benzodiazepine users had longer reaction times than non-
users, which was not the case with low dosage users. This indicates 
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that tolerance to this side effect of the benzodiazepines did not develop 
(completely). 
conclusions
In this large research cohort, benzodiazepine use was mainly initiated 
by patients with a diagnosis of insomnia or anxiety. The most vulnerable 
patients, i.e. the old and psychologically or physically ill, were at highest 
risk of inappropriate (and especially chronic) benzodiazepine use. Patients 
with a diagnosis of insomnia and alcohol dependence or those who used 
antidepressants were at highest risk of benzodiazepine dependence. 
Benzodiazepine users only differed from non-users on few stresssystem 
measures, indicating small effects and the development of tolerance. 
However, a higher dose of benzodiazepine use was associated with 
prolonged reaction times, suggesting that tolerance to this psychomotor 
effect of benzodiazepines does not seem to develop completely. 
Many chronic benzodiazepine users seem to believe in the 
maintained effectiveness of the benzodiazepines, although supportive 
research evidence is largely missing. Additionally, chronic benzodiazepine 
users are usually those who suffer from the most severe anxiety and 
insomnia. This raises the question whether benzodiazepines are actually 
still effective in reducing symptoms of anxiety and insomnia. Future 
research should focus on long-term therapeutic effects and side effects of 
benzodiazepine use, so that a clear risk-analysis can be established for 
long-term benzodiazepine users. 
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DeUtscHe ZUsAMMeNFAssUNG
Benzodiazepine sind psychotrope Medikamente mit angstlösender, 
zentral muskelrelaxierender, sedierender und hypnotischer Wirkung. 
In der klinischen Praxis werden sie vor allem verschrieben zur 
Reduktion von Angst-, Unruhe-, und Schlafstörungssymptomen. Für 
die kurzfristige Effektivität der Benzodiazepine besteht eine breite 
empirische Fundierung. Da die Einnahme jedoch mit einem hohen 
Risiko für Nebenwirkungen, Toleranzentwicklung und Abhängigkeit 
einhergeht, empfehlen internationale Verschreibungsrichtlinien, nur 
streng zeitlich befristete Benzodiazepine Rezepte für die Dauer von zwei 
bis drei Monaten auszustellen. Dennoch halten sich die Patienten und die 
verschreibenden Ärzte nicht immer an diese Richtlinien. Die Prävalenz 
des chronischen Benzodiazepine Gebrauchs – teilweise über den 
Zeitraum vieler Jahre - ist hoch. Darüber hinaus erhalten viele Patienten 
zu hohe Dosierungen oder Rezepte für mehr als einen Benzodiazepine 
Wirkstoff. Da viele Benzodiazepine Nutzer Langzeitkonsumenten sind, 
sollten Verschreibungsentscheidungen für diese Patienten auf den 
Ergebnissen klinischer Studien basieren. Dennoch beschäftigen sich nur 
wenige wissenschaftliche Studien mit Langzeitkonsumenten. Aus diesen 
Gründen untersuchte die vorliegende Dissertation die Determinanten und 
Konsequenzen von langfristigem Benzodiazepine Konsum. Als Grundlage 
dienten die Daten der Niederländischen Studie zu Depression und Angst 
(NESDA). Dabei handelt es sich um eine longitudinale Kohorten Studie 
mit einer Stichprobe von 2 981 Teilnehmern im Alter von 18 bis 65 
Jahren.
Das erste Ziel dieser Dissertation war die Identifikation der 
unabhängigen Korrelate und Determinanten von Benzodiazepine 
Konsum im Allgemeinen, sowie von neuem, inadäquatem und 
chronischen Konsum und Benzodiazepine Abhängigkeit. In der NESDA 
Studie befanden sich 429 Benzodiazepine Konsumenten (15.0%). Nur 
15.2% der Nutzer nahmen Benzodiazepine konform der internationalen 
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Verschreibungsrichtlinien ein. Die meisten Verstöße lagen in der 
Überschreitung der empfohlenen Länge des Gebrauchs (82.5%). Es 
wurde jedoch auch die vorgeschriebene tägliche Dosierung überschritten 
und/oder mehr als ein Benzodiazepine Wirkstoff zugleich eingenommen. 
Folgende Faktoren waren mit dem Gebrauch von Benzodiazepinen 
assoziiert: fortgeschrittenes Alter, alleinstehend sein, Arbeitslosigkeit, 
psychiatrische Behandlung, viele Hausarztkontakte im letzten halben 
Jahr, das Vorliegen einer ernsthaften Angststörung, Schlafstörungen, 
einer depressiven Störung oder einer komorbiden Störung (Angst und 
Depression) sowie der Gebrauch von Antidepressiva (Kapitel zwei). Je 
fortgeschrittener das Alter und und je höher die Anzahl der vorliegenden 
chronischen, körperlichen Erkrankungen waren, desto höher lag der 
inadäquate Konsum von Benzodiazepinen. Daraus lässt sich schließen, 
dass mentale und physische Anfälligkeit häufig mit der Einnahme von 
Benzodiazepinen einhergeht. Die empfindlichsten Menschen dieser 
Gruppe, nämlich Menschen fortgeschrittenen Alters, die an physischen 
Krankheiten litten, zeigten das höchste Risiko für die unangemessene 
Einnahme von Benzodiazepinen. 
Während der zweijährigen follow-up Periode wurden 4.9% der 
Studienteilnehmer, die zuvor keine Benzodiazepine gebraucht hatten, 
zu Benzodiazepine Nutzern (Kapitel drei). Der Beginn der Einnahme 
von Benzodiazepinen wurde durch das Auftreten von Schlafstörungen, 
andauernden Angstsymptomen, dem Start einer Behandlung in einer 
psychiatrischen Einrichtung und Konsum von Benzodiazepinen in der 
Vergangenheit vorhergesagt. Positive Lebensereignisse, die während dieser 
zweijährigen Periode auftraten, reduzierten das Risiko der Einnahme von 
Benzodiazepinen. Mehr als die Hälfte der Teilnehmer, die zu Beginn der 
Studie Benzodiazepine nahmen (54.2%), setzten den Gebrauch über die 
komplette Messperiode hinweg fort. Dieser chronische Konsum wurde 
durch ein fortgeschrittenes Alter, ernsthafte Angst und eine lange 
vorangegangene Dauer des Konsums von Benzodiazepinen vorhergesagt. 
Wir schlussfolgerten daraus, dass Schlafstörungen und Angst die größten 
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Risikofaktoren für den Beginn der Einnahme von Benzodiazepinen sind. 
Fortgeschrittenes Alter und das Vorliegen ernsthafter Angstsymptome 
bilden jedoch die größten Risikofaktoren für den chronischen Gebrauch.
Abhängigkeit von Benzodiazepinen wurde durch die Dimensionen 
Bewusstsein des problematischen Konsums von Benzodiazepinen, 
(zwanghafte) gedankliche Beschäftigung (mit der Einnahme von) 
Benzodiazepinen und mangelnde Befolgung der Rezeptvorgaben gemessen 
(Kapitel vier). Die Anzahl der Kontakte mit dem Hausarzt in den letzten 
sechs Monaten sowie die Schwere der Schlafstörung gingen mit einem 
höheren Bewusstsein des problematischen Benzodiazepine Konsums 
einher. Der Schweregrad der Angstsymptome, der Gebrauch von 
Antidepressiva, Alkoholabhängigkeit und eine höhere Tagesdosierung der 
Benzodiazepine hingen mit einer stärkeren (zwanghaften,) gedanklichen 
Beschäftigung mit Benzodiazepinen zusammen. Fortgeschrittenes 
Alter, Arbeitslosigkeit, Schlafstörungen, Antidepressiva Gebrauch und 
Alkoholabhängigkeit waren assoziiert mit mangelnder Befolgung der 
Rezeptvorgaben (zum Beispiel durch Überschreitungen der Tagesdosis). Da 
Benzodiazepine Konsumenten mit Schlafstörungen, Alkoholabhängigkeit 
und gleichzeitigem Gebrauch von Antidepressiva hohe Werte auf zwei 
der drei Abhängigkeitsdimensionen hatten, ist dies die Gruppe mit 
dem höchsten Abhängigkeitsrisiko. Komorbide Psychopathologie und 
Substanzabhängigkeit kann die Lebensqualität der Betroffenen erheblich 
beeinträchtigen. Darum sollten die Symptome der betroffenen Patienten 
in regelmäßigen Kontrollbesuchen abgefragt und adäquat behandelt 
werden. 
Da die verschreibenden Ärzte den Benzodiazepine Konsum ihrer 
Patienten möglicherweise beeinflussen, untersuchten wir zudem die 
Einstellungen und Eigenschaften von Hausärzten als mögliche Korrelate 
des Benzodiazepine Konsums ihrer Patienten (Kapitel fünf). Bislang 
existieren zu dieser Fragestellung nur sehr wenige empirische Studien. Der 
Fokus lag in der Vergangenheit meist auf den Eigenschaften der Patienten 
selbst. Die Prävalenz des Benzodiazepine Konsums der Patienten im 
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Allgemeinen sowie des inadäquaten Gebrauchs unterschieden sich nicht 
signifikant zwischen den untersuchten Hausärzten. Darüber hinaus 
war der Konsum von Benzodiazepinen unter den Patienten nur mit 
sehr wenigen Eigenschaften der Hausärzte assoziiert. Lediglich die vom 
Hausarzt wahrgenommene, eigene Unfähigkeit, Traurigkeit von Depression 
zu unterscheiden ging mit leicht weniger Benzodiazepine Konsum der 
Patienten einher. Bei Hausärzten, die sich im Umgang mit psychisch 
kranken Patienten kompetent fühlten, wichen weniger Patienten in ihrem 
Benzodiazepine Konsum von den Richtlinien ab. Dies weist darauf hin, 
dass die Einstellungen und Eigenschaften von Hausärzten kaum mit 
dem Konsum von Benzodiazepinen unter den Patienten einhergehen. 
Stattdessen scheinen die Patienteneigenschaften entscheidender für den 
(inadäquaten) Konsum von Benzodiazepinen zu sein. 
 Das zweite Ziel dieser Dissertation war es zu untersuchen, 
ob es empirische Belege dafür gibt, dass der chronische Konsum von 
Benzodiazepinen die Funktion der zwei menschlichen Stresssysteme 
(Hypothalamus-Hypophysen-Nebennierenrinden-Achse und Autonomes 
Nervensystem) beeinflusst. Der Großteil der bisherigen empirischen 
Studien war experimentell und untersuchte die kurzfristigen Effekte 
der Benzodiazepine auf das Stresshormon Kortisol als Endprodukt 
der Hypothalamus-Hypophysen-Nebennierenrinden- Achse. In diesen 
Studien wurde gezeigt, dass der Konsum von Benzodiazepinen die Kortisol 
Produktion unterdrückt, ob dieser Effekt bei langfristigem Gebrauch 
bestehen bleibt, wurde allerdings nicht betrachtet. In der NESDA 
Studie fanden wir, dass Konsumenten von Benzodiazepinen niedrigere 
Abendkortisolwerte hatten als Nicht-Konsumenten (Kapitel sechs). Es 
wurden allerdings auf keinem anderen Kortisolindikator Unterschiede 
gefunden. Da Benzodiazepine meist abends vor dem Schlafengehen 
eingenommen werden, könnten die reduzierten Kortisolwerte am Abend 
darauf hindeuten, dass Benzodiazepine auch bei Langzeitnutzern einen 
transienten, suppressiven Effekt auf die Hypothalamus-Hypophysen-
Nebennierenrinden-Achse haben. 
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Bezüglich des Autonomen Nervensystems wurde bisher hauptsächlich der 
Effekt von kurzzeitigem Konsum von Benzodiazepinen in experimentellen 
Studien untersucht. Ein Teil der Studien berichtete, dass kurzzeitiger 
Benzodiazepine Konsum die Aktivität des sympathischen Nervensystems 
sowie die Herzratenvariabilität verringert. Jedoch existierten ebenso 
gegenteilige Resultate, die Ergebnisse waren also inkonsistent. 
Darüber hinaus war unklar, ob die Effekte der Benzodiazepine auf 
das Autonome Nervensystem bei Langzeitnutzern bestehen bleiben 
oder sich eine Toleranz entwickelt. Aus diesem Grund haben wir 
die prospektiven Zusammenhänge zwischen Veränderungen im 
Gebrauch von Benzodiazepinen und Veränderungen der Aktivität des 
Autonomen Nervensystems untersucht. Probanden, die während der 
zweijährigen follow-up Periode mit dem Gebrauch von Benzodiazepinen 
begonnen hatten, zeigten eine Verringerung der sympathischen 
Aktivität. Demgegenüber bestand bei chronischen Konsumenten von 
Benzodiazepinen ein Anstieg der sympathischen Aktivität (Kapitel sieben). 
Es konnten keine Effekte auf das parasympathische Nervensystem 
gefunden werden. Diese Ergebnisse legen nahe, dass Benzodiazepine 
die Aktivität des sympathischen Nervensystems im Kurzzeitgebrauch 
verringern. Dieser Effekt bleibt im Langzeitgebrauch bestehen, wird 
jedoch – möglicherweise durch Toleranzentwicklung - kleiner. 
Das dritte Ziel dieser Dissertation war es zu untersuchen, ob 
der häufig gefundene Zusammenhang zwischen der Einnahme von 
Benzodiazepinen und längeren Reaktionszeiten langfristig bestehen bleibt 
oder eine Toleranzentwicklung stattfindet (Kapitel acht). Der Großteil der 
bestehenden Studien fand, dass sich die Reaktionszeiten im Labor nach 
Einnahme von Benzodiazepinen in der Interventionsgruppe gegenüber 
der Kontrollgruppe verlängerten. Vereinzelte Studien untersuchten 
auch die Effekte von Langzeitkonsum auf Reaktionszeiten. Diese 
zeigten allerdings, möglicherweise aufgrund von Designunterschieden, 
inkonsistente Ergebnisse. Wir betrachteten den Zusammenhang zwischen 
Langzeitbenzodiazepinegebrauch und Reaktionszeiten von Konsumenten 
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aus der NESDA Studie: Chronische Nutzer, die hohe Tagesdosierungen 
einnahmen, hatten in dieser Stichprobe erhöhte Reaktionszeiten. Dies 
war nicht der Fall für Konsumenten mit niedrigeren Dosierungen. Dieses 
Ergebnis deutet an, dass keine vollständige Toleranzentwicklung für die 
Effekte der Benzodiazepine auf Reaktionszeit in Langzeitkonsumenten 
vorliegt. 
schlussfolgerungen
Im Rahmen der vorliegenden Kohorten Studie begannen hauptsächlich 
Personen mit einer Angststörung oder Schlafproblemen mit der 
Einnahme von Benzodiazepinen. Die emotional anfälligsten Patienten, 
nämlich die fortgeschrittenen Alters und mit psychischen und 
körperlichen Erkrankungen, waren am meisten von inadäquater 
Benzodiazepine Nutzung betroffen. Probanden mit Schlafproblemen, 
Alkoholabhängigkeit und Antidepressiva Gebrauch waren häufig abhängig 
von Benzodiazepinen. Benzodiazepine Nutzung ging nur mit kleinen 
Aktivitätsveränderungen der beiden Stresssysteme einher, was auf eine 
Toleranzentwicklung hindeutet. Hohe Benzodiazepine-Tagesdosierungen 
waren mit einer verlängerten Reaktionszeit assoziiert. Dieses Ergebnis 
zeigt, dass sich keine komplette Toleranz bezüglich dieser Effekte der 
Benzodiazepine zu entwickeln scheint. 
Viele chronische Benzodiazepine Nutzer scheinen an die 
anhaltende Effektivität dieses Medikaments zu glauben, obwohl kaum 
stützende, empirische Belege für die bleibende therapeutische Wirkung 
vorhanden sind. Darüber hinaus sind die chronischen Konsumenten von 
Benzodiazepinen meist diejenigen, die an den schwerwiegendsten Angst- 
und Schlafstörungen leiden. Dies wirft die Frage auf, ob Benzodiazepine 
im Langzeitgebrauch noch ausreichend effektiv sind, um Angst- und 
Schlafstörungssymptome zu verringern. Zukünftige Untersuchungen 
sollten sich auf die langfristigen therapeutischen Effekte und 
Nebenwirkungen richten, mit dem Ziel, eine deutliche Kosten-Nutzen-
Analyse für Langzeitgebraucher zu erarbeiten. 
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NeDerLANDse sAMeNVAttiNG
Benzodiazepines zijn psychotrope middelen met anxiolytische, sederende, 
spierverslappende en hypnotische effecten. In de praktijk worden 
zij voornamelijk ingezet voor de symptoombehandeling van angst en 
slaapstoornissen. Korte termijn effectiviteit van benzodiazepines werd 
in verschillende experimentele studies aangetoond. Dit effect gaat 
gepaard met verschillende bijwerkingen (zoals slaperigheid overdag 
en verminderd reactie- en concentratievermogen), het ontstaan van 
tolerantie en het ontwikkelen van verslaving. Daarom bevelen interna-
tionale richtlijnen aan het gebruik te beperken tot korte termijn (2-3 
maanden). Desondanks houden gebruikers en voorschrijvers van 
benzodiazepinen zich niet altijd aan deze richtlijnen, en langdurig 
gebruik – vaak gedurende vele jaren - is een veel voorkomend fenomeen. 
Bovendien krijgen veel benzodiazepinegebruikers meerdere soorten 
benzodiazepines tegelijk voorgeschreven, of gebruiken zij een te hoge 
dosering. Het is belangrijk om het voorschrijfgedrag te baseren op de 
resultaten van wetenschappelijke studies. Er zijn echter nog weinig 
studies uitgevoerd onder langetermijngebruikers. Om die reden werd 
het hoofddoel van dit proefschrift de determinanten en consequenties 
van lange termijn benzodiazepinegebruik in kaart te brengen. Daarvoor 
maakte dit proefschrift gebruik van de data van de Nederlandse Studie naar 
Depressie en Angst (NESDA). NESDA is een longitudinale, prospectieve 
cohort studie, in welke 2981 deelnemers in de leeftijd tussen 18 en 65 
worden gevolgd.
Het eerste doel van dit proefschrift was het in kaart brengen 
van de onafhankelijke correlaten van benzodiazepinegebruik in het 
algemeen en van nieuw, inadequaat en chronisch gebruik, evenals 
van benzodiazepineverslaving. In het NESDA sample gebruikten 429 
mensen (15.0%) benzodiazepines. Van deze groep gebruikten maar 
15.2% volgens internationale behandelrichtlijnen. Deze overtreding werd 
meestal veroorzaakt door het overschreiden van de aanbevolen duur 
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van gebruik (82.5%). Sommige gebruikers overschreden de aanbevolen 
dagelijkse dosis of gebruikten meerdere soorten benzodiazepines 
tegelijk. Benzodiazepinegebruik was geassocieerd met oudere leeftijd, 
alleenstaand zijn, werkeloosheid, behandeld worden in de tweede lijn, 
meer contacten met de huisarts in de laatste zes maanden, ernst van 
de angststoornis, depressie, comorbiditeit van angst en depressie en het 
gebruik van antidepressiva (hoofdstuk twee). Onafhankelijke correlaten 
van inadequaat benzodiazepinegebruik waren oudere leeftijd en het aantal 
chronische ziekten. We concludeerden dat psychisch en fysiek kwetsbare 
mensen een verhoogd risico op het gebruik van benzodiazepines hebben. 
De meest kwetsbare uit deze groep, namelijk de ouderen en de somatisch 
zieken, lopen het hoogste risico op inadequaat gebruik.
Tijdens de twee-jaar follow-up periode begonnen 4.9% van 
de niet-gebruikers vanaf nul met het gebruik van benzodiazepines 
(hoofdstuk drie). Dit nieuwe benzodiazepinegebruik werd voorspeld 
door slaapproblemen, aanhoudende angstsymptomen, behandeling 
in de tweede lijn en benzodiazepinegebruik in het verleden. Positieve 
levensgebeurtenissen tijdens de follow-up periode reduceerden 
de kans op het beginnen met benzodiazepines. Van de nieuwe 
benzodiazepinegebruikers gingen 54.2% tijdens de gehele follow-up 
periode door met het gebruik van benzodiazepines. Dit chronisch gebruik 
werd voorspeld door oudere leeftijd, ernstige angstsymptomen, en een 
lange duur van benzodiazepinegebruik in het verleden. Mensen die uit 
de tweede lijn ontslagen werden hadden een grotere kans op stoppen van 
het benzodiazepinegebruik. Concluderend waren slapeloosheid en angst 
de belangrijkste voorspellers van nieuw benzodiazepinegebruik. Hogere 
leeftijd en de ernst van angst waren de belangrijkste risicofactoren van 
chronisch gebruik. 
Benzodiazepineverslaving werd door drie dimensies gemeten: 
(bewustzijn van het) problematisch benzodiazepinegebruik, preoccupatie 
met de beschikbaarheid van benzodiazepines en gebrek aan therapietrouw 
(hoofdstuk vier). Het problematisch gebruik werd voorspeld door 
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meer huisartscontacten in de afgelopen zes maanden en ernst van de 
slapeloosheid. Preoccupatie met de beschikbaarheid van benzodiazepines 
was geassocieerd met de ernst van angst, het gebruik van antidepressiva, 
alcoholverslaving en een hogere dagelijkse dosis benzodiazepines. 
Gebrek aan therapietrouw was gerelateerd aan hogere leeftijd, 
werkeloosheid, slapeloosheid, het gebruik van antidepressiva, en een 
alcoholverslaving. Omdat benzodiazepinegebruikers met slaapproblemen, 
antidepressivagebruik en alcoholverslaving hoge scores op twee van 
drie verslavingsdimensies hadden, lopen deze mensen het hoogste 
risico op het ontwikkelen van een benzodiazepineverslaving. Comorbide 
psychopathologie en verslaving aan middelen kan de levenskwaliteit van 
de betrokken mensen ernstig compromitteren. Daarom is het belangrijk 
de symptomen regelmatig te monitoren en adequaat te behandelen. 
Omdat de voorschrijvende huisartsen ook invloed op (inadequaat) 
gebruik door hun patiënten zouden kunnen hebben, hebben we de 
eigenschappen en attitudes van huisartsen als mogelijke correlaten van 
het benzodiazepinegebruik van hun patiënten in kaart gebracht (hoofdstuk 
vijf). Er is maar weinig onderzoek naar dit onderwerp gedaan en in de 
meeste studies stonden de karakteristieken van de patiënten centraal. Het 
benzodiazepinegebruik en het inadequate benzodiazepinegebruik van de 
NESDA deelnemers verschilden niet significant tussen de verschillende 
huisartsen. Het benzodiazepinegebruik van de patiënten was daarnaast 
slechts met enkele karakteristieken van huisartsen geassocieerd. 
Alleen de door de huisarts waargenomen eigen onbekwaamheid om 
bedroefdheid van een depressie te onderscheiden was geassocieerd 
met minder benzodiazepinegebruik onder de patiënten. Bij huisartsen, 
die zich comfortabel en competent in de omgang met patiënten met 
psychische stoornissen voelden, kwam minder inadequaat gebruik 
onder de onderzochte patiënten voor. Onze resultaten duiden erop dat 
de karakteristieken en attitudes van de huisartsen weinig invloed op het 
benzodiazepinegebruik van hun patiënten hadden. In plaats daarvan 
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blijken de karakteristieken van de patiënten veel belangrijker te zijn voor 
(inadequaat) gebruik van benzodiazepines.
Het tweede doel van dit proefschrift was te onderzoeken of er 
bewijs is voor de hypothese dat chronisch benzodiazepinegebruik de 
twee menselijke stresssystemen, de hypothalamus-hypofyse-bijnier-as 
en het autonome zenuwstelsel beïnvloed. Het grootste deel van onderzoek 
tot nu toe over de hypothalamus-hypofyse-bijnier as was experimenteel 
en bekeek de korte termijn effecten van benzodiazepines op het stress 
hormoon cortisol (als eindproduct van de hypothalamus-hypofyse-
bijnier as). Deze korte termijn studies vonden, dat de inname van 
benzodiazepines cortisolspiegels verlaagden. Er was echter nog weinig 
onderzoek naar de effecten van lange termijn benzodiazepinegebruik op 
de hypothalamus-hypofyse-bijnier as gedaan. In de NESDA studie hadden 
benzodiazepinegebruikers lagere avondcortisolspiegels vergeleken 
met niet-gebruikers (hoofdstuk zes). Op de andere cortisolindicatoren 
werden echter geen verschillen tussen benzodiazepinegebruikers en 
niet-gebruikers ontdekt. Omdat benzodiazepines meestal in de avond 
voor het naar bed gaan worden ingenomen, zouden de verlaagden 
avondcortisolwaardes een indicator kunnen zijn voor een tijdelijk 
onderdrukkend effect van de benzodiazepines op de hypothalamus-
hypofyse-bijnier as. 
Met betrekking tot het autonome zenuwstelsel werd voornamelijk 
het effect van korte termijn benzodiazepinegebruik in experimentelen 
studies onderzocht. In deze studies werd herhaaldelijk gevonden 
dat benzodiazepines de werking van het sympathische zenuwstelsel 
onderdrukken en de hartslagvariabiliteit verlagen. Er waren echter 
ook studies die tegenovergestelde effecten rapporteerden. Bovendien 
was het onduidelijk of benzodiazepines hun effecten op het autonome 
zenuwstelsel tijdens langetermijngebruik zouden blijven houden of dat 
er tolerantie optreed. Vanwege deze tegenstrijdigheden, hebben wij de 
associatie onderzocht tussen veranderingen in benzodiazepinegebruik en 
autonome zenuwstelselactiviteit in een twee jaar durende prospectieve 
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studie. In NESDA lieten de deelnemers die tijdens de follow-up periode 
met benzodiazepinegebruik waren begonnen een verlaagde sympathische 
zenuwstelselactiviteit zien (hoofdstuk zeven). Daartegenover hadden 
chronische gebruikers een verhoogde sympathische zenuwstelselactiviteit. 
Er werden geen effecten gevonden van het benzodiazepinegebruik op 
de activiteit van het parasympathische zenuwstelsel. Deze bevindingen 
duiden erop dat kortetermijn benzodiazepinegebruik sympathische 
zenuwstelselactiviteit verlaagt en dat dit effect in langetermijngebruik 
blijft bestaan, maar kleiner wordt vanwege het ontstaan van tolerantie.
Het derde doel van dit proefschrift was de relatie tussen 
benzodiazepinegebruik en reactietijd te onderzoeken. De reactietijd-
verhogende werking van benzodiazepines tijdens kortetermijngebruik 
is door diverse wetenschappelijke studies aangetoond. Of deze effecten 
in langetermijngebruik nog steeds aanwezig zijn is echter nauwelijks 
onderzocht. De weinige bestaande lange termijn studies corrigeerden 
niet altijd voor belangrijke verstorende variabelen en kwamen tot 
inconsistente resultaten. Daarom hebben wij de associatie tussen lange 
termijn benzodiazepinegebruik en reactietijd in deelnemers van de 
NESDA studie bekeken. We vonden langere reactietijden in chronische 
benzodiazepinegebruikers, die hoge doseringen gebruikten in vergelijking 
tot niet gebruikers. Dit verschil werd niet tussen gebruikers van lagere 
doseringen en niet gebruikers geconstateerd. Deze resultaten suggereren 
dat in hoge dosis gebruikers geen volledige tolerantie tot het effect van 
benzodiazepine op reactietijd ontstaat.
conclusies
In deze grote cohortstudie begonnen voornamelijk deelnemers met 
angst en slaapproblemen het gebruik van benzodiazepines. De meest 
kwetsbare deelnemers, de ouderen met chronische lichamelijke 
ziektes, liepen het hoogste risico op inadequaat benzodiazepinegebruik. 
Deelnemers met slaapproblemen en alcoholverslaving en deelnemers die 
antidepressiva gebruikten waren ernstiger verslaafd aan benzodiazepines. 
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Benzodiazepinegebruikers verschilden maar weinig van niet gebruikers 
op de meeste indicatoren van de stress systemen. Deze kleine effecten 
van benzodiazepines op de stress systemen suggereren het ontstaan 
van tolerantie voor het suppressieve effect van benzodiazepines op 
het autonome zenuwstelsel en de hypothalamus-hypofyse-bijnier as. 
Desondanks waren de reactietijden in langetermijngebruikers nog steeds 
verhoogd. 
Veel chronische benzodiazepinegebruikers lijken in de 
aanhoudende effectiviteit van de benzodiazepines te geloven, hoewel 
er maar weinig empirisch bewijs voor deze bewering is. Bovendien zijn 
chronische gebruikers over het algemeen die mensen met de meest 
ernstige angst en slaapproblematiek. Daarom is het maar de vraag of 
benzodiazepines die over een langere termijn gebruikt worden nog 
steeds effectief angstsymptomen en slaapproblemen kunnen reduceren. 
Toekomstig onderzoek moet zich op de therapeutische effecten en 
bijwerkingen in langetermijngebruikers richten, zodat een duidelijke 
kosten/batenanalyse kan worden uitgevoerd.
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List oF ABBreViAtioNs 
ActH adrenocorticotropic hormone 
AD antidepressant 
ANoVA  analysis of variance 
ANs autonomic nervous system
Atc anatomical therapeutic code
AUcg area under the curve with respect to the ground 
AUci area under the curve with respect to the increase 
BAi  Beck Anxiety Inventory 
Bendep-srQ  Benzodiazepine-Dependence-Self-Report-Questionnaire 
BZD benzodiazepine
cAr cortisol awakening response
ci confidence interval
ciDi Composite International Diagnostic Interview
crH corticotrophin-releasing-hormone
crtt choice reaction time task
cVD cardiovascular disease
d Cohen’s d
DAQ  Depression Attitude Questionnaire 
DDD Defined Daily Dosage
DsM-iV Diagnostic and Statistical Manual of Mental Disorder IV
Dst dexamethasone suppression test
ecG electrocardiogram
fte  full-time equivalents
GABA gamma-aminobutric acid 
GP general practitioner
Gr  glucocorticoid receptor
HPA  hypothalamic - pituitary - adrenal axis
Hr heart rate
HrV heart rate variability 
iAt Implicit Association Test 
icG impedance cardiogram 
iQr interquartile range 
irs Insomnia Rating Scale 
iDs-sr  Inventory of Depressive Symptomatology Self Report 
Lci Life Chart Interview 
LMM  Linear Mixed Models
Lte-Q List of Threatening Events Questionnaire 
MD medical doctor
MDD Major Depressive Disorder 
Mr  mineralocorticoid receptor
NesDA Netherlands Study of Depression and Anxiety
Neo-FFi Neuroticism Extraversion Openness-Five Factor Inventory 
or odds ratio
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PeP pre-ejection period 
PVN paraventricular nucleus 
PNs parasympathetic nervous system 
PNcQ  Perceived Need for Care Questionnaire
rsA  respiratory sinus arrhythmia 
rt reaction time
sD standard deviation 
sNs sympathetic nervous system
sPss Statistical Package for Social Science
ssri selective serotonin reuptake inhibitor
t  time point
tcA  Tricyclic Antidepressant
tic-P  Trimbos/iMTA questionnaire for costs associated with 
psychiatric illness
UBos-c  Utrecht Burn-Out Scale
VU-AMs  Vrije Universiteit Ambulatory Monitoring System 
WHo World Health Organization
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